



RESIDUE EVALUATION OF CERTAIN VETERINARY DRUGS

Joint FAO/WHO Expert Committee on Food Additives

66th meeting 2006



RESIDUE EVALUATION OF CERTAIN VETERINARY DRUGS

Joint FAO/WHO Expert Committee on Food Additives

66th meeting 2006

The designations employed and the presentation of the material in this information product do not imply the expression of any opinion whatsoever on the part of the Food and Agriculture Organization of the United Nations concerning the legal or development status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.

ISBN 92-5-105553-X

All rights reserved. Reproduction and dissemination of material in this information product for educational or other non-commercial purposes are authorized without any prior written permission from the copyright holders provided the source is fully acknowledged. Reproduction of material in this information product for resale or other commercial purposes is prohibited without written permission of the copyright holders. Applications for such permission should be addressed to:

Chief
Electronic Publishing Policy and Support Branch
Information Division
FAO
Viale delle Terme di Caracalla, 00100 Rome, Italy
or by e-mail to:
copyright@fao.org

© FAO 2006

TABLE OF CONTENTS

List of participants.....	v
Abbreviations.....	vii
Introduction.....	ix
References.....	xi
General considerations.....	1
Colistin.....	7
Erythromycin.....	29
Flumequine.....	53
Melengestrol acetate(MGA).....	61
Ractopamine hydrochloride.....	65
Triclabendazole.....	71
Annex 1: Summary of recommendations from the 66 th JECFA on Compounds on the Agenda and Further Information Required.....	89
Annex 2: Summary of JECFA evaluations of veterinary drug residues from the 32 nd meeting to the present.....	91
Corrigendum to FNP 41/12, 1999.....	101

Use of JECFA reports and evaluations by registration authorities

Most of the evaluations and summaries contained in this publication are based on unpublished proprietary data submitted to JECFA for use when making its assessment. A registration authority should not consider to grant a registration based on an evaluation published herein unless it has first received authorization for such use from the owner of the data or any second party that has received permission from the owner for using the data.

JOINT FAO/WHO EXPERT COMMITTEE ON FOOD ADDITIVES
(66TH MEETING)
Rome, 22 – 28 February, 2006

Members

- Professor Arturo Anadón, Faculty of Veterinary Medicine, Universidad Complutense de Madrid, Spain
- Dr Dieter Arnold, Berlin, Germany (*Vice-Chairman*)
- Professor Alan R. Boobis, Faculty of Medicine, Imperial College, London, England
- Dr Richard Ellis, Consultant, Myrtle Beach, South Carolina, USA
- Dr Adriana Fernández Suárez, Instituto Nacional de Tecnología Agropecuaria, Buenos Aires, Argentina (unable to participate)
- Dr Kevin Greenlees, Food and Drug Administration, Rockville, MD, USA
- Dr James MacNeil, Canadian Food Inspection Agency, Saskatoon, Saskatchewan, Canada
- Professor Emeritus J.G. McLean, Camberwell, Victoria, Australia (*Chairman*)
- Professor Joao Palermo-Neto, Faculty of Veterinary Medicine, University of São Paulo, São Paulo, Brazil
- Dr José Luis Rojas Martínez, Ministerio de Agricultura y Ganadería, Heredia, Costa Rica
- Dr Pascal Sanders, Agence Française de Sécurité Sanitaire des Aliments, Laboratoire d'Etudes et Recherches sur les Médicaments Vétérinaires et les Désinfectants, Fougères, France
- Professor G.E. Swan, Faculty of Veterinary Science, University of Pretoria, Pretoria, South Africa
- Dr Janenuj Wongtavatchai, Faculty of Veterinary Science, Chulalongkorn University, Bangkok, Thailand (unable to participate)

Secretariat

- Dr Carl E. Cerniglia, Food and Drug Administration, Jefferson, AR, USA (*WHO Temporary Adviser*)
- Dr Maria de Lourdes Costarrica, Nutrition and Consumer Protection Division, Food and Agricultural Organization, Rome, Italy (*FAO Staff Member*)
- Dr Lynn G. Friedlander, Food and Drug Administration, Rockville, MD, USA (*FAO Expert*)
- Dr Sang-Hee Jeong, Ministry of Agriculture and Forestry, Anyang City, Republic of Korea (*WHO Temporary Adviser*)
- Dr Jacek Lewicki, Faculty of Veterinary Medicine, Warsaw Agricultural University, Warsaw, Poland (*FAO Expert*)
- Dr Phil T. Reeves, Australian Pesticides and Veterinary Medicines Authority, Kingston, ACT, Australia (*FAO Expert*)
- Dr Scott McEwen, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada (*WHO Temporary Adviser*)

Dr Shogo Ozawa, National Institute of Health Sciences, Tokyo, Japan (*WHO Temporary Adviser*) (unable to participate)

Professor Len Ritter, Department of Environmental Biology, University of Guelph, Ontario, Canada (*WHO Temporary Adviser*)

Dr Gladwin Roberts, Greenway, Australia (*WHO Temporary Adviser*)

Ms Marla Sheffer, Orleans, Ontario, Canada (*WHO Editor*)

Dr Steven Sundlof, Food and Drug Administration, Rockville, MD, USA (*WHO Temporary Adviser*)

Dr Angelika Tritscher, International Programme on Chemical Safety, World Health Organization, Geneva, Switzerland (*WHO Joint Secretary*)

Dr Annika Wennberg, Nutrition and Consumer Protection Division, Food and Agriculture Organization, Rome, Italy (*FAO Joint Secretary*)

ABBREVIATIONS

ADI	Acceptable daily intake	min	Minimum or minute
AOAC	AOAC International	MGA	Melengestrol acetate
AUC	Area under the curve	mL or ml	milliliter
BW or bw	Body weight	MIC	Minimum Inhibitory Concentration
CAC	Codex Alimentarius Commission	MRL	Maximum Residue Limit
CAS	Chemical Abstracts Service	MRM	Multiple reaction monitoring
CCRVDF	Codex Committee on Residues of Veterinary Drugs in Foods	MS	Mass spectrometry
CI	Clearance rate	MW or mw	Molecular weight
C _{max}	Maximum concentration	N	Negative
CR	Renal clearance	NA or na	Not analyzed or not applicable
CV	Coefficient of variation	NADA	New Animal Drug Application
C _{v_r}	Repeatability	NC or nc	Not calculated
C _{c_R}	Reproducibility	ND	Not detected
ECD	Electron capture detector	NICI	Negative ion chemical ionization
EDI	Estimated daily intake	NOEL	No effect level
EMA	European Medicines Agency	NQ	Non quantifiable
FAO	Food and Agriculture Organization of the UN	P	Positive
FDA	US Food and Drug Administration	QA	Quality assurance
GC	Gas chromatography	QC	Quality control
GLP	Good laboratory practice	RfD	Acute reference dose
H or h	Hour	RP	Reverse phase
HPLC	High pressure liquid chromatography	SC	Subcutaneous (injection)
IM	Intramuscular	SD	Standard deviation
IR	Infrared	S/N	Signal to noise ratio
IU	International Unit	SPE	Solid phase extraction
IUPAC	International Union of Pure and Applied Chemistry	SD	Standard deviation
IV	Intravenous	s.e.	Standard error
JECFA	Joint FAO/WHO Expert Committee on Food Additives	t _{1/2}	Half life
JMPR	Joint Committee on Pesticide Residues	TR	Total residue
Kg or kg	Kilogram (10 ³ grams)	TLC	Thin layer chromatography
LC	Liquid chromatography	TMDI	Theoretical maximum daily intake
LOD	Limit of detection	TRR	Total radiolabelled residues
LOQ	Limit of quantitation	TRS	Technical Report Series
µg	microgram (10 ⁻⁶ grams)	TSP	Thermospray
mg	milligram (10 ⁻³ grams)	USP	United States Pharmacopoeia
		UV	Ultraviolet
		V _d	Volume of distribution
		WHO	World Health Organization

INTRODUCTION

The monographs in this volume of the FAO JECFA Monographs on the residues of, statements on, or other parameters of the veterinary drugs on the agenda were prepared by the invited experts for the sixty-sixth meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA) held in Rome, Italy, 22-28 February, 2006. This was the seventeenth meeting of JECFA convened specifically to consider residues of veterinary drugs in food animals. The Committee has evaluated residues of veterinary drugs in food animals at the 12th, 26th, 27th, 32nd, 34th, 36th, 38th, 40th, 42nd, 43rd, 45th, 47th, 48th, 50th, 52nd, 54th, 58th, 60th, and 62nd meetings (Ref. 1-15 and 19-22, respectively). The tasks for the Committee were to further elaborate principles for evaluating the safety of residues of veterinary drugs in food and for establishing acceptable daily intakes (ADIs) and recommend maximum residue limits (MRLs) for substances on the agenda when they are administered to food producing animals in accordance with good veterinary practice in the use of veterinary drugs. The enclosed monographs provided the scientific basis for the recommendations of MRLs.

There are two significant items in this volume of the FAO JECFA Monographs to bring to the attention of readers. First, this volume is the first in a new format for the presentation of monographs from meetings of the Committee. Second, this was the first meeting of JECFA subsequent to the completion of the workshop to update the principles and methods of risk assessment for MRLs for pesticides and veterinary drugs, held jointly by FAO/RIVM/WHO, in Bilthoven, The Netherlands, 7 - 11 November, 2005. Specifically, the Committee decided to implement one of the more significant recommendations in the workshop report – the concept of using median residue values to estimate daily intakes of residues of veterinary drugs in food for chronic exposure intake estimates (Ref. 24).

Background

In response to the growing use of veterinary medicines in food animal production systems internationally and the potential implications for human health and fair trading practices, a Joint FAO/WHO Expert Consultation on Residues of Veterinary Drugs was convened in Rome, November 1984 (Ref. 16). Among the major recommendations of this consultation were the establishment of the Codex Committee on Residues of Veterinary Drugs in Foods (CCRVDF) and the periodic convening of an appropriate expert body to provide independent scientific advice to this Committee and to member countries of FAO and WHO. At its first session in Washington, DC in November 1986, the CCRVDF reaffirmed the need for such a scientific body and made a number of recommendations and suggestions to be considered by JECFA (Ref. 17). In response to these recommendations, the 32nd JECFA meeting was devoted entirely to the evaluation of residues of veterinary drugs in food – a new responsibility to the Joint FAO/WHO Expert Committee on Food Additives. Sixteen such meetings of JECFA have been held prior to this meeting of JECFA.

66th Meeting of JECFA

This present volume in its new format contains monographs of the residue data on six of the nine substances originally scheduled for the meeting. No data were provided for two substances and one substance was for review of toxicological data only and no residue monograph was prepared. The monographs are prepared in a uniform format consistent with the data provided and the specific request for risk assessment by CCRVDF. The format includes identity of substance, residues in food and their evaluation, metabolism studies, tissue residue depletion studies, methods of residue analysis, a final appraisal of the study results, and if appropriate, recommendations on MRLs. There is one unique report in this

particular volume. It was noted in the editing of the monograph for melengestrol acetate at the 62nd JECFA that an inconsistency in the approach to recommend MRLs using appropriate biological activity of the pertinent metabolites was detected that could not be fully corrected. To address the unresolved issues, the corrected accounting of the biologically active residues was completed in this monograph without any additional data provided to JECFA. A summary of the recommendations on compounds on the agenda and further information required is included in Annex 1. In addition, a summary of JECFA evaluations of residues of veterinary drugs in foods from the 32nd meeting to the present 66th meeting is found in Annex 2. ***The monographs and general considerations on risk assessment principles of this volume must be considered in context of the full report of the meeting, which will be published in the WHO Technical Report Series No. 939.***

On-line edition of Residues of some veterinary drugs in animals and foods (FAO Food and Nutrition paper Number 41)

The monographs and statements that have been published in the FAO Food and Nutrition Paper 41 (sixteen volumes since 1988) are available online at www.fao.org/es/esn/jecfa/archive_en.stm. The search interface is available in five languages (Arabic, Chinese, English, French and Spanish) and follows searching for compounds, functional classes, ADI and MRL status. For each veterinary drug assessed by JECFA an excerpt is available that summarizes the opinion of JECFA with respect to the ADI and MRLs. The on-line edition will be updated to include the monographs contained in this volume.

Contact and Feedback

More information on the work of the Committee is available from the FAO homepage of JECFA at www.fao.org/ag/agn/jecfa/index_en.stm. Readers are invited to address comments and questions on this publication and other topics related to the work of JECFA to:

jecfa@fao.org

REFERENCES

1. Specifications for the Identity and Purity of Food Additives and their Toxicological Evaluation: Some antibiotics (Twelfth Report of the Joint FAO/WHO Expert Committee on Food Additives), FAO Nutrition Meetings Report Series No. 45, 1969; WHO Technical Report Series No. 430, 1969.
2. Evaluation of Certain Food Additives and Contaminants (Twenty-Sixth Report of the Joint FAO/WHO Expert Committee on Food Additives). WHO Technical Report Series No. 683, 1982.
3. Evaluation of Certain Food Additives and Contaminants (Twenty-Seventh Report of the Joint FAO/WHO Expert Committee on Food Additives). WHO Technical Report Series No. 696, 1983.
4. Evaluation of Certain Veterinary Drug Residues in Foods (Thirty-Second Report of the Joint FAO/WHO Expert Committee on Food Additives). WHO Technical Report Series No. 763, 1988.
5. Evaluation of Certain Veterinary Drug Residues in Foods (Thirty-Fourth Report of the Joint FAO/WHO Expert Committee on Food Additives). WHO Technical Report Series No. 788, 1989.
6. Evaluation of Certain Veterinary Drug Residues in Foods (Thirty-Sixth Report of the Joint FAO/WHO Expert Committee on Food Additives). WHO Technical Report Series No. 799, 1990.
7. Evaluation of Certain Veterinary Drug Residues in Foods (Thirty-Eighth Report of the Joint FAO/WHO Expert Committee on Food Additives). WHO Technical Report Series No. 815, 1991.
8. Evaluation of Certain Veterinary Drug Residues in Foods (Fortieth Report of the Joint FAO/WHO Expert Committee on Food Additives). WHO Technical Report Series No. 832, 1993.
9. Evaluation of Certain Veterinary Drug Residues in Foods (Forty-second Report of the Joint FAO/WHO Expert Committee on Food Additives). WHO Technical Report Series No. 851, 1995.
10. Evaluation of Certain Veterinary Drug Residues in Foods (Forty-third Report of the Joint FAO/WHO Expert Committee on Food Additives). WHO Technical Report Series No. 855, 1995.
11. Evaluation of Certain Veterinary Drug Residues in Foods (Forty-fifth Report of the Joint FAO/WHO Expert Committee on Food Additives). WHO Technical Report Series No. 864, 1996.
12. Evaluation of Certain Veterinary Drug Residues in Foods (Forty-seventh Report of the Joint FAO/WHO Expert Committee on Food Additives). WHO Technical Report Series No. 876, 1998.
13. Evaluation of Certain Veterinary Drug Residues in Foods (Forty-eighth Report of the Joint FAO/WHO Expert Committee on Food Additives). WHO Technical Report Series No. 879, 1998.
14. Evaluation of Certain Veterinary Drug Residues in Foods (Fiftieth Report of the Joint FAO/WHO Expert Committee on Food Additives). WHO Technical Report Series No. 888, 1999.
15. Evaluation of Certain Veterinary Drug Residues in Foods (Fifty-second Report of the Joint FAO/WHO Expert Committee on Food Additives). WHO Technical Report Series No. 893, 2000.

16. Residues of Veterinary Drugs in Foods, Report of a Joint FAO/WHO Consultation, Rome, 29 October - 5 November 1984. FAO Food and Nutrition Paper No. 32, 1985.
17. Report of the First Session of the Codex Committee on Residues of Veterinary Drugs in Foods. Washington, D.C., 27-31, October 1986.
18. Report: JECFA/JMPR Informal Harmonization Meeting, 1-2 February, 1999, Rome, Italy, 1999.
19. Evaluation of Certain Veterinary Drug Residues in Foods (Fifty-fourth Report of the Joint FAO/WHO Expert Committee on Food Additives). WHO Technical Report Series No. 900, 2001.
20. Evaluation of Certain Veterinary Drug Residues in Foods (Fifty-eighth report of the Joint FAO/WHO Expert Committee on Food Additives). WHO Technical Report Series No. 900, 2001.
21. Evaluation of Certain Veterinary Drug Residues in Foods (Sixtieth report of the Joint FAO/WHO Expert Committee on Food Additives). WHO Technical Report Series, No. 918, 2003.
22. Evaluation of Certain Veterinary Drug Residues in Animals and Foods (Sixty-second report of the Joint FAO/WHO Expert Committee on Food Additives). WHO Technical Report Series, No. 925, 2004.
23. Standards Australia. *Australian Standard.™ Numerical values — Rounding and interpretation of limiting values*. Australian Standard AS 2706-2003. December 2003 (ISBN 0-7337-5471-6).
24. Final report from Workshop on Update of Principles and Methods of Risk Assessment – MRLs for pesticides and veterinary drugs. FAO/RIVM/WHO, Bilthoven, the Netherlands, 7-11 November, 2005.

GENERAL CONSIDERATIONS

Note: Only the general considerations on risk assessment principles discussed and adopted by the Committee at its 66th meeting which are considered pertinent for the reading of the monographs and for future assessments of veterinary drug residues are provided here.

Considerations related to the terms of reference of JECFA

Criteria for compounds to come on the JECFA agenda

The Committee considered the current criteria established by Codex for veterinary drugs to be evaluated by JECFA. These criteria are:

In order to be placed on the CCRVDF priority list for the development of an MRL, the candidate veterinary drug, when used in accordance with good veterinary practices, should meet some, but not necessarily all, of the following criteria:

1. Use of the drug will have potential to cause public health and/or trade problems;
2. Drug available as commercial product;
3. Commitment that a dossier will be available.

The Committee considered that the process of prioritization of veterinary drugs for evaluation by Codex and the process of risk assessment of the veterinary drug by JECFA would be greatly improved by adherence to these criteria and provision of the information to the JECFA Secretariat.

Issues relating to data availability

In reaching its conclusions on ADIs and MRLs, the Committee evaluates the available data, including those submitted by the sponsor and those identified in a search of the open literature. The Committee's decisions depend on consideration of the primary data. Limited reliance is placed on summary or review data alone, if not supported by relevant primary data. On a number of occasions, limited or at times no data are available for evaluation of compounds on the meeting agenda. Hence, in these instances, the Committee is unable to complete its evaluation because of significant gaps in the database. On such occasions, the Committee will identify the critical gaps and will suggest those additional data that should enable the evaluation to be concluded. The Committee is concerned that even after a reasonable time interval, appropriate data are not being either generated or submitted to the Committee. It is important to note that JECFA is not a regulatory body and has no means to compel data submission. Hence, possible strategies to help resolve these issues were sought.

The Committee proposes that two lists of veterinary drugs of public health concern be introduced. These lists would include the following categories of veterinary drugs:

- i) Veterinary drugs for which significant concerns had been identified, either because of incomplete information or pending resolution of a problem identified in the evaluation;
- ii) Veterinary drugs for which the significant concerns noted in i) were not addressed, despite requests for data to resolve the outstanding issues. It is recommended that these compounds should not be used in food-producing animals until outstanding data are provided and evaluated by JECFA.

Compounds would remain in category i) for a specified period and then either would be removed from the list because of resolution of the concerns or would be moved to category ii). The Committee recommends that CCRVDF take an active role in establishing and supporting such lists and should emphasize the need for Codex members and commercial entities to fulfil their responsibility in submitting relevant data in a timely manner.

Information on approved uses

Assessment of efficacy is not within the mandate of the Committee. However, since one of the criteria for scheduling a compound for JECFA evaluation is that the veterinary product containing the active compound is currently registered by a national or regional authority, confirmation of its authorization, including approved dosages and conditions of use, should be provided in the data submission.

Risk–benefit comparison

The Committee recognizes that CCRVDF may use risk–benefit considerations in prioritizing compounds for evaluation. The number of veterinary drugs available and approved for certain therapeutic indications is very limited, and there is general concern that loss of a compound may have significant impact on food animals and derived products. Consideration of the relative benefit provided by the availability of such a drug is outside the scope of the Committee, which has neither the mandate nor the expertise to address such questions. Hence, JECFA will continue to restrict its considerations to the human health risks of the compound.

Considerations related to flexibility in the scientific process of JECFA risk assessments

The Committee discussed the rapid developments in science typified by the fields of genomics, proteomics, analytical chemistry, mathematical modelling and toxicological testing, together with the need to be able to bring to bear the most appropriate tools in the evaluation of veterinary drugs. The Committee recognized the continued need for flexibility in its approach and the importance of balancing this flexibility with consistency. The Committee also recognized that some of these new tools and technologies may require validation.

JECFA risk assessment should not be tied to specific approaches. JECFA will continue to apply the necessary flexibility to bring to bear the most appropriate science and risk assessment techniques.

A decision-tree approach in the evaluation of veterinary drugs by JECFA

The Committee recommended that the JECFA Secretariat convene a working group to develop a general decision-tree for the evaluation of veterinary drugs, which would identify different options for hazard identification, hazard characterization and exposure assessment. The proposed approach will then be discussed at the next JECFA meeting dedicated to the assessment of veterinary drugs. The decision-tree would be anticipated to provide a tool to assist in assessing different options in the evaluation of the veterinary drug, including the determination of a “traditional” ADI and recommended MRL. The decision-tree is envisioned as a flexible document that will be adapted to advancement in science and in response to the nature of the compounds under evaluation. The working group will be expected to develop possible branches to the decision-tree to make use of the best science available. Other options that may be considered are the use of a threshold of toxicological concern as an alternative to an ADI and recommendations for analytical methods for the detection of residues of the drug in the absence of a formal MRL.

Expression of the ADI and derivation of the MRL

CCRVDF at its 15th session discussed rounding practices when establishing ADIs and recommending MRLs for veterinary drug residues and requested JECFA to comment on certain practices suggested by CCRVDF.

The Committee considered the expression of the ADI at its thirty-sixth meeting in 1990. The Committee decided to express the ADI numerically to only one significant figure. If an ADI is calculated from a NOEL that has more than one significant figure, the ADI would therefore be rounded to one significant figure, consistent with accepted rounding procedures.

In the past, JECFA has applied its rounding practice to the derivation of ADIs for 25 veterinary drugs, resulting in 14 ADIs that have been rounded down and 11 ADIs that have been rounded up. Most of the veterinary drugs that have been reviewed by JECFA resulted in a calculated ADI of one significant figure without rounding.

The present Committee noted that the recommendation from CCRVDF in its report of the 15th session suggests a misunderstanding of the relationship between the ADI and the derivation of the MRL.

One of the functions of JECFA is to establish health-based guidance values for residues of veterinary drugs, most often an ADI. The ADI is an output of a risk assessment of the compound, following application of the first two steps of the risk assessment paradigm: hazard identification and hazard characterization. As such, it represents a health-based guidance value, where exposure is considered to represent a negligible risk to consumers if it does not exceed this value. The ADI has a number of uses in risk assessment and risk management, only one of which is in helping to derive the recommended MRLs.

The MRL and the ADI are separate outputs of the risk assessment process and serve different purposes.

The ADI is derived from the NOEL or lowest-observed-effect level (LOEL) from the appropriate toxicological studies, using a safety factor. Given that there are assumptions and uncertainties in deriving the ADI, such as the use of safety factors, the use of a range of doses in toxicological studies and normal biological variation, it is more meaningful to express the ADI to only one significant figure to avoid any inference of inappropriate precision.

The general rounding rule for mid-way values (x.5) is to round up, in line with common convention (see, for example, Australian Standard AS 2706-2003 (reference 23)). Examples for rounding to one significant figure are as follows: 1.25 becomes 1, 0.73 becomes 0.7 and 1.5 becomes 2.


The MRL recommendation procedure is an iterative process. The MRL is not derived directly from the ADI. If the ADI is based on toxicological end-points, all residues of toxicological relevance are considered; if the ADI is based on microbiological end-points, all residues of microbiological relevance are considered. The MRL recommendation procedure also takes into account the conditions of use (e.g. use of the veterinary drug according to good practice in the use of veterinary drugs, or GPVD) and the residues that result from such use (e.g. residue depletion studies). It also considers results of radiolabelled residue studies, the bioavailability of bound residues, the identification of target tissues and a marker residue, the availability of practical analytical methods, estimated exposure resulting from recommended MRLs and consideration of extension of the MRLs to tissues, eggs and milk of other species.

The initial consideration in recommending an MRL is whether it is sufficiently protective of human health. If the use of the veterinary drug yields an estimated intake of veterinary drug residues consistent with the ADI, the recommended MRLs may then be adjusted accordingly when taking into account the other factors noted above. As a general principle, the Committee will not normally recommend an MRL that results in residue levels that lead to dietary intake exceeding the ADI based on toxicological or microbiological considerations.

To protect consumers in all segments of the population, historically the Committee has based its recommendations on intakes estimated using a conservative model diet consisting of 300 g of muscle, 100 g of liver, 50 g of kidney and fat, 1.5 kg of milk and 100 g of eggs. Previously, the Committee estimated intakes by using MRLs to derive a theoretical maximum daily intake (TMDI). At the current meeting, the Committee modified this procedure and is now using the median residue levels to derive an estimated daily intake (EDI) to better reflect estimates of chronic (lifetime) exposure (see section 2.4.1).

Figure 1 is an update of the figure prepared during the Bilthoven MRL workshop (reference 24).

Figure 1: The JECFA residue evaluation process




The Committee confirmed that the rounding practices used in expressing the ADI are scientifically and mathematically sound. In addition, since the ADI is not directly used in the derivation of the MRL, the JECFA rounding practices have no direct consequence on the MRL.

New procedure for estimating chronic dietary intakes

The estimation of long-term (chronic) dietary intakes of residues of veterinary drugs by the Committee was in the past closely linked to the determination of the MRLs recommended by the Committee. The Committee used a calculated figure of total residue of toxicological or microbiological concern, the “theoretical maximum daily intake” (TMDI), for comparison with the ADI. The new procedure uses the same formula as used previously for the calculation of the TMDI, including factors such as the ratio of marker to total residue concentrations, the only exception being that the median concentration replaces the MRL as the point estimate of the residue concentration in the formula.

The MRL and the median concentration are derived from the same time point of the depletion data of the marker residue. The MRL is a point on the curve describing the upper one-sided 95% confidence limit over the 95th percentile. The median is the corresponding point on the regression line for the same time point. Both figures are obtained from a statistical evaluation of the data (see Figure 2).

Figure 2: Explanation of the relationship between MRL and the median concentration used for the calculation of the estimated daily intake (EDI)



In developing this new calculation procedure, the present Committee concluded that the TMDI was no longer the most suitable estimate of chronic intake, because the MRL was a single concentration representing the estimated upper limit of a high percentile of the distribution of marker residue present in a given tissue of the treated animals. The Committee concluded that it was not realistic to use an extreme value of the distribution in a scenario describing chronic intakes. In such a scenario, all concentrations of the distribution of residues should be considered. The median concentration represents the best point estimate of a central tendency over a prolonged period of time, because the concentrations of residues in a given tissue consumed varies from day to day, as reflected in the distribution. Therefore, the Committee decided to use the median of the residue distribution to substitute for the MRL in the intake estimate. The new estimate of intake is called “estimated daily intake” (EDI). In calculating the median from an array of results, including values below the limit of quantification (LOQ) or below the limit of detection (LOD), half of the respective limit is used for the calculation of median concentrations of residues.

COLISTIN

First draft prepared by
Lynn G. Friedlander, Rockville, MD, United States
and
Dieter Arnold, Berlin, Germany

IDENTITY

International Non-proprietary names (INN): Colistin sulphate, Colistimethate sodium (sodium colistin methanesulfonate)

Synonyms Polymyxin E₁ = Colistin A, Polymyxin E₂ = Colistin B, Polymyxin E sulfate = Colistin sulphate, Colistini sulfas, Multimycine, Colomycin, First Guard Sterile Powder

International Union of Pure and Applied Chemistry (IUPAC) Names


Colistin A: N-[3-amino-1-[[1-[[3-amino-1-[[6,9,18-tris(2-aminoethyl)-3-(1-hydroxyethyl)-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]carbamoyl]propyl]carbamoyl]-2-hydroxypropyl]carbamoyl]propyl]-6-methyl-octanamide

Colistin B: N-[3-amino-1-[[1-[[3-amino-1-[[6,9,18-tris(2-aminoethyl)-3-(1-hydroxyethyl)-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]carbamoyl]propyl]carbamoyl]-2-hydroxypropyl]carbamoyl]propyl]-5-methyl-heptanamide

Colistimethate sodium: pentasodium[3-[[3-(1-hydroxyethyl)-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-6,9,18-tris[2-(sulfonatomethylamino)ethyl]-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]carbamoyl]-3-[3-hydroxy-2-[2-(6-methyloctanoylamino)-4-(sulfonatomethylamino)butanoyl]amino-butanoyl]amino-propyl]aminomethanesulfonate

Chemical Abstract Service Number: Colistin base: CAS 1066-17-7
Colistin sulfate: CAS 1264-72-8
Colistimethate sodium: CAS 8068-28-8

Structural formula of the main components:



Dbu is α, γ -diaminobutyric acid.
R = 5-methylheptyl (iso-octyl) in colistin A
R = 5-methylhexyl in colistin B

Molecular formula:

Colistin A:	$C_{53}H_{100}N_{16}O_{13}$
Colistin B:	$C_{52}H_{98}N_{16}O_{13}$
Colistimethate sodium:	$C_{58}H_{105}N_{16}Na_5O_{28}S_5$

Molecular weight: (The Merck Index, 2001, European Pharmacopoeia 5.0, 01/2005:0319; European Pharmacopoeia 5.3, 01/2006:320):

Colistin A:	1169.460
Colistin B:	1155.430
Colistimethate sodium:	1749.840

OTHER INFORMATION ON IDENTITY AND PROPERTIES

Pure active ingredient: Colistin (as sulfate or methansulphonate salt)

Appearance: Crystalline powder

Melting point: 215-219 °C (colistin sulfate)
222-223 °C (colistimethate sodium)

Solubility: Colistin salts are freely soluble in water. At 20° C, less than 1 mL of water is required to dissolve 1 g colistin.
Colistin salts are practically insoluble in ether, acetone and chloroform and slightly soluble in methyl alcohol. At 20° C, more than 10,000 mL of these solvents are required to dissolve 1 g colistin

Optical rotation: Polymyxin E₁ = $[\alpha]_{5461}^{22} = -93.3^\circ$ (2% Acetic Acid)
Polymyxin E₂ = $[\alpha]_{5461}^{22} = -94.5^\circ$ (2% Acetic Acid)

UVmax: 220 nm

RESIDUES IN FOOD AND THEIR EVALUATION**Conditions of Use**

An antibiotic originally named “colimycin” was first isolated by Koyama et al, from the broth of *Bacillus polymyxa* var. *colistinus* in 1950 (Koyama et al., 1950). Colistin comprises a multi-component family of polymyxins. It differs from polymyxin B, the other therapeutically used polymyxin, only by one amino acid in position 6 (D-Leucine in colistin, Phenylalanine in polymyxin B). The general structure comprises a cyclic heptapeptide moiety with a straight tripeptide side chain. The peptide contains six L- α,γ -diaminobutyric acid (DAB) residues. The peptides are cyclised through the α -amino and carboxyl groups of the DAB residue in position 4. The linear peptide chain is attached through the γ -amino group of this residue. The N-terminal amino group in the side chain is acylated.

Although colistin was first separated into three components, A, B, and C, in 1953, the basic structure of these components was elucidated in the years 1953-1965 (Suzuki et al., 1963a; Suzuki et al., 1963b; Suzuki et al., 1963c; Studer et al., 1965).

Several (hyphenated) chromatographic techniques and chemical syntheses have been used to analyze the complex composition of these products further and this has resulted in the discovery of a great number of minor components (Thomas et al., 1980; Elverdam et al., 1981; Ikai et al., 1998; Kline et al., 2001; Orwa et al., 2001; Govaerts et al., 2002; Govaerts et al., 2003).

Colistins are highly effective against strains of *Escherichia coli*, *Pseudomonas aeruginosa*, *Salmonella* spp., *Haemophilus* spp., *Shigella* spp., *Pasteurella* spp., *Brucella* spp., *Aerobacter aerogenes*, and *Bordetella bronchiseptica*. Gram-positive bacteria are generally less sensitive. However, there are sensitive strains of *Staphylococcus* spp., *Bacillus* spp., *Streptococcus pyogenes* and *Corynebacterium* spp. (Storm et al., 1977).

The polymyxin broad-spectrum of activity against Gram-negative bacteria involves binding to lipid A, the anchor for lipopolysaccharide, the main constituent of the outer membrane of these bacteria. The presence on the (positively charged) cyclic heptapeptide of both the tripeptide and the terminal acyl group are considered necessary for the full bactericidal effects of colistin (Nakajima, 1967). Polymyxins containing the longer 6-methyloctanoic acid seem to be more active than the 6-methylheptanoic acid derivatives. Removal of the acyl moiety results in a 30% decrease of the activity. One may assume as a general model that the lipophilic part of the molecule lies on or inserts into the hydrophobic portion of the membrane while the poly-cationic peptide part interacts with membrane polar groups (Pristovšek and Kidrič, 1999). These interactions lead to disruption of the structure and rapid permeability changes of the membranes. Other known effects, e.g., inhibition of respiration, may be secondary to these primary effects. The polymyxins, including colistin, also have important lipopolysaccharide neutralizing effects (Pristovšek and Kidrič, 2001).

Colistin is available as the sulfate salt and as colistimethate sodium. It is administered orally (colistin sulfate) and parenterally (colistin sulfate, colistimethate sodium). A formulation intended for intramammary use is available and, in humans, colistimethate sodium is administered as an aerosol (Li et al., 2003).

Colistin is used for the prevention and treatment of diseases caused by sensitive bacteria in a variety of species, including cattle, sheep, goats, pigs, poultry and rabbits. In cattle, swine, and poultry, colistin is used to treat digestive diseases caused by *Escherichia coli* and *Salmonella* spp (EMA, 1995; EMA, 2002). In humans, colistin is used to treat infections caused by drug-resistant *Pseudomonas aeruginosa* (Li et al., 2003). According to a very recent review performed by Falagas and Kasiakou (2005), intravenous polymyxin therapy (mostly colistin therapy) has been re-introduced in clinical practice for treatment of infections caused by multi-drug-resistant Gram-negative bacteria.

Colistin is marketed as a single component product and in formulations containing other antimicrobial agents (e.g., various sulfonamides, spiramycin, erythromycin, trimethoprim, neomycin, and oxytetracycline). Formulations containing colistin also are available with antidiarrhoeal agents (e.g., N-butyl scopolamine, kaolin) and vitamins (Meiji Seika Kaisha, Ltd., 1992a).

Dosage

Dosages for colistin are provided in international units (IU) or by weight (mg). An International Standard for Colistin Sulfate has been established and an International Unit defined as the activity contained in 0.00004878 mg of this preparation. The unit was defined

on the basis of a collaborative assay in which nine laboratories from six different countries participated (Lightbown, et al., 1973, WHO Expert Committee on Biological Standardization, 21st Report, 1969). According to the European Pharmacopoeia (5.0, 01/2005:0319), one mg of colistin methanesulfonate should not have a potency less than 11,500 IU.

From the definition of the IU, the material contains 20500 IU/mg. A sponsor has analysed three production batches and five official reference standards, including the WHO standard, for their contents of impurities. Using HPLC, a minor peak in addition to colistin A and B, was detected in all samples. The concentration equivalents ranged from 17.4 to 19.1% for the production batches and was 20.4% for the WHO standard. The European Pharmacopoeia defines colistin sulfate as: “A mixture of the sulfates of polypeptides produced by certain strains of *Bacillus polymyxa* var. *colistinus* or obtained by any other means. It contains a minimum of 77% of the sum of polymyxin E₁, polymyxin E₂, polymyxin E₃, polymyxin E₁₋₁ and polymyxin E₁₇MOA” (Martindale, 1999; Sweetman, 2006).

Doses vary by product and species but generally the daily dose recommended for colistin sulfate is 75,000 IU/kg in poultry and 100,000 IU/kg in the other species (calves, pigs and rabbits). These doses correspond to approximately 3.75-5 mg/kg b.w., respectively. Colistin may be administered in water, milk, complete feed, or by injection. Colistin is administered as 0.01-0.02% of daily milk intake. In water, colistin is administered at 25-50 mg/L. Colistin is administered in complete feed as medicated premixes containing 20 to 40 M IU/100g at a rate of 5-10 kg/tonne (Meiji Seika Kaisha, Ltd., 1992a). Injectable colistin is administered to 1-3-day-old chickens at a dose of 0.2 mg colistin activity/chick (US FDA, 1998)

PHARMACOKINETICS AND METABOLISM

Pharmacokinetics in Humans and Laboratory Animals

In humans, laboratory animals and the target species, colistin sulfate is poorly absorbed following oral administration (Schwartz, 1964; Blood and Radostits, 1989). Plasma concentrations are usually undetectable after oral administration. Enhanced oral absorption is seen in neonatal animals (Schwartz, 1964). Absorption from mucous surfaces and the mammary gland is minimal (Blood and Radostits, 1989). Plasma concentrations were higher following administration of colistimethate sodium than colistin sulfate (Al-Khayyat and Aronson, 1973; Blood and Radostits, 1989).

In humans, intramuscular administration of colistimethate sodium (30 mg base activity) resulted in therapeutic drug concentrations in serum that persisted for 6 hours. A dose of 75 mg colistin base produced peak serum concentrations of 3 µg/mL in 2 hours and detectable serum concentrations for 12 hours. When the dose was increased to 150 mg colistin base, serum concentrations averaged 7.6 mg/mL in 2 hours and persisted for 24 hours (Schwartz, 1964). In patients with cystic fibrosis, intravenous administration of colistin sulfate and colistimethate resulted in mean plasma elimination half-lives ranging from approximately 2 hours for colistimethate sodium to more than 4 hours for colistin (Li et. al, 2003).

Following intramuscular administration of colistin sulfate in dogs, peak plasma concentrations were reported approximately 0.5-1 hour after dosing. Maximum plasma concentrations were 2.8 µg/mL, 7.1 µg/mL and 17.7 µg/mL, respectively, for the 1.1 mg/kg, 2.2 mg/kg and 4.4 mg/kg intramuscular doses. The excretion half-life was approximately 2.7 hours, irrespective of dose. Colistin sulfate had a percent volume of distribution of 33-74%, thus exceeding the extracellular fluid space. Higher doses produced lower distributions. For colistimethate sodium, the volume of distribution was approximately equal to the extracellular space (i.e., 23%). Drug accumulated in liver, kidneys and brain and was mainly present as a bound residue. The renal clearance of colistimethate sodium was 3.85 mL/min/kg, or approximate 79% of the inulin clearance (i.e., 3.85 mL/min/kg for colistimethate sodium vs.

4.91 mL/min/kg for inulin). In dogs, excretion was via the urine following parenteral administration. There were no detectable residues in faeces. Conversely, following oral administration, excretion was via the faeces, often bound to intestinal phospholipids. Following both parenteral and oral administration, colistin is excreted in an inactive form (Al-Khayyat and Aronson, 1973).

Pharmacokinetics in Food Producing Animals

In milk-fed calves, intravenous administration of colistin sulfate, 5 mg/kg, resulted in a peak serum concentration of approximately 16 µg/mL. The volume of distribution was 1.3 L/kg and renal clearance was approximately 3.4 mL/min/kg. Colistin is significantly bound to tissues following an intravenous dose of 5 mg/kg. The excretion half-life was 4-6 hours (Ziv et al, 1982; Blood and Radostits, 1989).

Following intramuscular administration of colistimethate sodium (50,000 IU/kg equivalent to 4 mg/kg) to lactating dairy cows and calves, residues persisted in serum for several hours. In cows, the maximum serum concentrations occurred between 0.5 and 3 hours after dosing. The mean maximum concentration was 60 IU/mL. In calves, peak serum concentrations were reached between 1 and 2 hours after dosing. The mean maximum concentration was 81 IU/mL. The calculated elimination half-life was nearly double in cows compared to calves (i.e., 6.8 hr vs. 4.5 hr). Concentrations in the milk were generally low and were detectable through 2 milkings. Oral administration of colistin sulfate in veal calves resulted in no residues in excess of the limit of detection for the well-diffusion microbiological method (i.e., 1 IU/mL) (Archimbault et al., 1980). In another report, the peak concentration of colistin in serum occurred 2 hours after dosing and colistin was detectable in the serum for only 6 hours after intramuscular administration. Serum concentrations ranged from 0.1 to 1 µg/mL. There were no detectable serum concentrations following oral administration (Escoula et al., 1981).

In ewes, intramuscular administration of colistimethate sodium resulted in higher serum concentrations than did intramuscular administration of colistin sulfate for doses of 7.5 mg/kg and 3.5 mg/kg. Serum protein binding was higher for colistin sulfate than for colistimethate (Ziv and Sulman, 1973). These findings are identical to those determined for dogs (Al-Khayyat and Aronson, 1973).

Plasma protein binding of colistin in cattle and sheep is 40% and 70%, respectively.

In chickens, maximum concentrations of 10.2 µg/mL and 5.7 µg/mL are detected in serum and bile, respectively, approximately 2 hours after an oral dose of 50 mg/kg b.w.. In pigs, concentrations of 1.0 µg/mL and 4.0 µg/mL are detected in serum and bile, respectively, after an oral dose of 25 mg/kg b.w.. Concentrations of 8.3 µg/mL and 9.0 µg/mL are detected in serum and bile, respectively, after an oral dose of 50 mg/kg b.w. (Sato et al., 1972).

Pigs were treated intravenously with colistin sulfate at two doses: 25 mg potency/kg and 50 mg potency/kg. Peak serum concentrations of 1.0 µg/mL and 8.3 µg/mL were reached at 1 hour after administration for the 25 mg/kg and 50 mg/kg doses, respectively. Serum concentrations were undetectable at sampling times thereafter (Sato et al., 1972). In another study, no detectable concentrations of colistin were detected in the serum of gnotobiotic piglets fed colistin sulfate, 40mg/kg, in sterilized milk (Terakado et al., 1972).

In a more recent study, pigs were treated intramuscularly with colistin sulfate at doses of 5.0 mg/kg and 2.5 mg/kg and intravenously at a dose of 2.5 mg/kg. For the intramuscular route of administration, peak plasma concentrations were reached 30 minutes after dosing. The elimination half-life for all doses and routes was approximately 4-4.5 hours and the clearance rate was approximately 3 mL/kg/min (Lin et al., 2005).

Metabolism in Laboratory Animals

Information on the metabolism of colistin in laboratory animal species is limited.

Rats

In an *in vitro* study intended to determine whether low recovery of colistin activity from rat tissue homogenates was due to tissue binding or metabolism, colistin sulfate and colistimethate were added to homogenates of rat kidney and liver tissues, with and without 2 M HCl. In the absence of HCl, only 15% of the added colistin was recovered from the kidney and liver homogenates. Adding equal volumes of 2 M HCl to the homogenates resulted in complete (103%) recovery of the added colistin. Recovery of colistimethate from rat kidney homogenates in the absence of 2M HCl was approximately 81%. Because stability of colistin sulfate had previously been demonstrated in the presence of 2 M HCl, it was concluded that the loss of colistin activity in the homogenates was due to tissue binding rather than metabolism (Al-Khayyat and Aronson, 1973).

Dogs

There are limited data to suggest that dogs can metabolize colistin to a compound devoid of antimicrobial activity (Al-Khayyat and Aronson, 1973). At the doses studied, approximately 67% of the colistin excreted in the urine consisted of antibacterially active colistin whereas 33% consisted of an antibacterially inactive metabolite (Al-Khayyat and Aronson, 1973). The authors note, however, that the tested doses were higher than normal therapeutic doses and may not reflect the importance of metabolism at doses in the therapeutic range. Additionally, there was no attempt made to identify the metabolite.

Metabolism in Food Producing Animals

Cattle

In cattle treated intraruminally with colistin and erythromycin, no colistin activity was detected in rumen fluid (Escoula et al., 1981).

Chickens

In a radiolabelled study, radioactivity in cage droppings was determined following a single subcutaneous administration of colistimethate to day-old chickens. Less than 33% of the administered dose was recovered through 28 days of sampling. In samples collected for the first 12 hours, antimicrobial activity represented less than 0.1% of the total dose. Activity was confirmed to be colistin by HPLC. Subsequent excreta samples had no antimicrobial activity (US FDA, 1998).

TISSUE RESIDUE DEPLETION STUDIES

Radiolabelled Residue Depletion Studies

General

Radiolabelled residue data were not provided for orally administered colistin sulfate in any species.

Limited radiolabelled data are available for injectable colistimethate sodium in day-old chickens (US FDA, 1998). Chicks were treated subcutaneously one time with ¹⁴C-colistimethate sodium to provide 0.2 mg colistin potency. Residue concentrations were

comparable for male and female chicks. Total radiolabelled residues were determined at 14, 21 and 28 days after treatment and are summarized in Table 1.

Extraction studies demonstrate that most of the residues in muscle were bound to tissue. While little residue was extracted following acid protease digestion (mean = 1.4%), more than 65% was extracted when the protease treatment was followed by alkaline extraction. When the alkaline extracts were tested for antimicrobial activity, none was detected. In a second study, the antimicrobial activity in enzyme-extracted tissues from treated chickens was compared to antimicrobial activity in enzyme-extracted control tissues. There was no difference in the antimicrobial activity of the tissues from treated and control birds activity (US FDA, 1998).

Table 1: Total radiolabelled residues in chicken tissues following a single subcutaneous administration of ¹⁴C-colistimethate sodium at a dose of 0.2 mg colistin potency/chicken

Tissue	Concentration Colistin equivalents (mg/kg)					
	Withdrawal Time (days)					
	14		21		28	
	Males	Females	Males	Females	Males	Females
Liver	0.51	0.52	0.17	0.18	0.07	0.08
Muscle	0.51	0.55	0.23	0.24	0.12	0.14
Skin/fat	0.29	0.32	0.12	0.12	0.07	0.07
Injection site	0.51	0.65	0.21	0.22	0.12	0.12

Residue Depletion Studies with Unlabelled Drug

Cattle

In a study in calves, animals were treated orally for 3 days with colistin sulfate to provide 5 mg potency/kg body weight or 10 mg potency/kg body weight. This represents the highest normal dose and twice the normal dose, respectively. Drug was administered by gastric catheter in 150 mL tap water. Blood samples were collected before administration and at 1, 2, 4, 6, 24, and 72 hours after the final dose. Tissues were collected 72 hours after the final dose. Samples were analyzed using a microbiological assay (test organism = *Bordetella bronchiseptica*, ATCC 4617) with a limit of detection of 0.05 µg potency/g (bile = 0.1 µg potency/g). In a recovery test, recovery of colistin from all tested samples was good with acceptable CVs. None of the tested samples had concentrations of colistin activity above the limit of detection of the assay (Research Institute for Animal Science in Biochemistry and Toxicology, 1990a).

In a more recent study (Meiji Seika Kaisha, Ltd., 1999e), four calves were treated with milk replacer containing colistin to provide 100,000 IU/kg b.w.. Animals were treated twice daily for 7 days. Drug was mixed in 1/3 of the total volume of milk to be administered morning and evening. Calves were slaughtered 6 hours after the final treatment. Samples of muscle, liver, kidney and fat were collected and kept frozen (- 80°C) until analyzed. Concentrations of colistin in tissues were determined using a validated HPLC method (see Methods of Analysis, below). Residues were detected in three of four kidney samples. One of the three kidneys contained 139 µg/kg of residues. The study was conducted in compliance with GLP.

Pigs

In a study in pigs, animals were treated orally for 3 days with colistin sulfate to provide 10 mg potency/kg body weight or 20 mg potency/kg body weight. This represents the highest normal dose and twice the normal dose, respectively. Drug was administered by gastric catheter in 150 mL tap water. Blood samples were collected before administration and at 1, 2, 4, 6, 24, and 72 hours after the final dose. Tissues were collected 72 hours after the final dose. Samples were analyzed using the microbiological assay described above. In a recovery test, recovery of colistin from all tested samples was good with acceptable CVs. A low concentration of residual drug was detected in plasma collected 1 hour after the final dose. Thereafter, no detectable drug was found in plasma. None of the tissue samples had concentrations of colistin activity above the limit of detection of the assay (Research Institute for Animal Science in Biochemistry and Toxicology, 1990b).

In a second study in pigs, animals were treated orally for 4 months with colistin sulfate to provide 40 mg potency/kg body weight or 200 mg potency/kg body weight. This represents the highest normal dose and five times the normal dose. Drug was administered in commercial feed. Tissues were collected on the day of drug withdrawal, 1-day following the final dose and 3 days following the final dose. Samples of muscle, fat, liver and kidneys were analyzed using the microbiological assay described above with a limit of detection of 0.03 µg potency/g. In a recovery test, recovery of colistin from all tested samples was acceptable. None of the tissue samples had concentrations of colistin activity above the limit of detection of the assay at any of the withdrawal times (Meiji Seika Kaisha, Ltd., 1978).

In a more recent study (Meiji Seika Kaisha, Ltd., 2000d), four pigs were treated with colistin to provide 100,000 IU/kg b.w.. Animals were treated twice daily for 5 days. Drug was mixed with a small quantity of feed and given by oral gavage before the morning and evening meals at the recommended dose. Pigs were slaughtered 6 hours after the final treatment. Samples of muscle, liver, kidney and skin+fat were collected and kept frozen (-80°C) until analyzed. Concentrations of colistin in tissues were determined using the validated HPLC method (see Methods of Analysis, below). Colistin was detected in all samples of liver and of skin and fat and in one sample of kidney, however, no quantifiable residues were found. Individual residue values (integration of the polymyxin E₁ and polymyxin E₂ peaks) are summarized in Table 2. The study was conducted in compliance with GLP.

Table 2: Colistin residues (µg/kg) in tissues of pigs

Withdrawal (hours)	Animal #	Muscle	Liver	Kidney	Skin+Fat
6	1M	<LOD	<LOQ	<LOQ	<LOQ
	2M	<LOD	<LOQ	<LOD	<LOQ
	7F	<LOD	<LOQ	<LOD	<LOQ
	8F	<LOD	<LOQ	<LOD	<LOQ

These samples were subsequently used to validate the microbiological assay (Meiji Seika Kaisha Ltd, 2001). All of the incurred pig samples had residues below the microbiological assay LOQ of 100 µg/kg.

Chickens

In a study (Meiji Seika Kaisha, Ltd., 2000c), six chickens were treated with colistin to provide 100,000 IU/kg b.w.. Animals were treated twice daily for 5 days. Drug was mixed with a small quantity of feed and given by oral gavage before the morning and evening meals. This is the recommended dose. Chickens were slaughtered 6 hours after the final treatment.

Samples of breast muscle, liver, kidney and skin+fat were collected and kept frozen (-80°C) until analyzed. Concentrations of colistin in tissues were determined using the validated HPLC method (see Methods of Analysis, below). Colistin was detected in one sample of fat and skin and in three samples of kidney. The kidney of one female contained 184 µg/kg of residues. Individual residue values (integration of the polymyxin E₁ and polymyxin E₂ peaks) are summarized in Table 3. The study was conducted in compliance with GLP.

Table 3: Colistin residues (µg/kg) in tissues of chickens

Withdrawal (hours)	Animal #	Muscle	Liver	Kidney	Skin+Fat
6	1M	<LOD	<LOD	<LOD	<LOQ
	2M	<LOD	<LOD	<LOD	<LOD
	3M	<LOD	<LOD	<LOD	<LOD
	10F	<LOD	<LOD	<LOQ	<LOD
	11F	<LOD	<LOD	<LOQ	<LOD
	12F	<LOD	<LOD	184	<LOD

Turkeys

In a study (Meiji Seika Kaisha, Ltd., 2000f), six turkeys were treated with colistin to provide 100,000 IU/kg b.w. Animals were treated twice daily for 5 days. Drug was mixed with a small quantity of water and given by oral gavage before the morning and evening meals. This is the recommended dose. Turkeys were slaughtered 6 hours after the final treatment. Samples of breast muscle, liver, kidney and skin+fat were collected and kept frozen (-80°C) until analyzed. Concentrations of colistin in tissues were determined using the validated HPLC method (see Methods of Analysis, below). Colistin was found in all muscle samples, in five samples of skin and fat, and in one sample of kidney. The kidney of one female animal contained 194.5 µg/kg of residues. Skin and fat of the same animal contained 98 µg/kg. Individual residue values (integration of the polymyxin E₁ and polymyxin E₂ peaks) are summarized in Table 4. The study was conducted in compliance with GLP.

Table 4: Colistin residues (µg/kg) in tissues of turkeys

Withdrawal (hours)	Animal #	Muscle	Liver	Kidney	Skin+Fat
6	1M	<LOQ	<LOD	<LOD	<LOQ
	2M	<LOQ	<LOD	<LOD	<LOQ
	3M	<LOQ	<LOD	<LOD	<LOD
	4F	<LOQ	<LOD	<LOD	<LOQ
	5F	<LOQ	<LOD	194.5	98
	6F	<LOQ	<LOD	<LOD	<LOQ

All the residues were below the LOQ for the method with the exception of one animal in which the kidney sample contained 194.5 µg/kg and the skin+fat sample contained.

Rabbits

In this study (Meiji Seika Kaisha, Ltd., 2000g), twelve rabbits were treated with colistin to provide 100,000 IU/kg b.w.. Animals were treated twice daily for 5 days. Drug was mixed with a small quantity of water and given by oral gavage before the morning and evening meals. This is the recommended dose. Rabbits were slaughtered in groups of 4 rabbits each at 6, 24 and 48 hours after the final treatment. Samples of muscle, liver, kidney and fat were collected and kept frozen (-80°C) until analyzed. Concentrations of colistin in tissues were

determined using the validated HPLC method (see Methods of Analysis, below). Colistin residues were found in all fat samples, in four kidney samples and in two muscle samples. All the residues in muscle and liver were below the LOQ for the method. Two kidney samples collected 6 hours after the final treatment contained quantifiable residues. At later sampling times, kidney residues were below the LOQ for the method. Low but quantifiable concentrations were detected in all of the fat collected 6 hours withdrawal. Both fat samples collected from male rabbits at 24 hours withdrawal contained quantifiable residues while the residues in samples collected from female rabbits were below the LOQ. The fat of one male rabbit slaughtered 48 hours after the final dose contained quantifiable residues. Individual residue values (integration of the polymyxin E₁ and polymyxin E₂ peaks) are summarized in Table 5. The study was conducted in compliance with GLP.

Table 5: Colistin residues (µg/kg) in tissues of rabbits

Withdrawal (hours)	Animal #	Muscle	Liver	Kidney	Fat
6	1M	<LOQ	<LOD	1021	85
	2M	<LOQ	<LOD	<LOD	78
	3F	<LOD	<LOD	<LOQ	90
	4F	<LOD	<LOD	239	75
24	5M	<LOD	<LOD	<LOQ	227
	6M	<LOD	<LOD	<LOD	76
	7F	<LOD	<LOD	<LOD	<LOQ
	8F	<LOD	<LOD	<LOD	<LOQ
48	9M	<LOD	<LOD	<LOD	87
	10M	<LOD	<LOD	<LOD	<LOQ
	11F	<LOD	<LOD	<LOD	<LOQ
	12F	<LOD	<LOD	<LOD	<LOQ

All the above discussed tissue residue studies reported by Meiji Seika Kaisha authors were performed using the same lot of colistin sulfate (ACLB 8464). The more recent Virbac milk residue study (Virbac Laboratories, 1997a) used colistin sulfate from the same source (ACLB 7729, 20935 IU/mg).

Residues in Milk and Eggs

Bovine Milk

In a study in lactating dairy cows, animals were treated by intramuscular injection or intramammary infusion. Residue concentrations in milk were determined using a microbiological assay. Residues resulting from intramuscular treatment are summarized in Table 6. Residues resulting from intramammary infusion into all four quarters are summarized in Table 7. Residues resulting from intramammary infusion into a single quarter are summarized in Table 8. Residues in milk following intramammary infusion are higher than residues resulting from intramuscular administration. Notably, when only one quarter was treated, a small residue of colistin was detected in milk collected from the three untreated quarters (Moretain and Boisseau, 1987).

In a more recent study (Virbac Laboratories, 1997a), ten cows were treated intramuscularly with a dose of 100 mg amoxicillin and 250,000 IU colistin per 10 kg b.w. Animals were treated once daily for 5 days. Cows were milked individually, morning and evening. Pooled milk samples from each of the four quarters were mixed and kept frozen (-80°C) until analyzed. Concentrations of colistin were determined using the validated HPLC method (see Methods of Analysis, below). The study was conducted in compliance with GLP. Residue

values (integration of the polymyxin E₁ and polymyxin E₂ peaks) in morning milk samples are summarized in Table 9.

Quantifiable residues were detected in all milk samples collected during dosing and in the morning milk collected 1-day after the last treatment. Thereafter, the number of samples containing quantifiable residues declined. At three days withdrawal, 3 of 10 milk samples had residues minimally above the LOQ. At four days withdrawal, only 1 of 10 milk samples had residues minimally above the LOQ.

Sheep Milk

Colistin residues were determined in sheep's' milk following a single intramuscular administration of colistin sulfate and colistin methanesulphonate at 3.5 mg/kg and 7.5 mg/kg. Colistin methanesulphonate concentrations in milk were higher than the comparable concentrations produced by colistin sulfate. Peak concentrations of colistin methanesulphonate in milk were approximately 3 and 10 µg/mL while peak concentrations of colistin sulfate were approximately 1 and 1.5 µg/mL, for the 3.5 mg/kg and 7.5 mg/kg doses, respectively. Peak concentrations were reached 2-3 hours after treatment. Thereafter, the colistin residues declined, with residues of colistin sulfate declining more rapidly than the residues of colistin methanesulphonate.

Eggs

Laying hens were treated with colistin sulfate orally via drinking water at a dose of 1,000,000 IU/L to provide 90,000 IU/kg body weight for 5 day. A second group was treated once by intramuscular injection, 50,000 IU/kg body weight. Eggs were collected daily during oral treatment and following treatment for both routes of administration. Yolks and albumen were separated and assayed individually using the microbiological assay referenced previously. Albumen samples were heat-treated prior to analysis to remove inherent inhibitory activity native to albumen. Residues also were calculated for whole eggs by considering the relative contribution of yolk and albumen to total egg weight. Results for the intramuscular injection study are summarized in Table 10.

None of the samples from chickens treated orally contained detectable residues of colistin. The report notes, however, that low concentrations of colistin in albumen may reflect partial destruction of colistin due to the heating or inclusion of colistin in the coagulated albumen following heat treatment (Roudaut, 1989).

Table 6: Residues of colistin (IU/mL) in milk of cows treated by intramuscular injection ^(a)

Compound	Formulation	Milking									
		-2	-1	1	2	3	4	5	6	7	
Colistin sulfate	40,000,000 IU/40 mL; aq. sol.	2.73	3.34	3.91	2.28	1.54	0.47	0.16	-	-	
Colistin sulfate	25,000,000 IU/100 mL; oil susp.	2.31	3.83	4.61	2.21	0.96	0.29	-	-	-	
Colistin sulfate	25,000,000 IU/100 mL; oil susp.	2.38	3.68	4.99	2.80	1.53	0.86	0.27	0.14	-	
Colistimethate sodium	25,000,000 IU; sol. powder	1.21	1.58	1.74	0.88	-	-	-	-	-	

(a) three injections of 25,000 IU/kg after three consecutive milkings

Table 7: Residues of colistin (IU/mL) in milk of cows treated by intramammary infusion into all four quarters

Compound	Formulation	Milking									
		-2	-1	1	2	3	4	5	6	7	
Colistin sulfate ^(b)	500,000 IU/3g; gel	88.1	75.4	139.5	15.5	5.40	1.19	1.08	0.59	-	
Colistin sulfate ^(c)	100,000 IU/10 mL; gel	22.5	18.1	28.0	5.8	1.46	0.55	0.10	-	-	
Colistin sulfate ^(d)	125,000 IU/250 mL; aq. sol.	-	-	25.8	2.93	1.29	0.12	-	-	-	

(b) 3 administrations of 500,000 IU/quarter after three consecutive milkings

(c) 3 administrations of 100,000 IU/quarter after three consecutive milkings

(d) 1 administration of 125,000 IU/quarter

Table 8: Residues of colistin (IU/mL) in milk of cows treated by intramammary infusion into a single quarter

Compound	Formulation	Milking														
		-2	-1	1	2	3	4	5	6	7	8	9	10	11	12	
Withdrawal sampling time																
Colistin sulfate (b)	500,000 IU/3g; gel															
Front quarter treated		93.1	115.0	138.8	54.9	18.1	7.11	4.64	3.05	2.02	1.38	0.81	0.55	0.17	ND	ND
Three non-treated quarters		0.42	0.62	0.65	0.52	ND	-	-	-	-	-	-	-	-	-	-
Rear quarter treated		75.0	70.0	86.7	22.6	6.10	2.98	1.71	0.85	0.30	ND	-	-	-	-	-
Three non-treated quarters		0.60	0.62	0.57	ND	-	-	-	-	-	-	-	-	-	-	-
Colistin sulfate (c)	100,000 IU/10 mL; gel															
Front quarter treated		26.2	21.5	33.0	12.3	4.38	1.32	0.25	ND	-	-	-	-	-	-	-
Three non-treated quarters		ND	ND	ND	-	-	-	-	-	-	-	-	-	-	-	-
Rear quarter treated		18.0	20.5	17.5	5.70	1.98	0.98	0.19	ND	-	-	-	-	-	-	-
Three non-treated quarters		ND	ND	ND	-	-	-	-	-	-	-	-	-	-	-	-

(b) 3 administrations of 500,000 IU/quarter after three consecutive milkings

(c) 3 administrations of 100,000 IU/quarter after three consecutive milkings
 ND not detectable

Table 9: Residues (µg/kg) in cows' milk following intramuscular administration

Milking	1F	2F	3F	4F	5F	6F	7F	8F	9F	10F	Mean±SD
Pre-treatment	<LOQ	<LOQ	<LOQ	<LOQ	<LOQ	<LOQ	<LOQ	<LOQ	<LOQ	<LOQ	<LOQ
D2 morning	48	47	54	35	33	31	59	48	42	32	42.9±9.8
D3 morning	55	46	94	38	47	37	37	47	62	40	50.3±17.4
D4 morning	72	55	109	44	47	28	48	51	58	53	56.5±21.6
D5 morning	48	44	94	44	42	21	43	23	49	41	44.9±19.8
1-day withdrawal	45	30	81	31	70	26	78	36	74	36	50.7±22.3
2 days withdrawal	25	11	33	12	11	<LOQ	10	<LOQ	<LOQ	14	16.6±8.9
3 days withdrawal	13	<LOQ	16	<LOQ	<LOQ	<LOQ	<LOQ	<LOQ	12	<LOQ	13.7±2.1
4 days withdrawal	<LOQ	<LOQ	12	<LOQ	<LOQ	<LOQ	<LOQ	<LOQ	<LOQ	<LOQ	12

<LOQ: <10 µg/kg

Table 10: Residues of colistin (IU/g) in albumen, yolk and whole eggs after intramuscular injection of 50,000 IU/kg body weight

Tissue/Matrix	Time after injection (days)	Mean \pm SD
Albumen	1	<6
	2	<6
Yolk	1	<3
	2	
	3	12.5 \pm 4.2
	4	12.0 \pm 3.6
	5	11.2 \pm 3.9
	6	9.0 \pm 3.0
	7	5.7 \pm 2.3
	8	<3
Whole egg	1	
	2	3.38 \pm 1.20
	3	3.81 \pm 1.12
	4	4.00 \pm 1.27
	5	3.57 \pm 1.25
	6	2.93 \pm 0.82
	7	1.72 \pm 0.69

In a recent study (Meiji Seika Kaisha, Ltd., 2000h), fifteen laying hens were treated with colistin to provide 100,000 IU/kg b.w.. Animals were treated twice daily for 5 days. Drug was mixed with a small quantity of feed and given by oral gavage before the morning and evening meals. This is the recommended dose. Eggs were collected from treated hens on treatment (Day 3), on the day of treatment withdrawal (Day 5), and following a 1-day withdrawal (Day 6). Yolk and albumen were mixed for each egg and samples were kept frozen (-80°C) until analyzed. Eggs were analysed individually. Concentrations of colistin in eggs were determined using the validated HPLC method (see Methods of Analysis, below). No detectable residues of colistin were found in any eggs at any of the sampling times. The study was conducted in compliance with GLP.

METHODS OF ANALYSIS

Several methods have been used to monitor residues of colistin in tissues.

Microbiological Assay: A microbiological assay (test organism = *Bordetella bronchiseptica*, ATCC 4617) has been used in serum (Archimbault et al., 1980; Escoula et al., 1981), in tissues of calves (Virbac Laboratories, 1992; Research Institute for Animal Science in Biochemistry and Toxicology, 1990a) and pigs (Research Institute for Animal Science in Biochemistry and Toxicology, 1990b; Meiji Seika Kaisha, Ltd., 1978), eggs (Roudaut, 1989) and milk (Moretain and Boisseau, 1987; Meiji Seika Kaisha, Ltd., 1992b). In a more recent study in pigs, a microbiological assay using *Escherichia coli*, CMCC (B) 4413, is reported to be an effective alternative to the *B. bronchiseptica* assay (Lin et. al., 2005).

In the most recent validation of the *B. bronchiseptica* microbiological assay (Meiji Seika Kaisha, 2001), tissue residues from an oral residue depletion study in pigs were analysed with the microbiological assay after they had been analysed with a validated HPLC assay. In muscle, the study demonstrates accuracy of 90.1-114.7% for samples having concentrations from 100 μ g/kg to 1000 μ g/kg. The overall recovery (all tested tissues) is 113.9% with a standard deviation of 43%. For the tested tissues, the LOQ is considered 100 μ g/kg, the lowest value tested. All of the incurred pig samples had residues below the microbiological

assay LOQ of 100 µg/kg. In the HPLC assay, the residue concentrations were less than 75 µg/kg for muscle, liver and skin/fat and less than 100 µg/kg for kidney.

High Performance Liquid Chromatography Assay: A validated HPLC with fluorescence detection has been used in tissue residue studies in cattle (Meiji Seika Kaisha, Ltd., 1999e; Meiji Seika Kaisha, Ltd., 1999b), pigs (Meiji Seika Kaisha, Ltd., 2000d; Meiji Seika Kaisha, Ltd., 1999a), chickens (Meiji Seika Kaisha, Ltd., 2000c; Meiji Seika Kaisha, Ltd., 1999c), turkeys (Meiji Seika Kaisha, Ltd., 2000f; Meiji Seika Kaisha, Ltd., 2000b), rabbits (Meiji Seika Kaisha, Ltd., 2000g; Meiji Seika Kaisha, Ltd., 2000a), milk (Virbac Laboratories, 1997a; Virbac Laboratories, 1997b) and eggs (Meiji Seika Kaisha, Ltd., 2000e; Meiji Seika Kaisha, Ltd., 1999d). Samples are deproteinated with trichloroacetic acid, and extracted with acid methanol. The extract is passed through a C₁₈ cartridge prior to derivatization. The samples are derivatized with o-phthalaldehyde for fluorescence detection. A column-switching program is used to adsorb fluorescent derivative onto the first analytical column (end-capped RP18, 5µm, 8 x 4 mm) using an acetonitrile/phosphate buffer mobile phase at a flow rate of 0.6 mL/min. The derivatives are eluted onto the second analytical column (end-capped RP18, 5µm, 125 x 3 mm) using an acetonitrile/phosphate buffer mobile phase at a flow rate of 1.0 mL/min. The column temperature is 35°C. Detection is accomplished with an excitation wavelength of 340 nm and an emission wavelength of 440 nm. Polymyxin E₂ elutes between 12.0 and 14.3 minutes. Polymyxin E₁ elutes between 15.1 and 18.1 minutes. Quantitation is achieved by integration of the two polymyxin peaks.

LOQ: In the species for which validation data are provided, the method has an LOQ of 75 µg/kg for muscle, liver and fat (or skin/fat, as appropriate) and 100 µg/kg for kidney. The LOQ for milk is 10 µg/kg. The LOQ for eggs is 150 µg/kg.

LOD: The LOD varies by tissue and species and is summarized in Table 11.

Linearity: In the species for which validation data are provided, the method has an linear range of 75-300 µg/kg for muscle, liver and fat (or skin/fat, as appropriate) and 100-400 µg/kg for kidney. The linear range for milk is 10-1000 µg/kg. The linear range for eggs is 150-600 µg/kg.

Precision: The precision varies by tissue and species and is summarized in Table 12.

Table 11: Method LODs, (µg/kg) by species and tissue.

Species	Muscle	Liver	Kidney	Fat (or Skin/Fat, as appropriate)	Milk	Eggs
Cattle	60	45	45	32	3	NA*
Pig	51	30	49	45	NA	NA
Chickens	29	48	72	25	NA	47
Turkeys	6	33	49	31	NA	NA
Rabbits	34	58	50	30	NA	NA

*NA=not applicable

Table 12: Method precision(%) by species and tissue

Species	Muscle	Liver	Kidney	Fat (or Skin/Fat, as appropriate)	Milk	Eggs
Cattle	6.4-6.5	5.5	6.9	11.7-12.1	4.3-13.6	NA*
Pig	5.5-6.1	9.7-13.1	8.6-8.7	8.7-10.6	NA	NA
Chickens	6.3-7.2	5.6-5.9	7.6	9.4-11.1	NA	5.5-6.0
Turkeys	6.0%	10.6	3.9-9.0	7.9-11.5	NA	NA
Rabbits	11.3-12.1	4.6-5.4	7.3-11.6	7.6-11.4	NA	NA

*NA=not applicable

Accuracy: The accuracy varies by tissue and species and is summarized in Table 13.

Recovery: Acceptable recovery was demonstrated for the method.

Table 13: Method accuracies (%), by species and tissue

Species	Muscle	Liver	Kidney	Fat (or Skin/Fat, as appropriate)	Milk	Eggs
Cattle	96.9-103.8	98.0-102.5	95.4-103.9	96.0-105.6	98-110	NA*
Pig	98.9-100.9	98.4-101.1	94.0-104.2	96.2-104.6	NA	NA
Chickens	94.2-107.8	93.8-105.7	96.0-105.3	93.6-106.4	NA	92.6-106.8
Turkeys	98.9-101.0	94.6-104.8	98.5-101.8	94.0-107.5	NA	NA
Rabbits	95.6-103.2	96.1-104.4	96.7-103.1	97.0-103.5	NA	NA

*NA=not applicable

The method uses readily available reagents and materials and can be implemented easily under normal laboratory conditions.

In a recent study, the microbiological assay (Meiji Seika Kaisha, 2001) was used to assess residues in pig tissues previously analysed with the HPLC assay (Meiji Seika Kaisha, Ltd., 2000d). For tissues derived from pigs treated orally with colistin, both assays demonstrate the absence of detectable residues.

The Committee was aware that suitable microbiological assays are available for screening but these methods were not submitted for evaluation.

APPRAISAL

Colistin has not been previously reviewed by the Committee. Colistin is a cyclopeptide (polymyxin) antibiotic with activity primarily against the Gram-negative organisms. Colistin is available as the sulfate salt and as colistimethate sodium. It is administered orally (colistin sulfate) and parenterally (colistin sulfate, colistimethate sodium). Colistin is used for the prevention and treatment of diseases caused by sensitive bacteria in a variety of species, including cattle, sheep, goats, pigs, poultry and rabbits. In cattle, pig, and poultry, colistin is used to treat digestive diseases caused by *Escherichia coli* and *Salmonella* spp.

Colistin is poorly absorbed following oral administration. Limited radiolabelled data are available following subcutaneous administration in day-old chickens. Metabolism is minimal and antimicrobial activity is low in incurred tissues.

In unlabelled residue studies, most tissues contain residues below the LOQ for the methods used at the sampling times employed. There are low but detectable residues in cows' milk following treatment with injectable and intramammary formulations. Detectable residues are found sporadically in other tested tissues in various species. No residues are detected in the eggs from treated hens following oral administration but low concentrations were found when colistin was administered intramuscularly.

Colistin A + B can serve as the marker residue for colistin. It represents the most significant residue and corresponds to the major microbiologically active residues of concern. Since the proportion of the two components also depends on the purity and composition of the drug used, it is not reasonable to select a single chemical entity as the marker residue. In addition to a microbiological assay, a highly specific fluorescence HPLC method is validated to measure residues of colistin (as Colistin A + B) in tissues, milk, and eggs.

In the species for which the HPLC method has been validated, the method has an LOQ of 75 µg/kg for muscle, liver and fat (or skin/fat, as appropriate) and 100 µg/kg for kidney. The LOQ for milk is 10 µg/kg. The LOQ for eggs is 150 µg/kg. The method has a linear range of 75-300 µg/kg for muscle, liver and fat (or skin/fat, as appropriate) and 100-400 µg/kg for kidney. The linear range for milk is 10-1000 µg/kg. The linear range for eggs is 150-600 µg/kg. Precision and accuracy, which are species and tissue specific, are acceptable.

The HPLC method is suitable for monitoring residues of colistin in milk and tissues and is considered practicable as it uses readily available reagents and materials and can be implemented easily under normal laboratory conditions. The microbiological assay, while not specific for colistin, is suitable as a screening test.

MAXIMUM RESIDUE LIMITS

In recommending MRLs for colistin, the Committee considered the following factors:

- Residues of colistin following oral administration generally were below the LOQ for the method of analysis in most tissues of most species, even at very short withdrawal periods. Low but quantifiable residues were detected in the fat of orally treated rabbits and in eggs of hens treated by intramuscular injection. Quantifiable residues of colistin also were found in cows' milk following intramammary infusion and intramuscular injection.
- Colistin A+B is considered a suitable marker residue in tissues, eggs and milk and represents approximately 80% of the microbiologically active residues. This information is incorporated in the calculation of the intake estimates to ensure they correctly reflect residues of microbiological concern.
- The validated HPLC method, used to measure residues of colistin in the more recently conducted studies submitted for the Committee's review, is suitable for monitoring residues for regulatory purposes. The assay measures colistin A (polymyxin E₁) and colistin B (polymyxin E₂).
- The MRLs recommended for all edible tissues in all species and for hens' eggs are twice the LOQ for the HPLC method. Because detectable residues were found in these tissues, the theoretical intake values for all the edible tissues are included in the calculation of the Theoretical Maximum Daily Intake (TMDI).
- The MRL recommended for cows' milk takes into consideration the potential use of colistin by both the intramuscular and intramammary routes of administration.

- An ADI of 0-7 µg/kg of body weight was established by the Committee based on a microbiological endpoint. This ADI is equivalent to up to 420 µg for a 60 kg person.

The Committee recommended MRLs for colistin in cattle, sheep, pigs, chickens, turkeys, and rabbits of 150 µg/kg in liver, muscle and fat (including skin + fat, where applicable), and 200 µg/kg in kidney, 300 µg/kg in hens' eggs, and 50 µg/kg in cows' milk, determined with the HPLC assay as the sum of polymyxin E₁ (colistin A) and polymyxin E₂ (colistin B).

The MRLs recommended would result in a theoretical maximum daily intake of 229 µg or 55% of the ADI, based on the model daily food intake of 300 g muscle, 100 g liver, 50 g each of kidney and fat, 100 g eggs, and 1.5 kg of milk.

Tissue	MRL	Standard Food Basket	Microbiological activity	TMDI
Muscle	150 µg/kg	0.3 kg	0.8	56 µg
Liver	150 µg/kg	0.1 kg	0.8	19 µg
Kidney	200 µg/kg	0.05 kg	0.8	13 µg
Fat*	150 µg/kg	0.05 kg	0.8	9 µg
Milk	50 µg/kg	1.5 kg	0.8	94 µg
Eggs	300 µg/kg	0.1 kg	0.8	38 µg
TMDI				229 µg

* Skin + Fat, where applicable

The 66th meeting of the Committee agreed to apply the principle of using median residue concentrations to better estimate long-term (chronic) exposures to residues. Estimated daily intake (EDI) values were determined using median residue values for each tissue from each food-producing species for which data were available. Where residue values were below the LOD or LOQ of the validated method, values of ½ the LOD and ½ the LOQ, respectively, were used in the calculations. As with the calculations of the TMDIs, all EDI calculations incorporate an adjustment to account for the fact that colistin A+B represents only 80% of the microbiological activity. The resulting EDI values represent 4% (for chickens) to 9% (for cattle) of the ADI.

An EDI, using the highest median values from among the tissues and food-producing species, was calculated. This EDI represents 14% of the ADI.

Tissue	Median	Standard Food Basket	Microbiological activity	EDI
Muscle (turkey)	38 µg/kg	0.3 kg	0.8	14.3 µg
Liver (pigs)	38 µg/kg	0.1 kg	0.8	4.8 µg
Kidney (rabbits)	145 µg/kg	0.05 kg	0.8	9.1 µg
Fat*(rabbits)	82 µg/kg	0.05 kg	0.8	5.1 µg
Milk (cattle)	11 µg/kg	1.5 kg	0.8	20.6 µg
Eggs (chickens)	24 µg/kg	0.1 kg	0.8	3.0 µg
EDI				56.9 µg

* Skin + Fat, where applicable

REFERENCES

- Al-Khayyat, A.A., and Aronson, A.L.** (1973). Pharmacologic and toxicologic studies with the polymyxins. II. Comparative pharmacologic studies of the sulfate and methanesulfonate salts of polymyxin B and colistin in dogs. *Chemother.*, 19, 92-97.
- Anonymous.** (1968). Etude physique, chimique, pharmacodynamique et thérapeutique des antibiotiques. *Thérapie.*, 23, 127-174.
- Archimbault, P., Boutier, C., Fellous, R., and Muscat, G.** (1980). Etude pharmacocinétique de la colistine chez les bovins. *Rec. Méd. Vét.*, 156, 621-626.
- Blood, D.C., and Radostits, O.M.** (1989). Practical antimicrobial therapeutics: polymyxin B and colistin. In *Veterinary Medicine*, 7th Edition. Baillière Tindall (ed.), London. p. 151.
- EMEA** (1995). Committee for Veterinary Medicinal Products. Colistin. Summary report (1), EMEA/MRL/016/95-FINAL.
- EMEA** (2002). Committee for Veterinary Medicinal Products. Colistin. Summary report (2), EMEA/MRL/815/02-FINAL.
- Escoula, L., Coste, M., and Larrieu, G.** (1981). Biodisponibilité de l'association érythromycine-colistine chez les veaux. *Ann. Rech. Vet.*, 12, 321-326.
- Elverdam, I., Larsen, P., and Lund, E.** (1981). Isolation and characterization of three new polymyxins in Polymyxins B and E by high performance liquid chromatography. *J. Chromatogr.*, 218, 653-661.
- European Pharmacopoeia 5.0** (01/2005:0319). Colistimethate sodium, 1360-1361.
- European Pharmacopoeia 5.3** (01/2006:0320). Colistin sulphate, 3480-3481.
- Falagas, M.E., and Kasiakou, S.K.** (2005). Colistin: The Revival of Polymyxins for the Management of Multidrug-Resistant Gram-Negative Bacterial Infections. *Reviews of Anti-Infective Agents*, 40, 1333-1341.
- Govaerts, C., Orwa, J., Van Schepdael, A., Roets, E., and Hoogmartens, J.** (2002). Liquid chromatography – ion trap tandem mass spectrometry for the characterization of polypeptide antibiotics of the colistin series in commercial samples. *J. Chromatogr., A* 976, 65-78.
- Govaerts, C., Adams, E., Van Schepdael, A., and Hoogmartens, J.** (2003). Hyphenation of liquid chromatography to ion trap mass spectrometry to identify minor components in polypeptide antibiotics. *Analytical and Bioanalytical Chemistry*, 377, 909-921.
- Ikai, Y., Oka, H., Hayakawa, J., Kawamura, N., Mayumi, T., Suzuki, M., and Harada, K.** (1998). Total structures of colistin minor components. *J Antibiot (Tokyo)*, 51, 492-498 (abstract only).
- Kline, T., Holub, D., Therrien, J., Leung, T., and Ryckman, D.** (2001). Synthesis and characterization of the colistin peptide polymyxin E1 and related antimicrobial peptides. *J. Peptide Res.*, 57, 175-187.

- Koyama, Y., Kurosawa, A., Tuchiya, A., and Takahisada, K.** (1950). A new antibiotic “colistin” produced by spore-forming soil bacteria. *J. Antibiotics (in Japanese)*, 3, 457-458 (cited by Suzuki et al. 1963a, and Falagas and Kasiakou, 2005).
- Li, J., Coulthard, K., Milne, R., Nation, R.L., Conway, S., Peckham, D., Etherington, C. and Turnidge, J.** (2003). Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. *J. Antimicrobial Chemotherapy*, 52, 987-992.
- Lightbown, J.W., Bond, J.M., and Grab, B.** (1973). The international standard for colistin. *Bull Wld Hlth Org.*, 48, 65-74.
- Lin, B., Zhang, C., and Xiao, X.** (2005). Toxicity, bioavailability and pharmacokinetics of a newly formulated colistin sulfate solution. *J. Vet. Pharmacol. Therap.*, 28, 349-354.
- Martindale (The Extrapharmacopoeia)** (1999). K. Parfitt (ed.), 32th Edition, The Pharmaceutical Press, London, 195-196.
- Meiji Seika Kaisha, Ltd** (1978). Retention of Meiji colistin sulfate in swine. Meiji Seika Kaisha, Ltd.
- Meiji Seika Kaisha, Ltd** (1992a). Colistin Sulphate – Establishment of Maximum Residue Limits (MRLs) for Residues of Veterinary Medicinal Products in Foodstuffs of Animal Origin – B. Residue File – Application Form (Annex II). DataVet, Vendargues, France.
- Meiji Seika Kaisha, Ltd** (1992b). Validation of an analytical method for the determination of colistin in cow’s milk. Study report. DataVet, Vendargues, France.
- Meiji Seika Kaisha, Ltd** (1999a). Development and Validation of an HPLC Method to Assay Colistin in Pig Tissues. Study Report VAL039, DataVet, Vendargues, France.
- Meiji Seika Kaisha, Ltd** (1999b). Development and Validation of an HPLC Method to Assay Colistin in Bovine Tissues. Study Report VAL038, DataVet, Vendargues, France.
- Meiji Seika Kaisha, Ltd** (1999c). Development and Validation of an HPLC Method to Assay Colistin in Chicken Tissues. Study Report VAL040, DataVet, Vendargues, France.
- Meiji Seika Kaisha, Ltd** (1999d). Development and Validation of an HPLC Method to Assay Colistin in Hen Egg. Study Report VAL050, DataVet, Vendargues, France.
- Meiji Seika Kaisha, Ltd** (1999e). Colistin Sulphate – Residues in healthy calves following oral administration. Study Report MJI012, DataVet, Vendargues, France.
- Meiji Seika Kaisha, Ltd** (2000a). Development and Validation of an HPLC Method to Assay Colistin in Rabbit Tissues. Study Report VAL041, DataVet, Vendargues, France.
- Meiji Seika Kaisha, Ltd** (2000b). Development and Validation of an HPLC Method to Assay Colistin in Turkey Tissues. Study Report VAL049, DataVet, Vendargues, France.
- Meiji Seika Kaisha, Ltd** (2000c). Colistin Sulphate – Residues in healthy poultry (chickens) following oral administration. Study Report MJI008, DataVet, Vendargues, France.
- Meiji Seika Kaisha, Ltd** (2000d). Colistin Sulphate – Residues in healthy pigs following oral administration. Study Report MJI011, DataVet, Vendargues, France.

- Meiji Seika Kaisha, Ltd** (2000e). Colistin Sulphate – Residues in eggs following oral administration in laying hens. Study Report MJI013, DataVet, Vendargues, France.
- Meiji Seika Kaisha, Ltd** (2000f). Colistin Sulphate – Residues in healthy turkeys following oral administration. Study Report MJI009, DataVet, Vendargues, France.
- Meiji Seika Kaisha, Ltd** (2000g). Colistin Sulphate – Residues in healthy rabbits following oral administration. Study Report MJI010, DataVet, Vendargues, France.
- Meiji Seika Kaisha, Ltd** (2000h). Colistin Sulphate – Residues in eggs following oral administration in laying hens. Study Report MJI013, DataVet, Vendargues, France.
- Meiji Seika Kaisha, Ltd** (2001). Microbiological detection of colistin in pigs tissues – Study Report appended to Study MJI011, ACM Pharma, Bellegarde, France.
- Moretain, J.P., and Boisseau, J.** (1987). Elimination des antibiotiques polypeptidiques (colistine et bacitracine) dans le lait après administration intramusculaire ou intramammaire. *Ann. Rech. Vet.*, 18,406-413.
- Nakajima, K.** (1967). Structure-activity relationships of colistins. *Chem.Pharmac. Bull.*, 15, 1219-1224. (cited by Kline et al. 2001).
- Orwa, J.A., Govaerts, C., Busson, R., Roets, E., Van Schepdael, A., and Hoogmartens, J.** (2001). Isolation and structural characterization of colistin components. *J Antibiot (Tokyo)*, 54, 595-599 (abstract only).
- Pristovšek, P., and Kidrič, J.** (1999). Solution structure of polymyxins B and E and effect of binding to lipopolysaccharide: an NMR and molecular modelling study. *J. Med.Chem.*, 42, 4604-4613.
- Pristovšek, P., and Kidrič, J.** (2001). Peptides neutralizing lipopolysaccharide – structure and function. *Minireviews in Medicinal Chemistry*, 1, 409-416.
- Research Institute for Animal Science in Biochemistry and Toxicology** (1990a). Residual study of colistin sulfate in cattle (89214) – Final report.
- Research Institute for Animal Science in Biochemistry and Toxicology** (1990b). Residual study of colistin sulfate in pigs (89215) – Final report.
- Roudaut, B.** (1989). Depletion of colistin in eggs following medication of laying hens. *Vet. Quart.*, 11, 183-185.
- Sato, H., Ouchi, M., and Koumi, J.** (1972). Studies on the distribution of colistin sulfate in the body. Distribution and change with time in chickens and pigs by oral administration. *Japanese J. Antibio. (translation)*, 25, 239-245.
- Schwartz, B.S.** (1964). The polypeptides of the polymyxin group. In Schnitzer, R. and Hawkins, F., (Eds.). *Study Chemotherapy*. Academic Press, NY, 217-270.
- Storm, D.R., Rosenthal, K.S., and Swanson, P.E.** (1977). Polymyxin and related peptide antibiotics. *Ann Rev. Biochem.*, 46, 723-763.
- Studer, R.O., Lergier, W., Lanz, P., Bohni, E., and Vogler, K.** (1965). Syntheses in the polymyxin series. 10. Synthesis of colistin A (polymyxin E-1). *Helv Chim Acta*, 48 (6), 1371-78 (abstract only).

Suzuki, T., Inouye, H., Fujikawa, K., and Suketa, Y. (1963a). Studies on the Chemical Structure of Colistin: I. Fractionation, Molecular Weight Determination, Amino Acid and Fatty Acid Composition. *J. Biochem. (Tokyo)*, 34, 25-33.

Suzuki, T., Inouye, H., Fujikawa, K., and Nagsawa, S. (1963b). Studies on the Chemical Structure of Colistin. II. Amino Acid Sequence of Colistin A. *J. Biochem. (Tokyo)*, 54, 173-180.

Suzuki, T., Hayashi, K., and Fujikawa, K. (1963c). Studies on the Chemical Structure of Colistin. III. Enzymatic Hydrolysis of Colistin A. *J. Biochem. (Tokyo)*, 54, 412-418.

Sweetman S. (ed.), (2006). *Martindale: The Complete Drug Reference*. Pharmaceutical Press. Electronic Version, London.

Terakado, S., Azechi, H., Omae, K., Koyama, T., Ninomiya, K., and Kashiwazaki, M. (1972). Distribution of colistin sulfate and changes with time in intestinal *E. coli* counts in pigs following oral administration. Seventy-third Congress of Japan Society of Veterinary Medicine (translation), 5-22.

The Merck Index (2001). M.J. O'Neil (ed.), 13th Edition, Merck and Co., Inc., Whitehouse Station, NJ, USA, p. 433.

Thomas, A.H., Thomas, J.M., and Holloway, I. (1980). Microbiological and Chemical Analysis of Polymyxin B and Polymyxin E (Colistin) Sulphates. *Analyst (London)*, 105, 1068-1075.

US Food and Drug Administration (FDA) (1998). Freedom of Information Summary, NADA 141-069. <http://www.fda.gov/cvm/FOI/941.htm>

Virbac Laboratories (1992). Validation of the Assay Method for Colistin in Calf Tissues. Project code 905/0010, Carros, France.

Virbac Laboratories (1997a). Colistin: milk residue study in cows after intramuscular administration – Colistin Assay Report – Study Report VIR 97 019b – Biotec Centre, Orléans, France.

Virbac Laboratories (1997b). Colistin: validation of colistin assay method in bovine tissues, validation in milk – Study Report VIR 96 020 – Biotec Centre, Orléans, France.

WHO Expert Committee on Biological Standardization, 21st Report (1969). World Health Organization, Technical Report Series No. 413, p. 11.

Ziv, G., Nouws, F.M., and Van Ginnekin, C.A.M. (1982). The pharmacokinetics and tissue levels of polymyxin B, colistin and gentamicin in calves. *J. Vet. Pharmacol. Therap.*, 5, 45-58.

Ziv, G., and Sulman, F.G. (1973). Passage of Polymyxin from Serum into Milk in Ewes. *Am. J. Vet. Res.*, 34, 317-322.

ERYTHROMYCIN

First draft prepared by
Adriana Fernández Suárez
Buenos Aires, Argentina
and

Richard Ellis
Myrtle Beach, South Carolina, United States

IDENTITY

Chemical names International Union Pure and Applied Chemistry (IUPAC) name:
6-(4-dimethylamino-3-hydroxy-6-methyl-tetrahydropyran-2-yl)oxy-14-ethyl-7,12,13-trihydroxy-4-(5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydropyran-2-yl)oxy-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-dione)

C.A.S. number 114-07-8

Synonyms and abbreviations

Mixture of macrolide antibiotics, the main component (erythromycin A) being (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranosyl)oxy]-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-[3,4,6-trideoxy-3dimethylamino- β -D-xyllo-hexopyranosyl)-oxy]oxacyclotetradecane-2,10-dione

Structural formula See next page.

Molecular formula $C_{37}H_{67}NO_{13}$

Molecular weight **Erythromycin A:** Mz = 734; **Erythromycin B:** Mz = 718;
Erythromycin C: Mz = 720

OTHER INFORMATION ON IDENTITY AND PROPERTIES

Appearance White or slightly yellow powder or colorless or slightly yellow crystals


Degree of purity Erythromycin B \leq 5.0%
Erythromycin C \leq 5.0%
Any impurity \leq 3.0%
Sum of impurities \leq 7.0%

Qualitative composition of impurities

N-demethyl-erythromycin A, anhydroerythromycin A, erythromycin A enol ether, pseudoerythromycin A enol ether, erythromycin E, erythromycin F.

Description of physical properties

Slightly hygroscopic, slightly soluble in water but less soluble at higher temperatures, freely soluble in alcohol, soluble in methanol, sensitive to light.



Three erythromycins are produced during fermentation. Erythromycin A and B contain the same sugar moieties, desoxamine and cladinose (3-O-methylmycarose). They differ in position 12 of the aglycone, erytronolide, A having a hydroxyl group. Erythromycin C contains desoxamine and the same aglycone present in A, but differs by the presence of mycarose instead of cladinose (Merck Index). The principal product is erythromycin A with small proportions of B and C.

INTRODUCTION

Erythromycin was first reviewed by the Committee in 1968. No ADI was established but acceptable levels of residues were defined in milk (0-0.04 mg/ml), meat and eggs (0-0.3 mg/kg) (FAO/WHO, 1969).

Pharmacokinetic and metabolic studies in experimental animals, target animals and humans were evaluated, including original studies in calves and chicken and three new non radiolabelled residue depletion studies in chickens, two in laying hens and one in turkeys and the description and validation of the analytical methods used.

Conditions of use

General

Erythromycin, a macrolide antibiotic is effective *in vitro* against *Mycoplasma*, Gram positive *Coci*, *Neisseria*, some strains of *Haemophilus*, *Corynebacterium*, *Listeria*, *Pasteurella mutocida*, *Brucella*, and *Treponemes*. *Proteus*, *Pseudomonas* and *E.Coli* are relatively resistant to the drug. In veterinary medicine, this compound is used for the treatment of clinical and subclinical mastitis in lactating cows, for the treatment of infectious diseases due to erythromycin sensitive bacteria (cattle, sheep, swine, poultry) and for the treatment of chronic diseases due to mycoplasma in poultry (EMEA, 2000). In Europe, for broiler chickens and laying hens, the most often recommended dose (as erythromycin base) is 20 mg/kg/day. Uses and dose ranges are presented in Table 1.

Table 1: Formulation and dose ranges of erythromycin

Formulation	Country	Dosage
Erythromycin thiocyanate Oral powder 5 g per 100 g	Belgium France Germany	20 mg / kg / day for 5 days
	Netherlands	20 mg / kg / day for 5 to 7 days
	International zone*	5 g of erythromycin in 100 liter of drinking water for 3 to 5 days
Erythromycin thiocyanate Oral powder 5.1 g per 100 g	Greece	Curative treatment: 2-4 g of product / liter of drinking water Preventive treatment: 1-2 g of product / liter of drinking water
Erythromycin thiocyanate Oral powder 10 g per 100 g	France	20 mg / kg / day for 3 days
	Algeria	10 g of erythromycin / 100 liter of drinking water for 3 to 6 days
Erythromycin thiocyanate Oral powder 16.5 g per 100 g	Ireland and United Kingdom	25.5 mg / kg / day for 1 to 5 days
Erythromycin thiocyanate Oral powder 20 g per 100 g	France	20 mg / kg / day for 3 days
	Greece	50 mg / kg / day for 3 days
	Spain	130 mg erythromycin / liter of drinking water or 0.65 g erythromycin / liter of water For CRD: treatment for 5 days. For infectious coriza and sinusitis: treatment for 7 days
	International zone*	20 g of erythromycin in 200 liter (prevention) or 100 liter (treatment) of drinking water for 3 to 5 days
	International zone*	5 g of erythromycin per liter of drinking water for 1 to 5 days
Erythromycin Phosphate Oral powder 29.6 g per 100 g	Ireland and United Kingdom	25.5 mg / kg / day for 1 to 5 days

* Countries other than the European Union and United States

PHARMACOKINETIC AND METABOLIC STUDIES

Absorption

Erythromycin base is destroyed by gastric acid, except if administered with a protective enteric coating. Acidic media degrades erythromycin rapidly to form derivatives with little antimicrobial activity. Erythromycin stearate is more stable, however *in vitro* studies have demonstrated that erythromycin stearate dissolves in gastric acid, retains only 2% antibiotic activity and is rapidly destroyed (DiSanto and Chodos, 1981; Periti et al., 1989; Martindale, 1989). The major site of absorption in rat, dogs and humans is the small intestine. Erythromycin is only slightly absorbed from the stomach. In man, absorption occurs mainly in the duodenum (Anderson et al., 1959; Huber, 1977).

Humans

In humans, erythromycin is rather slowly absorbed after oral administration. Peak serum concentrations occur 1 to 6.3 hours after dosing and vary from 0.1 to 4.8 µg/ml, depending on the

formulation, and the coating of erythromycin administered. The oral absorption is less than 50% and erythromycin is degraded by gastric acid. It is absorbed in the small intestine as erythromycin base (DiSanto and Chodos, 1981; Griffith and Black, 1970; Burrows, 1980).

The oral bioavailability of unprotected erythromycin base and salts is less than 50 % of the dose. Food reduces the absorption of erythromycin (Griffith and Black, 1970; Burrows, 1980). Wilson and Van Boxtel (1978) observed that erythromycin propionate and stearate were better absorbed before rather than after breakfast.

Laboratory animals

In laboratory animals, erythromycin is rather slowly absorbed after oral administration in laboratory animals (except rats). Oral administration of propionyl erythromycin (25 mg/kg) in rats did not produce high peak serum concentrations ($<0.1\mu\text{m/ml}$). However, the maximum serum concentration was reached rapidly (1 hour after administration). At the end of six hours following oral administration, only a trace of antibiotic activity was found in rat serum (Anderson et al., 1959).

Calves

In calves, 2 hours after a single intramuscular treatment of 5 mg erythromycin/kg b.w., the mean highest concentration in plasma ($0.652\ \mu\text{g/ml}$) was reached. Twelve hours after treatment, the concentration of erythromycin in serum was about $0.22\ \mu\text{g/ml}$. After repeated intramuscular treatments of 5 mg erythromycin/kg bw/day for 5 days, no accumulation phenomenon was observed (Report PK 5251/E-00).

Chickens

In chickens, 30 minutes after the beginning of a repeated administration of erythromycin via drinking water at a dose of 25,000 IU/kg b.w./day for 3 days (approximately 27 mg/kg b.w.), the average serum levels ranged from 0.11 to $0.22\ \mu\text{g/ml}$. After the last administration, serum levels declined to approximately $0.04\ \mu\text{g/ml}$ (Report PK 8400/E-00).

Distribution

Plasma protein binding

In humans, erythromycin is highly bound to plasma proteins. The extent of protein binding is $>74\%$ *in vitro* and $>90\%$ *in vivo* (Wilson and Van Boxtel, 1978). Erythromycin undergoes a relatively low extent of binding to bovine serum proteins (37-43%) (Baggot and Gingerich, 1976).

Milk protein binding

Studies show that antibiotics are bound only to a minor extent to milk proteins. However, the unbound fraction of erythromycin may be decreased because it may be bound to milk casein. Erythromycin is $<25\%$ bound to dry udder secretion and to dry udder tissue homogenates (Ziv, 1980).

Serum levels

According to Wilson and Van Boxtel (1978), dose levels of 250 mg of erythromycin base or erythromycin stearate in adults produce similar peak serum concentrations ($0.4\ \mu\text{g/ml}$) within 2-4 hours after oral administration. In cattle, after intramuscular administration of erythromycin in cattle, peak serum concentrations are maintained for several hours and then decline slowly. The 12-hour levels are about 25% of peak concentration (Burrows, 1980).

The elimination half-life ($T_{1/2}$) of erythromycin following intravenous injection of a single dose in different species is shown in Table 2.

Table 2: Elimination half-life of erythromycin following intravenous injection

Species	Dose	$T_{1/2}$	References
Cow	12.5 mg/kg	3.16 ± 0.44 hours	Baggot and Gingerich, 1976
Dog	-	1 hour	Burrows, 1980
Man	100 mg	1.02 ± 0.17 hours	Wilson and Van Boxtel, 1978

Tissue distribution

Animal studies indicate that erythromycin is well distributed in the body and tissue levels (e.g. liver, spleen, kidneys, and lungs) are generally higher than serum levels and persist longer (Wilson and Van Boxtel, 1978).

Humans

In humans, erythromycin is distributed to various tissues and fluids. About 10% of erythromycin is estimated to cross the placenta and fetal blood levels are no higher than 10% (usually closer to 2%) of those present in normal circulation. An estimated 0.1% of a daily dose appears in breast milk in pregnant women (Wilson and Van Boxtel, 1978).

Rats

In rats given 100 mg erythromycin base per kg bw orally, erythromycin is concentrated in the liver, sub maxillary glands, spleen, adrenals, lungs and kidneys two hours after administration. Large amounts are also found in the thymus, skin, muscle, reproductive organs and heart (Lee et al., 1953).

Twenty hours after an intravenous treatment of 10 mg erythromycin (N-methyl-¹⁴C-erythromycin, 8 μ Ci) to rats, about 37-43% of the administered dose is recovered in the intestinal tract plus feces, 27.2 - 36.1% in the urine, and 21-29% in the expired air. It is rapidly metabolized in the liver, mainly through a demethylation process, and excreted in the bile as des-N-methyl-erythromycin, the major metabolite, present only in the bile and in the intestinal contents of rats. The isotopic methyl group is eliminated in the expired air as CO₂ (Lee et al., 1953)

Cattle

After intravenous administration, erythromycin is widely distributed in cows. The apparent volume of distribution (Vd) is 0.8 liter/kg. Tissue concentrations are higher than serum concentrations and erythromycin concentrations in milk of lactating cows (the dose fraction recovered in milk is 3.8%. At 6 hours, the percent of the dose of erythromycin in the central and tissue compartments were 6 and 19%, respectively, with 75% of the dose eliminated (Wilson and Van Boxtel, 1978; Ziv, 1980a). Compared to adult cows, a larger apparent volume of distribution and a higher body clearance rate were determined in calves (Burrows, 1980).

In lactating cows, erythromycin was well distributed in the body and mean erythromycin concentrations in renal cortex, muscle and liver varied from 0.09 to 0.14 μ g/g tissue, 16 hours after a single intramammary application of 1200 mg erythromycin base. The highest concentration was observed in the liver (Nouws and Ziv, 1979).

Five hours after intramuscular administration of erythromycin anhydrate (8.3 mg/kg bw) in cows, renal, muscle and liver concentrations were 0.11 to 0.92 μ g/g, with the highest values in the liver. At a dose of 9 mg/kg, concentrations were less than 0.03 to 0.06 μ g/g; 67 hours after intramuscular

injection of erythromycin base, the renal cortex concentration was 0.1 µg/g following a dose of 17.5 mg/kg (Nouws and Ziv, 1979).

Metabolism

The metabolism of erythromycin has been studied in different animal species and in humans. (Lee et al, 1956a; Lee et al, 1956b; Wilson and Van Boxtel, 1978; Pineau et al., 1990; Tsubaki and Ichikawa, 1985). These studies show that erythromycin is rapidly metabolized in the liver, mainly through an N-demethylation process in both rats and dogs and in the liver microsomal system of rabbits. Collectively, these studies strongly suggest that the metabolism of erythromycin by N-demethylation occurs in all species tested. Des-N-methyl-erythromycin is the major metabolite and the only microbiologically active metabolite of erythromycin. However, the antimicrobial activity is presumably low and the only form of erythromycin known to be active *in vivo* is the free base. It is excreted in the bile and eliminated through the faeces. Only erythromycin was found in the liver and the absence of des-N-methyl-erythromycin indicates that it is excreted in the bile immediately after erythromycin demethylation. It is absorbed from the intestinal tract but the very minute amount of des-N-methyl-erythromycin available in the body may explain its absence from urine.

The hepatic cytochrome P-450 isozymes that catalyse erythromycin demethylation in rat are highly similar to the form of liver cytochrome P-450 present in rabbit, hamster, gerbil and mouse and this may also extend to humans since human liver contains a protein equivalent to the rat cytochrome P-450. Similarly, a high degree of similarity was found between the ovine cytochrome P-450 involved in N-demethylation of erythromycin and the form isolated in rabbits. This suggests that an equivalent form of these liver cytochrome P-450 isozymes, with similar catalytic activities, is present in the species tested. In cattle a form of cytochrome P-450 isozyme exhibiting a high catalytic activity for N-demethylation was found; this activity was not measured for erythromycin but for other substrates having a N-methyl group structure.

Excretion

Renal excretion

In humans, the portion of an erythromycin dose excreted in the urine varies from 0.02 to 20% and the elimination half-life may be prolonged in renal disease. However, except complete renal failure, renal impairment has only a minor impact on the pharmacokinetics of erythromycin (Wilson and Van Boxtel, 1978).

Urinary excretion of erythromycin accounts for approximately 10% of an administered oral or IM dose (Burrows, 1980). Twenty hours after administration of isotopic erythromycin in rats, 27 to 36% of the radioactivity was recovered in the urine (Lee et al., 1956a).

Faecal Excretion

In humans, 15% of an administered dose was excreted in the bile (Griffith and Black, 1970).

In rats, erythromycin and its metabolites are excreted mainly by way of bile, but in part, also by direct passage through the intestinal wall (Baggot and Gingerich, 1976). Two hours following intravenous injection of isotopic erythromycin, 15.1% of the dose was excreted in the bile (Lee et al, 1956b). Twenty hours following intravenous injection of isotopic erythromycin, 37-43% of the radioactivity is recovered in the intestinal tract plus faeces (Lee et al. 1956a). An enterohepatic recirculation may also contribute to the high concentrations of erythromycin in faecal samples (Kroboth et al., 1982).

Pharmacokinetic studies in calves and poultry

Calves

A 1988 study (Report PK 5251/E-00) was performed in calves to determine:

- The pharmacokinetics and bioavailability of erythrocin (erythromycin thiocyanate) injectable following single and multiple IM administrations
- Pulmonary levels after a single IM administration of erythromycin
- Residues of erythromycin in tissues after multiple IM administration of injectable erythrocin

Erythromycin concentrations were assayed by a microbiological method on agar medium using *Micrococcus Luteus* as the sensitive organism (LOD: 0.02 IU/ml in serum; 0.16IU/g in all tissues).

Erythromycin was administered as a single intravenous injection to five calves at a dose of 5 mg erythromycin activity/kg. The study demonstrated a large apparent volume of distribution (V_d area, or $V_{d\beta}$ 1.95 l/kg), a short mean residence time (MRT 2.36 h) and an efficient ability of the organism to remove the drug (Cl 0.77 l/kg/h). As a second experiment in the same assay, a single intramuscular injection of a dose of 5 mg erythromycin activity/kg was administered to seven calves. Good bioavailability was observed (F 95%). Compared to the intravenous route, the elimination half-life and volume of distribution was apparently increased. This could be related to a slow-rate of absorption from the injection site.

In another study, three calves received five consecutive intramuscular injections in the neck or gluteal muscle at a dose of 5 mg/kg at 24-h intervals. No accumulation was observed. The peak concentrations observed after each injection were similar to the C_{max} values obtained after a single injection.

In a third study, ten calves received a single intramuscular injection in the neck or into the gluteal muscle alternatively at a dose of 5 mg/kg erythromycin during five days. Drug levels in lungs were always higher than in serum. These data are consistent with the well-known higher tissue than serum concentrations of erythromycin.

In the fourth study, ten calves received a single intramuscular injection in the neck or into the gluteal muscle alternatively at a dose of 5 mg/kg erythromycin during five days. Liver, kidney, muscle non-injection sites, the last three injection sites and fat tissues were collected at different withdrawal times after the last injection. Five days after the last injection, the tissues were free of antibiotic residues except some injection sites. Seven days after the end of the treatment, all tissues, including injection sites were negative. One calf slaughtered ten days after the last injection confirmed these results.

Poultry

A study (Report PK 8400/E-00) was performed in poultry to determine:

- Pulmonary and blood levels of erythromycin after a drinking water medication for three consecutive days
- Residues of erythromycin in chicken tissues after administration by oral route in drinking water for three consecutive days
- Residues of erythromycin in whole hen eggs after a drinking water medication for seven consecutive days

In the first study, 168 adult broilers were given erythromycin thiocyanate in their drinking water for 3 consecutive days. The treated water was changed every day but the water consumption during treatment was not measured. Assuming that the water consumption was similar during the treatment period and before treatment, where water consumption was 235ml/chicken on average, the dose

could be estimated to be 25 mg/kg/day. Blood and lung samples (2-10 birds/sampling time) were collected before the first administration and at:

- 30 min, 1h, 2h, 3h, 4h, 6h, 8h, 9h and 24h on day 1 and 2 of medication
- 30 min, 2h, 3h, 4h, 6h, 8h, 9h and 24h on day 3 of medication
- 3h, 4h, 6h, 8h, 9h and 12h after the end of medication

The microbiological method using *Micrococcus Luteus* as the sensitive organism was used to determine blood and lung levels (LOD: 0.02 IU/ml of serum; 0.2 IU/g tissue). Similar but low serum values were noted during the whole treatment period (0.03-0.2 IU/ml, on average), although large variations were observed between broilers, possibly due to differences in individual water consumption. Higher pulmonary (0.5-1 IU/g) than serum levels were observed during the three days treatment, with maximum levels occurring 4 - 12 hours after each changing of medicated water and an elimination time of eight hours. In samples collected 12 hours after the end of the medication, pulmonary levels were below the limit of detection.

In the second study, 15 adult broilers received one dose of erythromycin thiocyanate estimated to be 25 mg/kg/day by the oral route in their drinking water for 3 consecutive days with the treated water changed every 24 hours. At 3, 5, 7 and 10 days after the end of the treatment, the chickens were slaughtered and liver, muscle, fat and skin tissues were collected. The microbiological method noted above was used (LOD: 0.2 IU/g tissue). In all cases the amounts of erythromycin in chicken tissues were below the detection limits 3 days after the end of the treatment.

In the third study, 40 laying hens received the same treatment as the broilers in the previous experiment for seven consecutive days. Five eggs were collected at 3, 5 and 7 days during treatment. Erythromycin was determined in the whole egg with the microbiological method (LOD: 0.06 µg/ml whole egg). Concentration levels of the drug were below the detection limits six days after the end of the treatment.

RESIDUE DEPLETION STUDIES IN TARGET ANIMALS AND IN HENS' EGGS

No radiolabelled study was performed. The following new original residue depletion studies with unlabelled erythromycin were performed in poultry:

Table 3: Residues depletion studies with erythromycin in target animals and eggs

Species	Dose	Study number
Chicken	20 mg / kg / day for 3 days	MPK/5814/9812 MPK/Erythromycin/9957
	20 mg / kg / day for 8 days	MPK/5814/0301
	50 mg / kg / day for 3 days	MPK/210H1/0148
Laying hens	20 mg / kg / day for 3 days	MPK/5814/9908 MPK/Erythromycin/9961
	20 mg / kg / day for 7 days	MPK/5814/0417
Turkey	20 mg / kg / day for 3 days	MPK/5814/0225

The maximum recommended therapeutic dose is 20/mg/kg/day. The route of administration, the dose and the species are those intended for therapeutic use. These studies were performed in accordance with GLP and the European Community guidelines 87/18/EEC and 88/320/EEC, including all supplements published up to the day of the corresponding study start.

Residue Depletion Studies in Chicken

- Chickens treated for three consecutive days at the maximum recommended dose (MPK/5814/9812 and MPK/Erythromycin/9957)

A residue study was performed in order to assess the depletion of erythromycin and its metabolites (N-desmethyl erythromycin A) in edible tissues of broiler chickens after repeated administration. The test product was erythromycin thiocyanate 20% oral powder. Thirty six chickens (18 males and 18 females plus 6 extra birds to replace any that might become ill and not meeting the inclusion criteria were selected for the 7 day acclimatization period) were treated by oral administration of 20 mg/kg/day of erythromycin for 3 consecutive days. All birds belonged to the same strain, TR 551, and were healthy when they received the treatment. For the entire duration of the study, the experimental broiler chickens were in premises at temperature and hygrometry ranging from 16 - 20 °C and 46 - 76%, respectively. Animals were kept in individual cages and all animals were exposed to an alternating cycle of illumination (12 hours of light followed by 12 hours of darkness). Animals received an individual daily ration of maize, soya, sunflower and wheat supplemented with vegetables and had free access to water. They weighed 0.9±0.1 kg at the beginning of the treatment. Six animals per sampling time were slaughtered at 1 day, 2 days, 3 days, 4 days and 5 days after the end of treatment. Individual edible tissues collected from animals were: 100g of pectoral muscle, 100g of liver, 100g sample of kidneys and 100g of fat and skin in natural proportions.

A specific HPLC method coupled to a mass spectrometer detection system (LC/MS/MS) was used to determine erythromycin A, B and C and N-desmethyl-erythromycin-A in chicken tissues. Antimicrobial activity was measured by a microbiological plate assay. Erythromycin B and C were not detected in all samples, therefore only erythromycin A and N-desmethyl-erythromycin-A were reported. Mean concentrations of erythromycin A measured by both methods were below the LOD or the LOQ for all tissues at 1, 2, 3, 4 and 5 days after the end of the treatment (LOQ: 100 µg/g for all edible tissues and for both methods; LODs for the LC/MS/MS method were: 25 µg/kg for kidney, 30 µg/kg for liver, 3 µg/kg for muscle and 5 µg/kg for skin + fat; the LOD for the microbiological method was 50 µg /kg for all tissues). Mean concentrations of N-desmethyl-erythromycin A are presented in the following table.

Table 4: Mean concentrations of N- desmethyl-erythromycin A in edible tissues of broiler chickens receiving 20mg/kg/day for 3 days

Slaughter time after the end of treatment	Muscle (µg/kg)		Fat/skin (µg/kg)		Liver (µg/kg)		Kidney (µg/kg)	
	HPLC	Micro	HPLC	Micro	HPLC	Micro	HPLC	Micro
1 day	< LOD	< LOD	< LOQ	< LOD	< LOD	< LOD	< LOD	< LOD
2 days	< LOD	< LOD	< LOD	< LOD	282*	< LOD	< LOD	< LOD
3 days	< LOD	< LOD	< LOD	< LOD	163*	< LOD	< LOD	< LOD

Note: * one value

Results also show that only small concentrations of N-desmethyl-erythromycin A were measured by HPLC in liver up to 3 days in only two individual samples after the end of the treatment. For days 4 and 5, concentrations of the metabolite were under the LOD. Because the depletion rate of the residue was very rapid in all edible tissues, it was not possible to provide any correlation between both methods in broiler chickens.

Following the selection of Erythromycin A as the residue marker in edible tissues of broiler chickens, the following additional residue depletion studies were performed in the broiler chickens with different doses.

- Chickens treated for eight consecutive days at the maximum recommended dose (MPK/5814/0301)

Thirty six broiler chickens (18 males and 18 females plus 6 extra birds to replace any that might become ill and not meet the inclusion criteria) were selected for the acclimatization period (10 days) before the beginning of the treatment. The animals had an approximate age of 8 weeks at start of treatment and a mean weight of 1794g (1423-2154g). They were fed *ad libitum* with a pelleted concentrate ration and had free access to water. Chickens were treated by oral administration of 20% erythromycin A thiocyanate via drinking water at 20 mg/kg/day of erythromycin for 8 consecutive days. Six animals per sampling time were slaughtered at 12 hours, 1, 2, 3 and 4 days after the last administration. Individual edible tissues were collected from animals as follows: 400g sample of breast/leg muscle, entire liver, both kidneys and 200g sample of fat and skin in natural proportions.

The concentrations of residues in edible tissue were analyzed with the same LC/MS/MS validated method as the above reported study. Mean concentrations of erythromycin A were below the LOD or the LOQ for all tissues at 12 hours, 1, 2, 3, and 4 after the end of the treatment. The study demonstrated that, whatever the duration of administration, the 20 mg/kg b.w. dose of erythromycin, leads to concentrations of residues in edible tissues below the limit of quantification.

- Chickens treated for five consecutive days at two and one-half times the maximum recommended dose (MPK/210H1/0148)

A total of 36 broiler chickens (18 males and 18 females plus 6 extra birds to replace any might become ill and not meet the inclusion criteria) were selected for the acclimatization period (10 days) before the beginning of the treatment. The study was performed with a dose of 50 mg/kg body weight. The test product was a powder containing 5.5% erythromycin thiocyanate. The animals had an approximate age of 6 weeks at start of treatment and a weighed 800-1000g. They were fed *ad libitum* with a commercial feed and had free access to water. Chickens were treated by oral administration via drinking water for five consecutive days. Six animals per sampling time were slaughtered at 6h, 10h, 24h, 2, 5 and 7 days after the end of treatment. Individual edible tissues collected from animals were: 200g of muscle, entire liver, both kidneys and 40g of fat and skin in natural proportions. Erythromycin A was assayed with the same validated LC/MS/MS method as in the two previous studies. The results are presented in Table 5.

Table 5: Mean concentrations of Erythromycin A in edible tissues of chickens treated with 50mg/kg/day for 5 days

Sampling time after the end of treatment (hours)	Muscle (µg/kg)	Fat/skin (µg/kg)	Liver (µg/kg)	Kidney (µg/kg)
6	133 ± 16	131 ± 35	3220 ± 2080	308 ± 170
10	< LOQ	< LOQ	1760 ± 2840	185 ± 79
24	< LOD	< LOQ	631 ± 393	< LOD

Note: < LOQ: below the quantification limit (100 µg/g for all edible tissues); < LOD: below the detection limit (25 µg/kg for kidney, 30 µg/kg for liver, 3 µg/kg for muscle and 5 µg/kg for skin + fat).

Concentrations of erythromycin were measurable in all tissues at six hours after the end of the treatment but only in liver and kidney at ten hours after the end of the treatment (the concentrations in muscle and fat/skin were less than the LOQ). Residues at one day after the end of treatment were only found in liver; concentrations in other tissues were below the LOD or LOQ. At day 2 or further times post-treatment, concentrations in all tissues were below the LOQ or the LOD. The study demonstrates that the administration of doses higher than the recommended during consecutive days does not result in accumulation of residues.

Residue Depletion Studies in Laying Hens

- Laying hens treated for three consecutive days at the maximum recommended dose (MPK/5814/9908 and MPK/erythromycin/9961)

A residue study was performed in eggs from laying hens that received a repeated administration for three days. A total of 40 laying hens were selected for the acclimatization period (14 days) before the beginning of the treatment, 30 were selected for treatment according to individual egg production. From these, 25 laying hens were selected for sampling, keeping 5 animals to replace any that might become ill. All birds belonged to the same strain and were healthy when they received the treatment; no animal had received any treatment ten days before the beginning of the study. The laying hens were treated by oral administration of 20 mg/kg/day of erythromycin thiocyanate 20% oral powder. The laying hens weighed 2.1 ± 0.2 kg and were approximately 8 months at the beginning of the treatment. They were fed *ad libitum* with a commercial feed and had free access to water. All eggs produced were collected daily during the treatment and ten days after the end of the treatment. The production ranged from 19-26 eggs per day and 13-17 eggs per laying hen over the 16-day experimental period. Control samples were collected three days before the beginning of the treatment period. The total antimicrobial activity of residues was also determined with the microbiological plate assay. Test samples were a mixture of albumen and yolk of each egg at each time point. Only Erythromycin A and N-desmethyl-erythromycin-A were detected. Results are reported in the following table.

Table 6: Mean concentrations of erythromycin A and N-desmethyl-erythromycin A in eggs of laying hens treated with 20mg/kg/day for 3 days

Sampling time	Mean concentration erythromycin A ($\mu\text{g}/\text{kg}$)		Mean concentration N-desmethyl-erythromycin A ($\mu\text{g}/\text{kg}$)	Ratio HPLC / microbiological method for erythromycin A	Ratio HPLC / microbiological method for desmethyl-erythromycin A
	HPLC	Micro			
Beginning of treatment					
Day 0	109 \pm nc	194 \pm nc	< LOD	0.56	-
Day 1	78 \pm 12	158 \pm 76	< LOD	0.46	-
Day 2	83 \pm 24	198 \pm 76	< LOD	0.33	-
End of treatment					
1 day post treatment	57 \pm 6	221 \pm 80	97 \pm nc	0.23	-
2 day post treatment	71 \pm 6	207 \pm 59	120 \pm nc	0.25	0.76
3 day post treatment	54 \pm nc	118 \pm 21	69 \pm nc	-	-
4 day post treatment	< LOQ	< LOD	64 \pm nc	-	-
5 day post treatment	< LOQ	< LOD	< LOD	-	-
Mean				0.33	0.76

Note: <LOD: below the limit of detection (0.92 $\mu\text{g}/\text{kg}$ for the HPLC method and 50 $\mu\text{g}/\text{kg}$ for the microbiological method); <LOQ: below the limit of quantification (50 $\mu\text{g}/\text{kg}$ for the HPLC method and 100 $\mu\text{g}/\text{kg}$ for the microbiological method); nc: non calculated

Erythromycin A could only be quantified in 25% of eggs at day 1 and 12.5% of the eggs at day 2. Concentrations of erythromycin A after the end of the treatment measured by LC/MS/MS were near the LOQ of the method (50 $\mu\text{g}/\text{kg}$). N-desmethyl-erythromycin A had high concentrations but it has a very low antimicrobial activity. Both compounds were below the LOQ (50 $\mu\text{g}/\text{kg}$) six days after the end of treatment. Erythromycin A was identified as the marker residue for eggs.

- Laying hens treated for seven consecutive days at the maximum recommended dose (MPK/5814/0417)

Residues in eggs from laying hens were analyzed after repeated administration for seven days. The hens weighed 1.6 ± 0.16 kg and were approximately 23 weeks at the beginning of the treatment. Twenty laying hens were treated by oral administration of 20 mg/kg/day of erythromycin thiocyanate 20% oral powder. All birds belonged to the same strain and were healthy when they received the treatment after an acclimatization period of 21 days. The laying hens were fed *ad libitum* with wheat and a pelleted concentrated ration and had free access to water. Eggs were collected daily beginning five days before the start of the treatment, during the treatment and until 28 days after the last treatment. Ten eggs per day were randomly selected for sampling at each time point coming from the first ten hens having regularly laid one egg per day and throughout all study. Samples were a mixture of albumen and yolk of each egg selected at each time point. Only erythromycin A was measured in eggs with the LC/MS/MS method used in the above studies. The results are presented in Table 7.

Table 7: Mean concentrations of erythromycin A in eggs of laying hens treated with 20 mg/kg/day for seven days.

Sampling time	Mean concentration (µg/kg)
Beginning of treatment	
Day 1	< LOD
Day 2	< LOQ
Day 3	< LOQ
Day 4	72 ± 11.1
Day 5	$135 \pm nc$
Day 6	59 ± 7.1
Day 7	68 ± 18.3
End of treatment	
1 day post treatment	59 ± 0.7
2-8 days post treatment	< LOQ
9-21 days post treatment	< LOD

Note: < LOD: below the limit of detection (0.9 µg/kg);
 < LOQ: below the limit of quantification (50 µg/kg);
 nc: not calculated

Erythromycin could be quantified only 1 day after the end of the treatment. After this time, the concentrations of the residues were below the LOQ (50µg/kg). The study demonstrated that, whatever the duration of the administration, the administration of 20mg/kg b.w./day results in concentrations of erythromycin in eggs no higher than those found with fewer days of administration.

Residue Depletion Studies in Turkeys

- Treatment for three consecutive days at the maximum recommended dose (MP/5814/0225)

Thirty four white turkeys were treated by oral administration of 20 mg/kg/day of erythromycin thiocyanate 20% oral powder via drinking water for 3 consecutive days. All animals belonged to the same strain and were healthy when they received the treatment. Animals received a daily ration of commercial concentrated feed and had free access to water. They weighed 2289 ± 309 g at the beginning of the treatment. Turkeys were selected for the acclimatization period (14 days) before the beginning of the treatment. Six animals per sampling time were collected at 3, 4, 5, 6 and 8 days after treatment (1, 2, 3, 4 and 6 days after the last dose), 4 birds used as controls were sampled at six days after the end of the treatment. Individual edible tissues collected from animals were: whole liver, both kidneys, 400g of pectoral muscle, and approximately 20-50g of fat+skin in natural

proportions. The LC/MS/MS assay method for the detection of residues in turkeys was adapted from the chicken method. Three days after the end of the treatment, residues were detectable only in liver ($166 \pm 64 \mu\text{g/kg}$). At this time, residues were measured only in one sample of kidney, muscle and fat. After four days post-treatment, all concentrations of residues were below the LOQ or the LOD in all tissues. The results are presented in Table 8.

Table 8: Mean concentrations of erythromycin A in edible tissues of turkeys treated with 20mg/kg/day for three days.

Sampling time after treatment	Muscle ($\mu\text{g/kg}$)	Fat/skin ($\mu\text{g/kg}$)	Liver ($\mu\text{g/kg}$)	Kidney ($\mu\text{g/kg}$)
3 days	266*	318*	166 ± 63.6	424*
4, 5,6 and 8 days	< LOQ	< LOQ	< LOQ	< LOD

Note: * only one value; < LOQ: below the quantification limit ($100 \mu\text{g/kg}$ for all tissues); < LOD: below the detection limit ($4 \mu\text{g/kg}$ for skin/fat and $3 \mu\text{g/kg}$ for all other tissues).

METHODS OF ANALYSIS

Erythromycin A, B and C and N-methyl-erythromycin A by a LC/MS/MS method

Chicken (MPK/5814 /9812 and validation in MPK/erythromycin/9957).

Extraction procedure for muscle, liver and kidney: 1 g thawed tissue was shaken with 1 ml of double distilled water using a vortex mixer. Nine ml of acetonitrile was added and the mixture vortexed for an additional 20 seconds. The mixture was shaken for 10 minutes using a mechanical shaker. After decantation, $100 \mu\text{l}$ of the supernatant was added to $300 \mu\text{l}$ of the dilution solution and $15 \mu\text{l}$ was injected into the chromatographic system.

Extraction procedure for skin/fat: 1 g frozen tissue was shaken with 20 ml of acetonitrile for 20 seconds using a vortex mixer followed by 10 minutes using a mechanical linear shaker. After decantation, 1 ml of supernatant and 1 ml of double distilled water and 2 ml of n-hexane were added. The mixture was shaken 10 minutes using a mechanical shaker, centrifuged at 2500 rpm for 5 minutes, n-hexane was decanted off and $15 \mu\text{l}$ of solution were injected onto the chromatographic system.

Chromatographic procedure: $15 \mu\text{l}$ was injected onto the column using the autosampler. The column used was an RP 18ec $30 \times 4 \text{ mm}$, $5 \mu\text{m}$. The elution was done under isocratic conditions with acetonitrile/double distilled water 50:50 v/v with 1% formic acid. The retention times were 2.7 min for erythromycin A, 3.1 min for erythromycin B, 2.0 min for erythromycin C and 2.4 min for N-desmethyl-erythromycin A. Detection was done by mass-mass using a quadripole instrument with an electrospray source in the positive ionization mode. Multiple Reaction Monitoring (MRM) was applied and the following transition ions were monitored $734.6 \rightarrow 576.6$ for erythromycin A, and $718.6 \rightarrow 565.2$ for erythromycin B, $720.6 \rightarrow 576.5$ for erythromycin C, and $720.5 \rightarrow 562.2$ for N-desmethyl-erythromycin A. No internal standard was used. Quantification of both products was done after interpolation of unknown sample peak areas against the theoretical concentrations of calibration curves. Results were expressed as free erythromycin A and N-desmethyl-erythromycin A ($\mu\text{g/kg}$). The method was validated using the following criteria consistent with internationally recognized guidelines.

Specificity: The method was found specific from endogenous compounds, erythromycin B and C, N-desmethyl-erythromycin A, tylosin, tilmicosin and spiramycin.

Linearity: The linearity of detector response was assessed in the four tissues matched with standard solutions using $100\text{-}5000 \mu\text{g/kg}$. The correlation coefficients were 0.9996, 0.9993, 0.9998 and

0.9993 for erythromycin A in muscle, liver, kidney and skin/fat respectively and 0.9979, 0.9987, 0.9992 and 0.9976 for N-methyl-erythromycin A in the same tissues, respectively.

Stability: Stability was demonstrated at a concentration of 2000 µg/kg after 3 freeze-thaw cycles.

The within-day precision, day-to-day precision, accuracy, recovery rate, LOQ and LOD are presented in the following tables.

Table 9: Validation parameters for erythromycin A in chicken tissues

Erythromycin A	Muscle	Kidney	Fat / skin	Liver
Concentration (µg/kg)	100 - 5000	100 - 5000	100 - 5000	100 - 5000
Within-day precision (%)	1.95 - 7.57	2.30 - 7.24	2.51 - 7.80	2.89 - 8.19
Day-to-day precision (%)	2.28 - 7.57	2.30 - 7.24	2.51 - 9.36	4.31 - 13.6
Accuracy (E%)	-1.5 ≤ E% ≤ +2.0	-2.0 ≤ E% ≤ +2.4	-7.0 ≤ E% ≤ +10.1	-3.3 ≤ E% ≤ +3.0
Recovery rate (%)	> 98.9	> 92.1	> 87.4	> 98.1
LOQ (µg/kg)	100	100	100	100
LOD (µg/kg)	3	25	5	30

Table 10: Validation parameters for N-desmethyl-Erythromycin A in chicken tissues

N-desmethyl-Erythromycin A	Muscle	Kidney	Fat / skin	Liver
Range (µg/kg)	100 - 5000	100 - 5000	100 - 5000	100 - 5000
Within-day precision (%)	2.56 - 6.37	1.95 - 7.19	2.61 - 9.33	2.48 - 6.85
Day-to-day precision (%)	2.62 - 7.15	1.95 - 7.19	2.61 - 9.33	3.86 - 9.47
Accuracy (E%)	-3.0 ≤ E% ≤ +3.4	-1.2 ≤ E% ≤ +3.8	-4.0 ≤ E% ≤ +10.4	-4.2 ≤ E% ≤ +4.0
Recovery rate (%)	> 99.1	> 96.8	> 81.7	> 97.3
LOQ (µg/kg)	100	100	100	100
LOD (µg/kg)	3	25	24	48

Turkey (MPK/5814/0225)

The analytical method was adapted from the chicken method described above. It was validated using the criteria noted above. The method was partially validated as noted below. The retention time was approximately 3.6 min for erythromycin A.

Specificity: The method was found specific from endogenous compounds, erythromycin B and C, N-desmethyl erythromycin A, tylosin, tilmicosin and spiramycin.

Linearity: The linearity of detector response was assessed in the four tissues matched with standard solutions in the range of 100-5000 µg/kg. The correlation coefficients were 0.9998, 0.9997, 0.9988 and 0.9993 for erythromycin A in muscle, liver, kidney and skin/fat. The within-day precision, accuracy, recovery rate, LOQ and LOD are presented in Table 11.

Table 11: Validation parameters for erythromycin A in turkey tissues

Erythromycin A	Muscle	Liver	Kidney	Fat / skin
Range ($\mu\text{g}/\text{kg}$)	100 - 5000	100 - 5000	100 - 5000	100 - 5000
Within-day precision (%)	1.1 - 2.3	1.6 - 4.6	1.1 - 2.2	4.9 - 11.2
Accuracy (E%)	-5.0 - 6.5	-8.0 - 8.4	-6.8 - 0.2	-3.3 - 8.8
LOQ ($\mu\text{g}/\text{kg}$)	100	100	100	100
LOD ($\mu\text{g}/\text{kg}$)	3	3	3	4

Eggs (MPK/ 5814/9908 and validation in MPK/erythromycin/9961)

Extraction procedure: 1g frozen mixed egg was shaken with 1 ml of double distilled water for 20 seconds using a vortex mixer. Nine ml of acetonitrile were added and the mixture was shaken for 20 seconds using a vortex mixer and for 10 minutes using a mechanical linear shaker. After decantation, 500 μl of supernatant were added to 500 μl of acetonitrile, 1 ml of double distilled water and 2 ml of n-hexane. The mixture was shaken 10 minutes using a mechanical shaker, centrifuged, the n-hexane was decanted off and 10 μl of solution were injected onto the chromatographic system.

Chromatographic procedure: 15 μl were injected onto a RP 18ec 30 x 4 mm, 5 μm column. The elution was obtained under isocratic conditions with acetonitrile/double distilled water 50:50 v/v with 1% formic acid. The retention times were 3 min for erythromycin A and 2.5 min for N-desmethyl-erythromycin A. Detection was done by mass-mass using a quadripole instrument with a turbo ionspray source in the positive ionization mode. MRM was applied and the following transition ions were monitored 734.6 \rightarrow 158.0 for erythromycin A and 720.5 \rightarrow 144.2 for N-desmethyl-erythromycin A. No internal standard was used. Quantification of both products was done after interpolation of unknown sample peak areas against the theoretical concentrations of calibration curves. Results were expressed as free erythromycin A and N-desmethyl-erythromycin A.

Specificity: The method was found specific from endogenous compounds, erythromycin B and C, N-desmethyl erythromycin A, tylosin, tilmicosin and spiramycin.

Linearity: The linearity of detector response was assessed matched with standard solutions in the range of 50-5000 $\mu\text{g}/\text{kg}$. The correlation coefficients were 0.9993 and 0.9997 for erythromycin A and N-methyl-erythromycin A respectively.

Stability: The stability of erythromycin A and N-desmethyl-erythromycin A was evaluated at the concentration level of 2000 $\mu\text{g}/\text{kg}$ after 3 freeze-thaw cycles. The mean concentration was approximately 104% of the mean reference value. Long term stability was evaluated in both compounds in a mixed frozen egg stored at -80 $^{\circ}\text{C}$ for 1 month at the concentration level of 2000 $\mu\text{g}/\text{kg}$. The mean concentration of the pool was 102% and 104% of the nominal value of erythromycin A and N-methyl-erythromycin A, respectively.

The within-day precision, day-to-day precision, accuracy, recovery rate, LOQ and LOD are presented in Table 12.

Table 12: Validation parameters for erythromycin A and N-desmethyl-erythromycin A in eggs

	Erythromycin A	N-desmethyl-Erythromycin A
Range (µg/kg)	50 - 5000	50 - 5000
Within-day precision (%)	1.76 - 9.87	1.10 - 7.79
Day-to-day precision (%)	1.76 - 11.87	1.11 - 7.79
Accuracy (E%)	-5.0 ≤ E% ≤ +7.8	-1.3 ≤ E% ≤ +2.0
Recovery rate (%)	> 82.6	> 71.9
LOQ (µg/kg)	50	50
LOD (µg/kg)	0.92	2.2

Microbiological assay method for erythromycin in chicken tissues and eggs

A microbiological method was used for the assay of erythromycin A and its related metabolites with potential microbiological activity in edible tissues (muscle, kidney, liver and fat/skin) of chicken (MPK/erythromycin/9957) and eggs (MPK/Erythromycin/9961).

Extraction procedure: 1 g of test sample was vortexed with 4 ml of acetonitrile, placed in an ultrasonic bath for five minutes and on a liner shaker for ten minutes. The extract was centrifuged at 7500g for 10 minutes and the supernatant transferred into a disposable tube. Two wells of each Petri dish were filled with this mixture.

Petri dishes: Plates were prepared (diameter 100mm) using agar medium and *Micrococcus Luteus ATCC9341* as test organism. For each point, two plates with two replicates per plates were used. The diameter of bacterial growth inhibition was the measured response. Amounts of erythromycin were calculated by interpolating the inhibition diameter into the standard curve. The method has been validated according to the following criteria.

Specificity: The method shows specificity between erythromycin and endogenous component of the tissues. Three different matrixes are tested under experimental conditions for each tissue. No inhibition zone was observed for any tissue.

Linearity in chicken tissues: The linearity of detector response was assessed in the four tissues matched with standard solutions in the range from 100 to 2000µg/kg. The correlation coefficients were 0.9994, 0.9513, 0.9571 and 0.9969 for erythromycin A in muscle, liver, kidney and skin/fat, respectively. Other validation parameters are presented in the following tables for each tissue.

Linearity in eggs: The linearity of detector response was assessed matched with standard solutions in the range from 100 to 2000µg/kg. The correlation coefficient was 0.9567 as average of 9 standard curves. Other validation parameters are presented in the following tables.

Table 13: Validation parameters of the microbiological method for erythromycin in chicken**Table 13-A**

Concentrations (µg/kg).	Validation parameters for kidney						Overall
	100	200	500	1000	1500	2000	
Recovery rate (%) n=9	85.5	86.5	88.2	85.1	84.8	86.1	86.0
Repeatability, C _v ,% n=3 per day	5.9	9.4	7.8	10.8	5.7	6.0	-
Intermediate precision, C _v , %/ 3 days	12.9	12.8	13.5	10.8	5.7	10.5	-
Accuracy: difference (% value)	-5.11	3.78	7.07	4.02	-1.90	-4.27	0.60
Limit of Detection (LOD)				50 µg/kg			
Limit of Quantification (LOQ)				100 µg/kg			
- = not calculated							

Table 13-B

Validation parameters for fat + skin							
Concentrations (µg/kg).	100	200	500	1000	1500	2000	Overall
Recovery rate (%) n=9	101.5	102.9	100.0	97.5	97.1	96.6	99.2
Repeatability C_{v_r} % n=3 per day	3.7	5.6	4.6	7.5	6.9	6.7	-
Intermediate precision, CV_r %/ 3 days	3.7	5.6	5.4	7.5	6.9	6.7	-
Accuracy: difference (% value)	0.22	-0.22	-1.13	4.99	-3.44	0.67	0.18
Limit of Detection (LOD)				50 µg/kg			
Limit of Quantification (LOQ)				100 µg/kg			
- = not calculated							

Table 13-C

Validation parameters for muscle							
Concentrations (µg/kg).	100	200	500	1000	1500	2000	Overall
Recovery rate (%) n=9	94.1	94.0	93.6	92.6	93.1	95.9	93.9
Repeatability C_{v_r} % n=3 per day	9.4	13.3	7.9	4.6	7.3	4.5	-
Intermediate precision, CV_r %/ 3 days	9.8	13.3	7.9	4.6	7.3	6.2	-
Accuracy: difference (% value)	-3.22	5.22	2.53	-2.00	-1.45	1.06	0.36
Limit of Detection (LOD)				50 µg/kg			
Limit of Quantification (LOQ)				100 µg/kg			
- = not calculated							

Table 13-D

Validation parameters for liver							
Concentrations (µg/kg).	100	200	500	1000	1500	2000	Overall
Recovery rate (%) n=9	86.6	83.7	88.5	87.8	87.8	88.8	87.2
Repeatability, C_{v_r} % n=3 per day	5.2	7.6	7.0	8.8	6.1	6.3	-
Intermediate precision, CV_r %/ 3 days	9.2	7.9	13.3	8.8	6.2	6.3	-
Accuracy: difference (% value)	0.22	-5.72	9.47	4.04	1.26	-6.51	0.46
Limit of Detection (LOD)				50 µg/kg			
Limit of Quantification (LOQ)				100 µg/kg			
- = not calculated							

Table 14: Validation parameters of a microbiological assay method for erythromycin in eggs

Validation parameters							
Concentrations (µg/kg).	100	200	500	1000	1500	2000	Overall
Recovery rate (%) n=9	87.5	93.5	94.2	93.4	92.4	92.8	92.3
Repeatability, C_{v_r} % n=3 per day	2.9	2.6	4.7	3.9	4.3	4.6	-
Intermediate precision, CV_r %/ 3 days	5.0	4.5	5.1	5.7	4.5	4.6	-
Accuracy : difference (% value)	-4.89	3.11	3.87	5.77	-2.21	-4.59	0.18
Limit of Detection (LOD) :				50 µg/kg			
Limit of Quantification (LOQ) :				100 µg/kg			
- = not calculated							

Wang, et al. (2005) published a method for determination of five macrolide antibiotic residues in eggs (spiramycin, tilmicosin, oleandomycin, erythromycin and tylosin) using liquid chromatography/electrospray ionization tandem mass spectrometry. Data acquisition under MS/MS was achieved by multiple reaction monitoring of two or three fragment ion transitions for both quantification and confirmation. A full experimental design was used to study the measurement uncertainty arising from intermediate precision and trueness or proportional bias. The overall recoveries of spiramycin, tilmicosin, oleandomycin, erythromycin and tylosin at fortified levels of 60, 100, 200 and 300 µg/kg were 96.8, 98.2, 98.3, 98.8 and 95.4, respectively. The method detection limits (S/N ≥ 3:1) of five macrolides were <1.0 µg/kg).

APPRAISAL

Erythromycin is an old drug. It was first reviewed by the Committee in 1968. No ADI was established but acceptable levels of residues were defined in milk (0-0.04 mg/ml) and meat (0-0.3 mg/kg). Erythromycin is a mixture of three compounds produced during fermentation. The main product is erythromycin A with small portions of B (≤ 5%) and C (≤ 5%). In veterinary medicine, erythromycin is used for the treatment of clinical and subclinical mastitis in lactating cows, for the treatment of infectious diseases due to erythromycin sensitive bacteria (cattle, sheep, swine, and poultry) and for the treatment of chronic diseases due to mycoplasma in poultry. The maximum recommended therapeutic dose in veterinary use is 20/mg/kg/day as erythromycin base.

Data from pharmacokinetic and metabolic studies in experimental and target animals and humans were submitted for evaluation by the Committee together with two earlier residue studies in calves and chickens. Three new non radiolabeled residue depletion studies in chickens, laying hens and turkeys treated with erythromycin and the description and validation of the analytical procedures employed were provided.

Erythromycin is rather slowly absorbed in humans, rats, cattle and chicken with some differences related to the mode of administration (IM, IV and oral), the salt form and the coating of the administered compound. Protein binding is variable ranging from 90% in man to 38-45% in cattle. The major site of absorption is rats, dogs and humans is the small intestine. Erythromycin is only slightly absorbed in the stomach. The tissue concentrations are higher than in serum and persist longer. Erythromycin is mainly excreted in the faeces through the bile, 37 to 43 % of the dose was recovered in the intestinal tract plus faeces of rats. Urinary excretion ranged from 10 to 36 % in different species (human, rats and dogs).

Erythromycin is rapidly metabolized in the liver, mainly through an N-demethylation process in a variety of species of rodents, ruminants and humans. N-desmethyl-erythromycin was the major metabolite and the only microbiologically active metabolite of erythromycin. However, its antimicrobial activity is low and the only form of erythromycin known to be active *in vivo* is erythromycin free base.

Two studies were performed in 1988 in calves and poultry using erythromycin thiocyanate. In poultry, the residues of erythromycin were determined in chicken tissues after administration by the oral route in drinking water for 3 consecutive days. In a similar study the residues of erythromycin in whole eggs were determined following medication administered to laying hens for 7 consecutive days in drinking water. The concentration of the erythromycin in chicken tissues declined to values below the limit of detection three days after the end of treatment and six days after the end of treatment in whole eggs.

There was no radiolabelled study reported, however, four new residue depletion studies with unlabelled erythromycin were performed in poultry. The route of administration, the dose and the species are those intended for therapeutic use.

The residues with microbiological activity were measured in chickens and laying hens by a microbiological plate assay using agar medium and *Micrococcus luteus* ATCC9341 as test organism (LOD: 50 µg/kg for all chicken tissues and eggs; LOQ: 100 µg/kg for all chicken tissues and eggs). The concentration of erythromycin A and its metabolites were simultaneously assayed using a LC/MS/MS method. For chickens, erythromycin A, B and C, the LOD are as follows: 25 µg/kg for kidney, 30 µg/kg for liver, 3 µg/kg for muscle and 5 µg/kg for skin + fat and the LOQ is 100 µg/kg in all tissues. For N-desmethyl-erythromycin A, the LOD are as follows: 25 µg/kg for kidney, 48 µg/kg for liver, 5 µg/kg for muscle and 24 µg/kg for skin + fat and the LOQ is 100µg/kg in all tissues. For eggs, the erythromycin LOQ is 50 µg/kg and the LOD is 0.92 µg/kg. For turkey, the erythromycin LOQ is 100 µg/kg for all tissues and the LOD is 4 µg/kg for skin/fat and 3 µg/kg for all other tissues.

In the chicken studies, all tissue residue depletion results showed that from day 1 to day 3 after the end of the treatment period, low concentrations of erythromycin A and N-desmethyl-erythromycin A were measured in only a few liver samples. Prolonged treatment for up to eight days resulted in the same tissue residue concentration characteristics. In eggs, during the three days of treatment, mean concentrations of erythromycin A ranged from 109 µg/kg (day 1) to 83 µg/kg (day 3) measured by the LC/MS/MS method. Taking into account the standard deviation, there are no significant differences in residue concentration between days. The egg residues of erythromycin after the end of the treatment were 57±6 µg/kg, 71± 6 µg/kg and 54± nc µg/kg for days 1, 2 and 3, respectively.

Results show that erythromycin A and its metabolite N-desmethyl-erythromycin A were the major compounds observed (the ratio erythromycin/total active microbiological metabolites was 0.33 and the ratio of N-desmethyl-erythromycin/total active microbiological metabolites was 0.75). Erythromycin could only be quantified in 25% of eggs at day 1 and 12.5% of the eggs at day 2. Concentrations of erythromycin after the end of the treatment measured by LC/MS/MS were near the LOQ (50 µg/kg). N-desmethyl-erythromycin was present at higher concentrations but had very low antimicrobial activity. Both compounds were below the LOQ at 6 days after the end of treatment. Erythromycin A was identified as the marker residue for eggs.

Tissue residue depletion studies in turkeys yielded similar results. The LC/MS/MS assay method was adapted from the chicken method. At three days after the end of the treatment, residues were detected only in liver (166±64 µg/kg). At this time, residues were measured only in one sample of kidney, muscle and fat. Four days post-treatment, all concentrations of residues were below the LOQ or the LOD.

The 66th meeting of the Committee agreed to apply a new approach to estimate chronic (long term) exposure using the median residue concentration of residues, using the standard food basket, in addition to the historically used theoretical maximum daily intake calculation based on the MRL. For numerical values reported below the LOD and the LOQ, one-half the analytical limit was applied to each, respectively, for estimating daily exposure concentrations. For erythromycin, the summary of the median residue concentrations in chickens, turkeys and eggs are presented in the following tables, derived from using individual values in all studies using an Excel spreadsheet.

Table 15a: Median residues in chicken and turkey tissues (µg/kg)

Tissue & Time	Chicken			Turkey			
	12 hours	1 day	2 days	1 day	2 days	3 days	4 days
Muscle	1.5	1.5	1.5	50	50	1.5	1.5
Liver	15	15	15	50	50	15	15
Kidney	12.5	12.5	12.5	50	12.5	12.5	12.5
Fat+Skin	50	2.5	2.5	50	25.8	2.5	2.5

Table 15b: Median residues in chicken eggs (µg/kg)

Time (days)											
0 day	1 day	2 days	3 days	4 days	5 days	6 days	7 days	8 days	9 days	10 days	11days
0.45	25	25	25	25	25	25	41	25	25	25	25

The LC/MS/MS analytical methods provided are applicable for the determination of residues of erythromycin in chicken and turkey tissues (muscle, fat, kidney and liver) and eggs. The method was validated.

MAXIMUM RESIDUE LIMITS

In recommending MRLs for erythromycin, the Committee considered the following factors:

- The marker residue is erythromycin A. Metabolites exhibited little or no microbiological activity.
- Only MRLs in poultry tissues and eggs were considered.
- Residue studies in bovine and ovine tissues suggest mean ratios of marker residue to total residues for tissues to be 0.7 for muscle and kidney, 0.5 for liver and 0.85 for fat. The ratio was not always available for all species and when it was, it was only available based on few individual data. From submitted studies, the marker residue to total residues for eggs was estimated to be 0.33.
- Residue depletion studies generated very limited numbers of residue concentrations above the limit of quantification for all studies in chickens, turkeys and eggs.
- A validated LC/MS/MS method is available with a limit of quantification of 100 µg/kg for all tissues and 50 µg/kg for eggs. The limit of quantification of the microbiological method is 100 µg/kg for all tissues and eggs.
- For residue concentrations reported below the LOD and the LOQ, one-half the analytical limit was applied to each, respectively, for estimating daily exposure concentrations.
- The ADI for erythromycin A was 0 – 0.7 µg/kg body weight, equivalent to 42 µg per person per day.

Noting the factors noted above, the Committee recommended MRLs of 100 µg/kg for chicken and turkey muscle, liver, kidney and fat/skin and 50µg/kg for eggs at the limit of quantification of the LC/MS/MS method, measured as erythromycin A.

Applying the MRLs and the standard food basket, the theoretical maximum daily intake is 55 µg, equivalent to approximately 130% of the ADI. The 66th meeting of the Committee agreed to apply the principle of using median residue concentrations to better estimate long-term (chronic) exposures to residues. Estimated daily intake (EDI) values were determined using median residue values for each tissue from each food-producing species for which data were available. Median residue values were determined using an Excel[®] spreadsheet program. Where residue values were below the LOD or LOQ of the validated method, values of ½ the LOD and ½ the LOQ, respectively, were used in the calculations. Applying the highest estimated median residue concentrations in turkeys (50 µg/kg in all tissues) – the median residue concentrations in turkey tissues were higher than the corresponding median residue concentrations in chicken tissues - and eggs (41µg/kg), the estimated daily intake is 29.1 µg/kg, equivalent to approximately 69% of the ADI. Results are shown in Table 16.

Table 16: Estimated daily intake

Tissue	Median intake (µg/kg)	Standard Food Basket (kg)	Daily intake (µg)
Muscle	50	0.3	15
Liver	50	0.1	5
Kidney	50	0.05	2.5
Fat	50	0.05	2.5
Eggs	41	0.1	4.1
Total			29.1

REFERENCES

Anderson, R.C., Lee, C. C., Worth, H.M., and Harris, P.N. (1959). J. American Pharmaceutical Association, XLVIII, 11, 623-628.

Baggot J. D., and Gingerich, D. A. (1976). Pharmacokinetic interpretation of erythromycin and tylosin activity in serum after intravenous administration of a single dose to cows. Research in Veterinary Science, 21, 318-323.

Burrows, G. E. (1980). Pharmacotherapeutics of macrolides, lincomycins, and spectinomycin. JAVMA, 176 (10), 1072-1077.

DiSanto A. R., and Chodos, D .J. (1981). Influence of study design in assessing food effects on absorption of erythromycin base and erythromycin stearate. Antimicrobial Agents and Chemotherapy, 20 (2), 190-196.

EMEA (2000). Committee for Veterinary Medicinal Products. Erythromycin. Summary Report (1), EMEA/720/99-FINAL.

FAO/WHO (1969). Specifications for the identity and purity of food additives and their toxicological evaluation: some antibiotics (Twelfth Report of the Joint FAO/WHO Expert Committee on Food Additives). FAO Nutrition Meetings Report Series No. 45/WHO Technical Report Series No. 430.

Griffith R. S., and Black H. R. (1970). Erythromycin. Medical Clinics of North America, 54 (5), 1199-1215.

Huber, W. G. (1977). Streptomycin, chloramphenicol and other antibacterial agents- Erythromycin: Chemotherapy of microbial, fungal and viral diseases, Meyer-Jones, N.H. Booth and L.E. McDonald, editors. Veterinary Pharmacology and Therapeutics, 49(section 13), 953-954.

Kroboth, P. D., Brown, A., Lyon, J. A., Kroboth, F. J., and Juhl, R. P. (1982). Pharmacokinetics of a single dose erythromycin in normal and alcoholic liver disease subjects. Antimicrobial Agents and Chemotherapy, 21 (1), 135-140.

Lee, C.-C., Anderson, R C., and Chen, K. K. (1953). Tissue distribution of erythromycin in rats. Antibiotics and Chemotherapy, III (9), 920-924.

Lee, C.-C., Anderson, R C., and Chen, K. K. (1956a). Distribution and excretion of radioactivity in rats receiving N-methyl-C14-erythromycin, J. Pharmacology and Experimental Therapeutics, 117, 265-273.

Lee, C.-C., Anderson, R C., and Chen, K. K. (1956b). The excretory products of N-methyl-¹⁴C-erythromycin in rats. *J. Pharmacology and Experimental Therapeutics*, 117, 274-280.

Martindale (The Extra Pharmacopoeia) (1989). Erythromycin (Reynolds, editor), 222-227.

Merck Index. Erythromycin (Budivari, editor), 577-578.

Nouws, J. F M., and Ziv, G. (1979). Distribution and residues of macrolide antibiotics in normal dairy cows. *Archiv für Lebensmittelhygiene*, 30, 202-208.

Periti, P., Mazzei, T., Mini E., and Novelli, A. (1989). Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states. *Clinical Pharmacokinetics*, 16 (4), 193-214.

Pineau, T., Galtier, P., Bonfils, C., Derancourt, J., Maurel, P. (1990). Purification of a sheep liver cytochrome P-450 from the P450III_A gene subfamily: its contribution to the N-dealkylation of veterinary drugs. *Biochemical Pharmacology*, 39 (5), 901-909.

Report No. PK 5251/E-00 (1988). Erythrocin injectable – Pharmacokinetic and residue study (in calves). SANOFI Santé Animale. Libourne, France.

Report No. PK 8400/E-00 (1988). Erythrocin soluble – Pharmacokinetic and residue study (in poultry). SANOFI Santé Animale. Libourne, France.

Report No. MPK/5814/9812 (1999). Depletion study of Erythromycin residues in edible tissues after repeated oral administrations of Erythrovet® to broiler chickens (20MG/KG/24H). SANOFI Santé Nutrition Animale. Libourne, France.

Report No. MPK/ERYTHROMYCIN/9957 (1999). Ratio of LC/MS/MS to microbiological determination of Erythromycin residues in edible tissues after oral administrations of Erythromycin to broiler chickens. SANOFI Santé Nutrition Animale. Libourne, France.

Report No. MPK/5814/0301 (2004). Residue study of Erythromycin in edible tissues of broiler chickens following repeated oral administrations of 5814 via the drinking water. CEVA Santé Animale. Libourne, France.

Report No. MPK/210H1/0148 (2004). Residue study of 210A in edible tissues following repeated oral administrations of 210H1 to broiler chickens. CEVA Santé Animale. Libourne, France.

Report No. MPK/5814/9908 (1999). Depletion study of Erythromycin-A and N-Desmethylethromycin-A residues in eggs after repeated oral administrations of Erythrovet® to laying hens (20MG/KG/24H). SANOFI Santé Nutrition Animale. Libourne, France.

Report No. MPK/ERYTHROMYCIN/9961 (1999). Ratio of LC/MS/MS to microbiological determination of Erythromycin residues in eggs after oral administrations of Erythrovet® to laying hens. SANOFI Santé Nutrition Animale. Libourne, France.

Report No. MPK/5814/0417 (2004). Residues study of erythromycin in eggs following repeated oral administrations of 5814 via the drinking water to laying hens (20MG/KG/24HOURS for 7 consecutive days). CEVA Santé Animale. Libourne, France.

Report No. MPK/5814/0225 (2003). Residue study of 210A in edible tissues following repeated oral administrations of 5814 to turkey (20MG/KG/24H). CEVA Santé Animale. Libourne, France.

Tsubaki, M., and Ichikawa, Y. (1985). Isolation and characterization of two consecutive forms of microsomal cytochrome P-450 from bovine liver. *Biochimica et Biophysica Acta.*, 830, 244-257.

Wang, J., Leung, D., and Butterworth, F. (2005). Determination of five macrolide antibiotic residues in eggs using liquid chromatography/electrospray ionization tandem mass spectrometry. *J. Agric. Food Chem.*, 53, 1857-1865.

Wilson, J. T., and Van Boxtel, C. J. (1978). Pharmacokinetics of erythromycin in man. *Antibiotics and Chemotherapy*, 25, 181-203.

Ziv, G. (1980). Practical pharmacokinetic aspects of mastitis therapy-3: Intramammary treatment. *Veterinary Medicine/Small Animal Clinician*, 657-670.

FLUMEQUINE

First draft prepared by
José Luis Rojas, Lanaseve, Costa Rica
Philip T. Reeves, Canberra, Australia

ADDENDUM


To the monographs prepared by the 48th, 54th and 60th meetings of the Committee and published in the FAO Food and Nutrition Papers 41/10, Rome 1998; 41/13, Rome 2000; and 41/15, Rome 2003

IDENTITY

Chemical name: 9-Fluoro-6,7-dihydro-5-methyl-1-oxo-1H,5H-benzo[*ij*]quinolizine-2-carboxylic acid

Synonyms: R-802, Apurone

Structural formula:



Molecular formula: C₁₄H₁₂NFO₃

Molecular weight: 261.26

OTHER INFORMATION ON IDENTITY AND PROPERTIES

Pure active ingredient: flumequine

Appearance: white microcrystalline powder

Melting point: 253-255°C

Solubility: Soluble in aqueous alkaline solutions and alcohol; insoluble in water

Optical rotation: Produced and used as a racemic mixture

BACKGROUND

Flumequine has previously been evaluated by the Committee at the 42nd, 48th, 54th, 60th and 62nd meetings. At its 42nd meeting, the Committee (WHO, 1995) was unable to establish an ADI for flumequine due to the lack of adequate information on the toxicological and microbiological hazards of flumequine and residue data were not provided for evaluation.

The 48th meeting of the Committee (WHO, 1998) established an ADI of 0-30 µg per kg of body weight based on the overall NOEL for hepatotoxicity of 25 mg per kg of body weight per day observed in a 13-week study in CD-1 mice and a safety factor of 1000. MRLs for flumequine of 500 µg/kg for muscle, 1000 µg/kg for liver, 3000 µg/kg for kidney and 1000 µg/kg for fat in cattle, expressed as parent drug, were recommended. Temporary MRLs of 500 µg/kg for muscle, 1000 µg/kg for liver, 3000 µg/kg for kidney and 1000 µg/kg for fat, expressed as parent drug, were recommended in sheep, chickens and pigs. The Committee also recommended a temporary MRL of 500 µg/kg for trout muscle (including normal proportions of skin), expressed as parent drug.

The 54th meeting of the Committee (WHO, 2001) evaluated data from studies conducted with radiolabelled flumequine in pigs, sheep, chickens and trout. Based on these studies, the Committee recommended MRLs of 500 µg/kg for muscle and liver, 3000 µg/kg for kidney and 1000 µg/kg for fat in cattle, pigs, sheep and chickens. The Committee also recommended an MRL of 500 µg/kg for trout muscle, including skin in natural proportions.

The 60th meeting of the Committee (WHO, 2003) evaluated new studies which further elucidated the mechanism of flumequine-induced hepatotoxicity in mice. Based on these studies, the Committee noted the possibility that flumequine induces tumours in the mouse liver by a mechanism that includes genotoxic effects. The Committee therefore withdrew the ADI that had been established at the 48th meeting and withdrew the MRLs that had been recommended at the 54th meeting.

The 62nd meeting of the Committee (WHO, 2004) reconsidered three short-term studies in mice that had been evaluated at the 60th meeting. The Committee also evaluated a new study conducted with flumequine in rat liver cells *in vivo* to assess unscheduled DNA synthesis. The Committee concluded that the available data supported a non-genotoxic, threshold-based mechanism for tumour formation by flumequine in the mouse liver. As a result, the Committee re-established the ADI of 0-30 µg/kg body weight that had originally been established for flumequine at its 48th meeting. The MRLs that had been recommended at its 54th meeting and withdrawn at its 60th meeting were also re-established.

The 62nd meeting of the Committee also recommended a temporary MRL of 500 µg/kg for muscle of black tiger shrimp (*Penaeus monodon*) based on the evaluation made at the 60th meeting. The MRL was temporary and the following information was requested by 2006:

- (i) A detailed description of a regulatory method, including its performance characteristics and validation data

The 60th meeting also evaluated residue depletion studies in shrimp. Flumequine was administered to shrimps at a rate of 12 mg/kg of body weight as a single intramuscular injection, or as a single forced oral dose, or as medicated feed for 5 consecutive days. Of the three methods of drug delivery, only medicated feed is practical for large-scale use in shrimp production. Flumequine delivery in feed resulted in the lowest concentration of residues in shrimp muscle, between 29.8 and 45.5 µg/kg of muscle during treatment, and depleting to less than the LOQ at 96 hours after withdrawal of medicated feed. Based on these data, dosing with 12 mg of flumequine per kg of body weight as medicated feed, the Committee considered it is unlikely to demonstrate efficacy against bacterial diseases in shrimp (FAO,

2003). In order to address this concern, the 62nd meeting, which re-established the ADI for flumequine, requested by 2006, information on the approved dose for treatment of black tiger shrimp and the results of the residue studies conducted at the recommended dose.

No new information was provided for evaluation by 2006.

Conditions of Use

Flumequine is a fluoroquinolone with antimicrobial activity against Gram-negative organisms. Fluoroquinolones specifically inhibit topoisomerase II (also referred to as DNA gyrase), an enzyme that controls the supercoiling of bacterial DNA by catalyzing the cleavage/reunion of the two strands in the DNA molecule. Binding of fluoroquinolones to DNA gyrase disrupts enzyme activity, resulting in rapid cell death. The bactericidal action of fluoroquinolones is rapid and concentration-dependent. However, activity is inhibited at very high concentrations through direct inhibition of RNA synthesis, which can be antagonized by protein synthesis inhibitors and RNA synthesis inhibitors (Maddison and Watson, 2002).

Flumequine is used in the treatment of enteric infections in food animals and in the treatment of bacterial infections in farmed fish. Flumequine also has limited use in humans for the treatment of urinary tract infections.

METHODS OF ANALYSIS

The 48th meeting of the Committee (FAO, 1998) considered an HPLC method with fluorescence detection for the analysis of flumequine and 7-hydroxyflumequine in the tissues of cattle, pigs, chickens, sheep, and trout. The method had not been properly validated for regulatory purposes. A similar analytical method, which had been validated and was suitable for regulatory purposes, was considered by the 54th meeting.

The 60th meeting of the Committee (FAO, 2003) considered an HPLC method with fluorescence detection for quantifying residues of flumequine in the muscle of black tiger shrimps. The Committee requested that detailed information on a regulatory method including method performance characteristics and method validation be submitted for review.

The present Committee considered two analytical methods for the determination of flumequine residues in shrimps. The first was a method submitted by the government of Thailand (ACFS, 2006) in response to a request by the 60th meeting of the Committee, and re-submitted for consideration by the 66th meeting. The second was a method reported by Pfenning et al. (1996) in the published literature.

Thailand submitted the method of Samuelsen (1990) modified for quantifying flumequine residues in shrimp. The tissue samples are mixed with anhydrous sodium sulfate and extracted twice with ethyl acetate. The sample mixture is centrifuged, and the organic phase removed, filtered and evaporated to dryness under nitrogen at 50-55°C. The residue is reconstituted in mobile phase for HPLC analysis using a C18 column with fluorescence detection (excitation 327 nm; emission 369 nm). A mobile phase of 0.1 M oxalic acid/acetonitrile/methanol (in a ratio, by volume, of 60:30:10) is applied at a flow rate of 1 mL/min.

A single laboratory validation study was conducted to demonstrate method performance. *Linearity* of calibration curves was demonstrated for concentrations of flumequine of 0.5-30 µg/kg ($r = 0.9997$) and 100-2000 µg/kg ($r = 0.9999$). *Accuracy* (recovery) was demonstrated at 5, 50 and 500 µg/kg. *Precision* (repeatability within laboratory) was demonstrated at 5, 50

and 500 µg/kg. The numerical performance characteristics for the method are summarized below.

Table 1: Performance characteristics of the liquid chromatographic assay for flumequine residues in shrimp muscle

Performance Characteristic	Shrimp Muscle
LOD (µg/kg)	1
LOQ (µg/kg)	5
Accuracy (%)	80-120
Precision (% CV)	5-7

The method submitted by the government of Thailand has been satisfactorily validated in a single laboratory study and is suitable for regulatory purposes.

Pfenning et al. (1996) reported a method for quantifying flumequine and nalidixic, oxolinic and piromidic acids in salmon and shrimp. The method is the same as that described by Munns et al. (1995) for analyzing residues of flumequine and nalidixic, oxolinic and piromidic acids in catfish. The method determines piromidic acid using liquid chromatography with UV detection, and flumequine, nalidixic acid and oxolinic acid using liquid chromatography with fluorescence detection (325 nm excitation, 360 nm emission). The analysis uses a polymer column in a 46° C oven. The mobile phase is 0.02 M phosphoric acid/acetonitrile/tetrahydrofuran (in a ratio, by volume, of 72:16:12). The identity of all four quinolones present as residues in muscle of salmon and shrimp was confirmed by gas chromatography/mass spectrometry (GC/MS).

Sample preparation involves homogenizing the tissue with acetone, evaporating the acetone and then defatting the extract with hexane and extracting the quinolone residues into chloroform. The extract is further purified by first partitioning into base and then back-extracting from a solution acidified to pH 6.0. The final residue is evaporated to dryness and dissolved in mobile phase for analysis.

Recovery determinations were conducted in composites of shrimp muscle at fortification concentrations of 5, 10, 20, 40 and 80 µg/kg of each quinolone. Average recoveries and relative standard deviations for shrimp, which represent an average of five concentrations for each of the four analytes, were from 81.3 to 91.2% and from 7.3 to 10.7%, respectively. The identity of all four analytes was confirmed in extracts of shrimp muscle fortified at 10 µg/kg by determination of decarboxylated quinolones by GC/MS. Recoveries and relative standard deviations for the determination of flumequine in shrimp muscle are presented in Table 2.

Table 2: Recovery of flumequine from fortified composites of shrimp muscle

Amount added, µg/kg	Mean (n=6), %	SD	RSD, %
5.23	108	11.6	10.8
10.46	94.4	5.82	6.2
20.92	79.4	7.46	9.4
41.84	87.1	3.82	4.4
83.68	87.0	10.5	12.0

No interference resulted from compounds co-eluting with flumequine at its retention time of approximately 12.8 minutes. The analysis of shrimp muscle for flumequine by this method presented no particular problems.

The liquid chromatography method reported by Pfenning et al. (1996) for quantifying flumequine in the muscle of shrimp is validated and suitable for regulatory purposes.

APPRAISAL

The 62nd meeting of the Committee requested information to allow consideration to be given to making the temporary MRL of 500 µg/kg for flumequine in muscle of black tiger shrimp (*Penaeus monodon*) permanent. The results of a single laboratory validation study of the modified Samuelson method were acceptable and the method was considered to be suitable for regulatory purposes. The Committee also considered a published report describing an analytical method for the determination of flumequine in shrimp (Pfenning et al., 1996). This method was similarly validated and considered suitable for regulatory purposes. These data satisfy the provision of new information in respect of a regulatory method as requested by the 62nd meeting.

The 60th meeting evaluated residue depletion studies in shrimp. Based on the available data, dosing with 12 mg of flumequine per kg of body weight as medicated feed is unlikely to demonstrate efficacy against bacterial diseases in shrimp (FAO, 2003). In order to address this concern, the 62nd meeting, which re-established the ADI for flumequine, requested additional information on the approved dose for the treatment of black tiger shrimps and the results of residue studies conducted at the recommended dose. No new information was provided for evaluation.

The present Committee noted the limited availability of approved veterinary drugs for the treatment of aquaculture species. This concern has been addressed by the Joint FAO/WHO Technical Workshop on Residues of Veterinary Drugs Without ADI/MRL, which convened in Bangkok in August 2004 (FAO/WHO, 2004). In the absence of data, the Committee could not apply any procedures to extrapolate between species. However, the Committee thought it appropriate to assign the temporary MRL for flumequine to the muscle of all freshwater and marine species of shrimp based on known species similarities.

MAXIMUM RESIDUE LIMITS

The Committee considered the following factors in recommending MRLs:

- An ADI of 0 – 30 µg per kg of body weight based on a toxicological endpoint, which results in a maximum daily intake of 1,800 µg for a 60 kg person.
- Flumequine is the marker residue in shrimp muscle.
- A validated liquid chromatography method with a LOQ of 0.5 µg/kg for flumequine in shrimp muscle is available and suitable for regulatory purposes.
- Information on the approved dose for the treatment of black tiger shrimp and the results of residue studies conducted at the recommended dose had been requested but no new data had been provided.
- The availability of veterinary drugs for the treatment of diseases in aquaculture species is limited.

Based on the above considerations, the Committee recommended maintaining the temporary MRL of 500 µg/kg for muscle of the black tiger shrimp (*Penaeus monodon*) and recommended a temporary MRL to all freshwater and marine species of shrimp. The theoretical maximum daily intake (TMDI) of flumequine residues accounts for 92% of the upper bound of the ADI (FAO, 2000). No suitable data were available to calculate an estimated daily intake (EDI) value. The Committee confirmed its previous request for

information on the approved dose for the treatment of diseases in shrimps and the results of residue depletion studies conducted at the recommended dose. This information is requested by the end of 2008.

REFERENCES

ACFS (National Bureau of Agricultural Commodity and Food Standards, Ministry of Agriculture and Cooperatives, Thailand) (2006). Determination of oxolinic acid and flumequine, National Food Institute, Laboratory Services Department, NFI T 9116, 8 February 2005.

CAC (2005). Report of the Fifteenth Session of the Codex Committee on Residues of Veterinary Drugs in Food (ALINORM 05/28/31).

FAO (1998). Flumequine. Residues of some veterinary drugs in animals and food (Monographs prepared by the forty-eighth meeting of the Joint FAO/WHO Expert Committee on Food Additives). FAO Food and Nutrition Paper 41/10, 59-70.

FAO (2000). Flumequine. Residues of some veterinary drugs in animals and food (Monographs prepared by the fifty-fourth meeting of the Joint FAO/WHO Expert Committee on Food Additives). FAO Food and Nutrition Paper 41/13, 43-52.

FAO (2003). Flumequine. Residues of some veterinary drugs in animals and food (Monographs prepared by the sixtieth meeting of the Joint FAO/WHO Expert Committee on Food Additives). FAO Food and Nutrition Paper 41/15, 43-46.

FAO/WHO (2004). Joint FAO/WHO Technical Workshop on Residues of Veterinary Drugs without ADI/MRL, 24-26 August 2004, Bangkok, Thailand.

Maddison, J.E., and Watson, A.D.J. (2002). Antibacterial drugs. In: Maddison, J.E., Page, S.W., Church, D., eds., *Small Animal Clinical Pharmacology*. W.B. Saunders, London, 144-145.

Munns, R.K., Turnipseed, S.B., Pfenning, A.P., Roybal, J.E., Holland, D.C., Long, A.R., and Plakas, S.M. (1995). Determination of residues of flumequine and nalidixic, oxolinic, and piromidic acids in catfish by liquid chromatography with fluorescence and UV detection. *J. AOAC International*, 78(2), 343-352.

Pfenning, A.P., Munns, R.K., Turnipseed, S.B., Roybal, J.E., Holland, D.C., Long, A.R., and Plakas, S.M. (1996). Determination and confirmation of identities of flumequine and nalidixic, oxolinic, and piromidic acids in salmon and shrimp. *J. AOAC International*, 79(5), 1227-1235.

Samuelsen, O.B. (1990). Simple and rapid method for the determination of flumequine and oxolinic acid in salmon (*Salmo salar*) plasma by high-performance liquid chromatography and fluorescence detection. *J. Chromatography*, 530, 452-457.

WHO (1995). Evaluation of certain veterinary drug residues in food (Forty-second report of the Joint FAO/WHO Expert Committee on Food Additives). WHO Technical Report Series, No. 851, Geneva.

WHO (1998). Evaluation of certain veterinary drug residues in food (Forty-eighth report of the Joint FAO/WHO Expert Committee on Food Additives). WHO Technical Report Series, No. 879, Geneva.

WHO (2001). Evaluation of certain veterinary drug residues in food (Fifty-fourth report of the Joint FAO/WHO Expert Committee on Food Additives). WHO Technical Report Series, No. 900, Geneva.

WHO (2003). Toxicological evaluation of certain veterinary drug residues in food (Prepared by the sixtieth meeting of the Joint FAO/WHO Expert Committee on Food Additives). WHO Food Additives Series, No. 51, Geneva.

WHO (2004). Evaluation of certain veterinary drug residues in food (Sixty-second report of the Joint FAO/WHO Expert Committee on Food Additives). WHO Technical Report Series, No. 925, Geneva.

MELENGESTROL ACETATE

**First draft prepared by
Philip T. Reeves, Canberra, Australia
Gerald E. Swan, Pretoria, South Africa**

ADDENDUM

to the monograph and its addendum prepared by the 54th, 58th and 62nd meetings of the Committee and published in FAO Food and Nutrition Papers 41/13, 41/14 and 41/16, respectively.

Melengestrol acetate (MGA) is an orally active progestogen. It is used to improve feed conversion efficiency, promote growth and suppress estrus in female beef cattle fed for slaughter. The range of approved doses is 0.25 to 0.50 mg/heifer daily. MGA is fed for the duration of the fattening/finishing period, usually 90 to 150 days. The Committee previously evaluated MGA at the 54th, 58th and 62nd meetings (FAO, 2000; FAO, 2002; FAO, 2004, respectively). An ADI of 0-0.03 µg/kg of body weight was established based on hormonal activity. At the 62nd meeting of the Committee, MRLs of 8 µg/kg for fat and 5 µg/kg for liver in cattle were recommended, considering the new studies for which sufficient material could be isolated to identify and measure the relative progestational activity of all metabolites from treated animals compared to parent drug. The Secretariat was made aware of an error in the calculation of the MRLs and placed MGA on the agenda for the purpose of recalculating the MRLs.

The 62nd meeting reported the structure and progestogenic activity of the major metabolites of MGA. The progestogenic activity of the metabolites relative to MGA ranged from 0.09% to 12%. The percent of the total progestogenic activity attributable to MGA and to its metabolites was estimated from the percent of the total radioactive residue attributable to MGA and to its metabolites, and by assuming the relative progestogenic potency of all metabolites of MGA was 12%. The present Committee used percent median tritium-labelled MGA data from the 54th meeting when estimating the percent of total progestogenic activity attributable to MGA and to its metabolites in fat, liver, muscle and kidney (Table 1).

Table 1: Conversion of total radioactivity to progestogenic activity for MGA-related residues in tissues

Tissue	% of total radioactive residue attributable to:		% of total progestogenic activity attributable to ^b		
	MGA ^a	MGA metabolites	MGA	MGA metabolites	Sum of progestogenic residues (%)
Fat	86	14	$\frac{86 \times 1 \times 100}{86 + (0.12 \times 14)}$	$\frac{14 \times 0.12 \times 100}{86 + (0.12 \times 14)}$	98.08 + 1.92 = 100
Liver	30	70	$\frac{30 \times 1 \times 100}{30 + (0.12 \times 70)}$	$\frac{70 \times 0.12 \times 100}{30 + (0.12 \times 70)}$	78.12 + 21.88 = 100
Muscle	40	60	$\frac{40 \times 1 \times 100}{40 + (0.12 \times 60)}$	$\frac{60 \times 0.12 \times 100}{40 + (0.12 \times 60)}$	84.75 + 15.25 = 100
Kidney	34	66	$\frac{34 \times 1 \times 100}{34 + (0.12 \times 66)}$	$\frac{66 \times 0.12 \times 100}{34 + (0.12 \times 66)}$	81.11 + 18.89 = 100

^a % Median ³H-MGA data from 54th meeting of the Committee.

^b The % of progestogenic activity of MGA-related residues is calculated by applying a weighting factor of 1 to MGA and of 0.12 (corresponding to the relative potency of the metabolite of MGA with the highest progestogenic activity) to all MGA metabolites in fat, liver, muscle and kidney, respectively.

The present Committee reconsidered data submitted to the 54th meeting. The Committee recommended that the MRLs should be derived from the 99th percentile of MGA concentrations in perirenal fat, collected either by biopsy or upon slaughter within short intervals after cessation of treatment, of feedlot animals treated with the highest recommended dose. The 54th meeting of the Committee had obtained this information by evaluating eight studies involving 370 animals treated at different doses (FAO, 2000). The majority of the animals (n=199) in two studies had been treated with the highest recommended dose of 0.5 mg MGA per heifer daily. The 99th percentile derived for MGA residues in perirenal fat for these animals was 18.5 µg/kg. There was relatively good agreement between this value and the 99th percentile value of 16.3 µg/kg for MGA residues in perirenal fat for all study animals derived by dose-response interpolations and dose extrapolations.

The median concentration of the marker residue obtained from a study with three animals treated with tritium-labelled MGA was 6.6 µg/kg for fat, 3.6 µg/kg for liver, 0.2 µg/kg for muscle and 0.6 µg/kg for kidney (Table 2). The proportion of the concentration found in the other three tissues, compared with perirenal fat that contains the highest residues, was derived from this study and was approximately 1:1.8 for liver, 1:33 for muscle and 1:11 for kidney.

MAXIMUM RESIDUE LIMITS

In recommending MRLs for MGA, the Committee considered the following factors:

- The parent drug, MGA, is the marker residue.
- Fat, which contains the highest residue, is the most suitable target tissue for the purpose of monitoring the residues of MGA.
- The median concentrations of the marker residue were 6.6 µg/kg for fat, 3.6 µg/kg for liver, 0.2 µg/kg for muscle and 0.6 µg/kg for kidney.
- The conversion of marker residue to total residue was based on the fraction of the total progestogenic activity attributable to the marker residue; this fraction was 0.98 for fat, 0.78 for liver, 0.85 for muscle and 0.81 for kidney.
- A validated analytical method previously identified is available and suitable for routine monitoring.
- The established ADI is 0-0.03 µg/kg bw, equivalent to 0-1.8 µg for a 60 kg person.

On the basis of the above considerations, the Committee recommended MRLs in cattle of 18 µg/kg in fat, 10 µg/kg in liver, 1 µg/kg in muscle and 2 µg/kg in kidney, expressed as MGA. The TMDI corresponding to these MRLs is 2.7 µg or 150 % of the upper bound of the ADI. The Estimated Daily Intake (see Table 2) is 0.9 µg or 50% of the upper bound of the ADI.

Table 2: Estimated daily intake of MGA residues

Tissue	Median MGA ^a (µg/kg)	Fraction of total progestogenic activity attributable to marker residue	Total residue (µg/kg)	Standard Food Basket (kg)	Intake of residues (µg)
Fat	6.62	0.98	6.8	0.05	0.34
Liver	3.60	0.78	4.6	0.1	0.46
Muscle	0.20	0.85	0.24	0.3	0.07
Kidney	0.61	0.81	0.75	0.05	0.04
EDI					0.9

^a Marker residue MGA

REFERENCES

FAO (2000). Melengestrol acetate. Residues of some veterinary drugs in animals and foods (Monograph prepared by the fifty-fourth meeting of the Joint FAO/WHO Expert Committee on Food Additives). FAO Food and Nutrition Paper 41/13, 75-86, Rome.

FAO (2002). Melengestrol acetate. Residues of some veterinary drugs in animals and foods (Monograph prepared by the fifty-eighth meeting of the Joint FAO/WHO Expert Committee on Food Additives). FAO Food and Nutrition Paper 41/14, 55-60, Rome

FAO (2004). Melengestrol acetate. Residues of some veterinary drugs in animals and foods (Monograph prepared by the sixty-second meeting of the Joint FAO/WHO Expert Committee on Food Additives). FAO Food and Nutrition Paper 41/16, 45-53, Rome.

RACTOPAMINE HYDROCHLORIDE

**First draft prepared by
Dr. James D. MacNeil, Saskatoon, SK, Canada,
Dr. Pascal Sanders, Fougères, France, and
Dr. Dieter Arnold, Berlin, Germany**

ADDENDUM

**to the Ractopamine Hydrochloride residue monograph prepared by the 62nd meeting
of the Committee and published in FAO Food and Nutrition Paper 41/16, Rome 2004**

The 62nd meeting of the Committee reviewed ractopamine hydrochloride and established an ADI of 0-1.0 µg per kg of body weight, equivalent to 0-60 µg for a 60 kg person, and recommended MRLs for edible tissues of pigs and cattle, expressed as ractopamine base: muscle, 10 µg/kg; liver, 40 µg/kg; kidney, 90 µg/kg; and fat, 10 µg/kg. The recommended MRLs result in a theoretical daily maximum intake of 50 µg, or 84% of the upper bound of the ADI, based on the JECFA model diet of 300 g of muscle, 100 g of liver and 50 g each of kidney and fat.

In considering these recommendations at its 15th Session in 2004, CCRVDF noted that the ADI recommended by JECFA had been rounded down resulting in a lower ADI than had been established by some member states (CAC, 2005). After further discussion concerning the JECFA policy on rounding the ADI to one significant figure, the CCRVDF agreed that JECFA should be requested to consider setting the MRLs using the calculated value obtained by dividing the NOEL by the safety factor and to recommend MRLs for ractopamine hydrochloride based on this result, not the one significant figure rounded value (0-1 µg per kg b.w.). The present Committee confirmed that the rounding practices used in expressing the ADI are scientifically and mathematically sound (see General considerations, page 2).

The present Committee reviewed the MRLs recommended at the 62nd meeting. The MRLs recommended for liver and kidney of pigs and cattle by the 62nd Committee were based primarily on the large set of available data from the pig studies, supported by the smaller number of studies and data for cattle. While these MRLs should accommodate the majority of situations involving slaughter within 12 hours of last treatment for both pigs and cattle, the available data for cattle suggest that the residue distribution between liver and kidney of cattle may not be the same as that in pigs.

The relationship between marker and total residues in cattle liver and kidney appears to be dose-dependent, so that the amount of marker residue in cattle liver may be as high as 80-85% of the marker residue found in kidney from the same animal. In one study (Study ABC-0408, 1989), conducted to assess relationships between marker and total residues, the mean residues found in livers and kidneys from 3 animals sacrificed 12 hours after the last treatment were 36 µg/kg and 43 µg/kg, respectively. This is higher than the residues ratio found in the cattle liver and kidney in other studies, where residues in liver varied from 32% of those found in kidney (Smith and Shelver, 2002) to 45% at 12 hours post-treatment (Study T4V739301, 1995). These studies were summarized in the FAO monograph prepared by the 62nd meeting of the Committee (FAO, 2004). No new data were provided for consideration at the present meeting of the Committee.

The study conducted at a dose equivalent to 45 mg/kg in feed by rumen insertion of a capsule containing the drug (Dalidowicz et al, 1987) was the only study where ractopamine parent

residues were detected in muscle and fat (0.02 and 0.01 mg/kg, respectively). Residues of parent ractopamine were not detected in the other studies where tissues were tested. Total radiolabelled residues were 0.01 to 0.05 mg/kg in muscle and fat at 12 hrs post-administration and depleted rapidly to non-detectable within a few days, even with administration above the recommended dose. Therefore, the recommendation of MRLs for muscle and fat of cattle based on the limit of quantitation (LOQ) was considered appropriate. The studies conducted at the recommended dose did not provide evidence that residues in liver and kidney of cattle would exceed the recommended MRLs for those tissues.

Pooled data from the depletion studies in pigs reviewed by the 62nd meeting of the Committee were evaluated using an Excel[®]-based worksheet. The data covering the time span from 12 to 120 hours after the last exposure used by the 62nd Committee in recommending the MRLs, were subjected to further statistical evaluations. Figures 1 and 2 show the data points, the linear regression line and a dotted line of the tolerance limits¹.

The Committee considered that the data available for residue depletion in cattle were not suitable for evaluation using the Excel[®] worksheet, due to the various dose rates and modes of administration used in the studies. A residue depletion study with unlabelled ractopamine administered in feed at the recommended maximum dose is required for the Committee to conduct this evaluation to reconsider the MRLs for cattle.




Figure 1: Depletion of marker residue in kidneys of ractopamine-treated pigs

¹ The upper limit of the one-sided 95 % confidence interval over the 95th percentiles is used throughout and referred to as “tolerance limit”.

The MRLs recommended by the 62nd JECFA are shown as a point “x” on the line showing the tolerance limits. The MRL for kidney is 90 µg/kg. The exact depletion time to reach this point is 9.324 hours. At this time point the distribution of marker residue concentrations between -4 and +4 standard deviations is shown in Figure 1. It has a median value of 14.97 µg/kg. The residue content corresponding to +4 standard deviations is 520 µg/kg; the content corresponding to -4 standard deviations is 0.431µg/kg, indicating that the residue contents in kidney show a high variability. The MRL for liver is 40 µg/kg. The exact time to reach this value is 2.39 hours. Figure 2 shows the distribution of residue contents at this time point. The median concentration is 9.8 µg/kg. The numerical value corresponding to +4 standard deviations is 151 µg/kg; the content corresponding to -4 standard deviations is 0.640 µg/kg. The concentrations in liver are lower than those measured in kidney and show a slightly smaller variability. The MRL in kidney determines the minimum depletion time to comply with both MRLs. The statistical approach using the Excel[®]-based worksheet would lead to approximately the same MRL recommendations made by the 62nd meeting of the Committee.




Figure 2: Depletion of marker residue in liver of pigs treated with ractopamine

The distribution of residue contents at time point “x” were used by the present Committee for testing different approaches to intake estimation. Based on one of the recommendations of the *Workshop on MRLs for Pesticides and Veterinary Drugs* held 7-10 November, 2005, in Bilthoven, The Netherlands, in the framework of the ongoing project “*Updating the Principles and Methods of Risk Assessment*”, the Committee considered the median value of the distribution of ractopamine residue concentrations (from which the MRL is derived) for

the calculation of conservative estimates of long-term (chronic) intakes. Different approaches were tested to investigate the variability of the estimate, taking account of the variability of the ratio between the marker residue and the total residue as functions of animal species, dose and time. After review of the results, the median value of the distribution of residue concentrations (from which the MRL is recommended) was used as a new point estimate instead of the recommended MRL. The calculations are based on the time (9.3 h) estimated to obtain 95% of ractopamine residues in kidney below the MRL of 90 µg/kg recommended for this tissue (Figure 1). The median residue concentrations calculated at this time were: liver, 8 µg/kg, kidney, 15 µg/kg, muscle, 5.0 µg/kg and fat 2.5 µg/kg. Using this approach, the data-derived factors for the transformation of marker residue concentrations to total residue concentrations were: muscle, 1.0; liver, 6.3; kidney, 3.1; fat, 1.0.

Applying this analysis to recommended MRLs, the Committee concluded that based on the available data the MRLs recommended by the 62nd Committee for liver and kidney of pigs and cattle remained appropriate. The Committee affirmed the MRLs recommended at the 62nd meeting of the Committee. Based on the median values and the data-derived factors, the corresponding daily intake estimate is 9.0 µg (see Table 1).

Table 1: Estimated Daily Intake of Ractopamine Residues from median value obtained from data for tissues from pigs

Food Item	Median (µg/kg)	Standard Food Basket (kg)	MR/TR ¹	EDI (µg)
Muscle	5.00	0.300	1.00	1.5
Liver	8.14	0.100	6.29	5.1
Kidney	14.97	0.050	3.05	2.3
Fat	2.50	0.050	1.00	0.1
Total:				9.0

¹ MR = marker residue (parent drug); TR = total residues

REFERENCES

CAC (2005). Report of the Fifteenth Session of the Codex Committee on Residues of Veterinary Drugs in Foods (ALINORM 05/28/31).

Dalidowicz, J.E., Lewis, J.J., Thomson, T.D. and Herberg, R.J. (1987). ¹⁴C-Ractopamine HCl Tissue Depletion Study in Cattle. Agricultural Biochemistry, Lilly Research Laboratories, Division of Eli Lilly and Company, Report Number ABC-0375.

FAO (2004). Ractopamine Hydrochloride. Residues of some veterinary drugs in animals and foods (Monograph prepared by the sixty-second meeting of the Joint FAO/WHO Expert Committee on Food Additives). FAO Food and Nutrition Paper 41/16, 75-92, Rome.

Smith, D.J. and Shelver, W.L. (2002). Tissue Residues of Ractopamine and Urinary Excretion of Ractopamine and Metabolites in Animals Treated for 7 days With Dietary Ractopamine. J. Anim. Sci., 80, 1240-1249.

Study ABC-0408 (1989). Tissue Residue Study in Cattle Dosed with 30 ppm of ¹⁴C-Ractopamine HCl. Agricultural Biochemistry, Lilly Research Laboratories, Division of Eli Lilly and Company, Report Number ABC-0408.

Study T4V739301 (1995). Determination of the Decline of Total Residues and Ractopamine HCl in Liver of Cattle Fed ¹⁴C-Ractopamine HCl. Animal Science Product Development, Lilly Research Laboratories, Division of Eli Lilly and Company, Report Number T4V739301.

TRICLABENDAZOLE

First draft prepared by
Dr. Janenuj Wongtavatchai, Bangkok, Thailand
Dr. J. D. MacNeil, Saskatoon, Saskatchewan, Canada

ADDENDUM
to the monograph prepared by the 40th meeting of the Committee
and published in FAO Food & Nutrition Paper 41/5


IDENTITY

Chemical name: 5-Chloro-6-(2,3-dichlorophenoxy)-2-methylthio-1H-benzimidazole
{ International Union of Pure and Applied Chemistry, or IUPAC, name};

Chemical Abstracts Service (CAS) number: 68786-66-3.

Synonyms: Triclabendazole (common name); CGA 89317, CGP 23030; proprietary names Fasinex[®], Fascinex[®], Soforen[®], Endex[®], Combinex[®], Parsifal[®], Fasimec[®], Genesis[™] Ultra.

Structural formula:



Molecular formula: C₁₄H₉Cl₃N₂OS

Molecular weight: 359.66

OTHER INFORMATION ON IDENTITY AND PROPERTIES

Pure active ingredient: triclabendazole

Appearance: White crystalline solid

Melting point: 175-176°C (Merck), α -modification; 162°C (β -modification)

Solubility: Soluble in tetrahydrofuran, cyclohexanone, acetone, *iso*-propanol, *n*-octanol, methanol; slightly soluble in dichloromethane, chloroform, toluene, xylene, ethyl acetate; insoluble in water, hexane.

RESIDUES IN FOOD

The 40th meeting of the Committee established an ADI of 0 – 3 μ g/kg body weight based on a long-term study in mice with a NOEL of 0.27 mg/kg body weight per day and a safety factor of 100. The Committee recommended MRLs in cattle and sheep. In cattle, the MRLs expressed as triclabendazole equivalents were: muscle and fat, 200 μ g/kg; liver and kidney, 300 μ g/kg. For sheep, MRLs for muscle, liver, kidney and fat were 100 μ g/kg. The marker residue was identified as 5-Chloro-6-(2', 3'-dichlorophenoxy)-benzimidazole-2-one. The 40th Committee concluded that more accurate estimates of total residues in edible tissues and the ratio of total residue concentrations to marker residue concentrations would be required before the MRLs for

triclabendazole in sheep could be reconsidered. The 15th Session of CCRVDF (Codex Committee on Residues of Veterinary Drugs in Foods) requested a new evaluation. Data were provided for cattle and sheep.

Conditions of Use

Triclabendazole is a benzimidazole anthelmintic used for the control of liver fluke, *Fasciola hepatica* and *Fasciola gigantica*, in sheep, goats and cattle. It is related both by chemical structure and pharmacological activity to other benzimidazole compounds, such as fenbendazole and thiabendazole.

Dosage

Triclabendazole is applied to cattle as a drench at 12 mg/kg body weight or as a pour-on at 30 mg/kg body weight. The recommended therapeutic oral dose for cattle is 12 mg/kg body weight and for sheep and goats is 10 mg/kg body weight. Veterinary advice differs from country to country regarding the interval for a possible repeat treatment, but typically at 8-10 week intervals during the fluke season, or at 5 to 6 week intervals when acute or sub-acute infection is present (FAO, 1993; EMEA, 1997).

PHARMACOKINETICS AND METABOLISM

The evaluation by the 40th Committee, that addressed studies using ¹⁴C-labelled triclabendazole in rats, rabbits, dogs, sheep, goats, cattle and pigs, considered that the absorption, distribution, metabolism and excretion of triclabendazole were qualitatively similar in both laboratory animals and food-producing animals. The biotransformation and excretion of triclabendazole was very rapid, with two major metabolic pathways identified: oxidation of the methylthiol group initially to a sulfoxide and subsequently to a sulfone metabolite, and 4-hydroxylation of the dichlorophenoxy ring (Figure 1). Five identified metabolites - triclabendazole, sulfoxide, sulfone, ring-hydroxylated metabolites and keto-triclabendazole accounted for approximately 40-60% of the administered dose, with quantitative differences in relative proportions of metabolites being observed between species. Faecal excretion of triclabendazole and its metabolites accounted for a principal portion of the dose.

Laboratory Animals

Rats


The absorption and disposition of ¹⁴C-triclabendazole was investigated in male rats following a single intravenous administration of 1 mg/kg body weight and by oral administration at different doses: single doses of 1, 10 and 80 mg/kg body weight, respectively; 10 daily doses of 1 mg/kg body weight (Study DM23/1991, 1996). Peroral absorption of triclabendazole was almost complete at the lower doses (1 mg/kg body weight) and decreased to about 50% at higher doses (10 mg/kg body weight). Within 48 hours, 87-92% of a 1 mg/kg dose (oral or intravenous administration) was excreted in urine and faeces. The major route of excretion was via the faeces, accounting for 82-85% of the dose. Maximum concentration of radioactivity in plasma was observed 8 hours after oral administration, irrespective of the dose levels. Concentrations of radioactivity measured at different periods after the administration indicated wide distribution of triclabendazole metabolites in rat tissues following oral and intravenous treatment.

In a subsequent GLP study, twelve male rats were given a single oral gavage dose of 12 mg/kg body weight ¹⁴C-triclabendazole (Study 1969/024, 2004). Recovery of radioactivity was quantified in the excreta and expired carbon dioxide collected daily from four rats for 10 days. Blood and tissues were collected at necropsy on days 10 (6 rats) and 28 (6 rats) for determination of radioactivity. The mean recovery in faeces from rats within 10 days after dosing was 96%, with a

mean recovery of 8% in urine. Less than 0.01% was detected in exhaled air. The major elimination of radioactivity in the faeces suggests that biliary excretion is significant in rats. Distribution of radioactivity in tissues (liver, kidney and muscle) showed the highest residue in kidney after 10 days and in kidney and muscle after 28 days. Chromatographic analysis of the radioactive extracts from excretions and tissues of rats killed on day 10 showed 4-12 metabolite fractions, none of which could be identified by comparison with the available reference standards.

In a GLP study of bioavailability of triclabendazole residues, male rats received a single dose of ¹⁴C-triclabendazole either orally by gavage or by intravenous administration or by addition to powdered diet or by dietary dose of ¹⁴C-triclabendazole derived residues from cattle tissues (Study 1969/026, 2004). Groups of rats which received ¹⁴C-triclabendazole derived residues from cattle tissues were given lyophilized liver, muscle and kidney from cattle that had been killed 28 days after receiving a single oral dose of 12 mg/kg body weight (Study 1969/023, 2004).

Figure 1: Proposed metabolic pathway of triclabendazole in laboratory and food-producing animals.



The maximum concentration of radioactivity in blood from rats after dietary administration of ¹⁴C-triclabendazole was found at 4 hours after gavage and 4.8 hours after dose in powdered diet, while the T_{max} was 12 and 6 hours in the groups administered lyophilised muscle and liver containing incurred residues of triclabendazole. Measurements of the area under the blood concentration time curve showed marked differences in the bioavailability of triclabendazole and triclabendazole-derived residues. The bioavailability of triclabendazole was 71.5% when given by gavage and 67.6% powdered diet, but reduced to 6.4% and 9.8% for triclabendazole-derived residues from lyophilized cattle muscle and liver, respectively.

The bioavailability of ¹⁴C-triclabendazole-derived residues in tissues collected from cattle and sheep was reported in two additional GLP studies using bile duct-cannulated male rats (Study 017AM04, 1995; Study 1969/025, 2004). In the first study (Study 017AM04, 1995), tissues containing triclabendazole residues were obtained from cattle that received a single oral dose of 12 mg/kg body weight (Study 380/214-1011, 1994) and sheep that received a single oral dose of 10 mg/kg body weight (Study 380/215-1011, 1994) respectively; and were terminated 28 days post-dosing. The lyophilized tissues were orally administered to rats as diet mixture for 24 hours. The observed amount of radioactivity into systemic circulation after the administration, the sum of the % of dose in urine, bile, tissues and carcass, defined the bioavailability. The bioavailability was 14% and 7% in kidney, 9% and 8% in liver, 4% and 5% in muscle for cattle and sheep, respectively. Similar to the bioavailability study using the areas under plasma concentration time curve (AUC) (Study 1969/026, 2004), the bioavailability of triclabendazole-derived residues from the lyophilized tissues was very low compared to the concentrations of triclabendazole observed following oral dosing to rats. The administered dose was almost completely eliminated within 48 hours, predominantly in faeces. The rats were killed 48 hrs after the initial administration and residues in tissues were determined by radioactivity. The residues were considered negligible and were only detected in livers and kidneys at concentrations less than the limit of quantification, 0.002 mg/kg.

In the second new GLP study of residue bioavailability (Study 1969/025, 2004), rats were offered, over a 24 hour period, lyophilized liver, muscle or kidney containing ¹⁴C triclabendazole residues from a cow dosed with triclabendazole at 12 mg/kg body weight and terminated at 28 days post administration (Study 1969/023, 2004). The bioavailability (defined as the % of dose in urine, bile, tissues and carcass) was 20%, 3.3% and 18% from liver, kidney and muscle, respectively. The mean recovery of radioactivity was > 90% with the majority eliminated in faeces (> 80%). Recovery in bile was 3-19% and in urine was < 1% of the administered dose. Absorbed residues did not depot in tissue of rats, as determined at 72 hours after dosing. Concentrations of radioactivity in tissues were very low or below the limit of quantification.

Dogs

A non-GLP study was reported in which 2 male dogs received doses of 0.5, 5 and 40 mg/kg body weight orally and 0.5 mg/kg body weight intravenously of ¹⁴C-triclabendazole (Study DM23/1991, 1996). The concentrations of ¹⁴C-triclabendazole-related residues in blood and plasma following oral administration showed that approximately 35-53% of a 0.5 mg/kg dose was absorbed at the lower doses, and the absorption decreased to about 25% at higher doses. In plasma, radioactivity attained the maximum concentration 8-24 hours after oral administration. Elimination of triclabendazole was almost exclusively *via* faeces. 79% and 54%, respectively, of the radioactivity associated with 0.5 mg/kg intravenous and oral dose of triclabendazole was recovered in faeces. Overall recovery in faeces and urine accounted for 80% of the intravenous dose and only 55% of the oral dose after 168 hours. Highest recovery of radioactivity in the excreta (90% of the dose) was found in the high dose of oral administration (40 mg/kg).

Food Producing Animals

Cattle

Studies considered by the 40th meeting of the Committee indicated rapid metabolism of triclabendazole following intravenous administration in cattle. The sulfoxide metabolites reached maximum concentrations in blood 4 hours after treatment, with terminal half-life of approximately 13 hours. The sulfone metabolites were produced more slowly with maximum plasma concentrations occurring 32 hours after dosing and terminal elimination half life of 40 hours (Study 86/12/1099, 1986; FAO, 1993).

In a new GLP study, two ruminating calves, one male and one female, were each given a single oral dose of ¹⁴C triclabendazole 12 mg/kg body weight (Study 380/214-1011, 1994). Excretion of radioactivity was measured in urine and faecal samples collected at 24 hour intervals for 7 days following administration. A small portion of the administered radioactivity was found in urine (2.2%), with excretion primarily in faeces (76%). As 4% of the dose was found in the faeces at 7 days post-dosing, it was considered that faecal elimination may not have been complete. Distribution of radioactivity was extensive into tissues at 28 days post-dosing. Highest concentrations of radioactivity were detected in liver (0.461 mg equivalents/kg), followed by muscle (0.33-0.35 mg equivalents/kg) and kidney (0.195 mg equivalents/kg). Only very low residues were detected in fat (0.05 - 0.08 mg equivalents/kg).

Further investigation of the urinary and faecal metabolites was conducted in another GLP study (Study 017AM02, 1995). Four metabolites were detected in the urine but could not be identified with the reference standards. However, no sulfate or glucuronide conjugates were detected in the urine. Eight metabolite fractions were detected in the faecal extracts, with the most polar fractions displaying a similar chromatographic behavior to the fractions found in urine. Parent triclabendazole was the major fraction, accounting for 17% of the dose. The other metabolites identified in the faecal extracts were 5-chloro-6-(2,3-dichloro-phenoxy)-2-methanesulfinyl-1H-benzimidazole, 5-chloro-6-(2,3-dichloro-phenoxy)-2-methanesulfonyl-1H-benzimidazole, 2,3-dichloro-4-(6-chloro-2-methylsulfonyl-3H-benzimidazole-5-yloxy)-phenol and 2,3-dichloro-4-(6-chloro-2-methanesulfonyl-3H-benzimidazole-5-yloxy)-phenol, representing, respectively, 3%, 5%, 4% and 3% of the dose.

In a subsequent GLP study (Study 1969/023, 2004); the distribution, metabolism and excretion of ¹⁴C triclabendazole was investigated in a ruminating male calf. Following a single oral dose of 12 mg/kg body weight, urine and faeces were collected for 10 days and the animal was killed 28 days after dosing. Similar to the previous studies (Study 380/214-1011, 1994; Study 017AM02, 1995), faecal elimination predominated, accounting for 78.2%, and urine contained only 3.4% of the dose. Triclabendazole was the major metabolite in faeces, with smaller amounts of sulfone, sulfoxide and hydroxylated metabolites. The majority of urinary metabolites were more polar than triclabendazole, including small amounts of 5-chloro-6-(2,3-dichloro-phenoxy)-2-methanesulfinyl-1H-benzimidazole, 5-chloro-6-(2,3-dichloro-phenoxy)-1,3-dihydro-benzimidazole-2-one, 2,3-dichloro-4-(6-chloro-2-methanesulfonyl-3H-benzimidazole-5-yloxy)-phenol, 2,3-dichloro-4-(6-chloro-2-methylsulfonyl-3H-benzimidazole-5-yloxy)-phenol and 2,3-dichloro-4-(6-chloro-2-methanesulfonyl-3H-benzimidazole-5-yloxy)-phenol. At 28 days after dosing, levels of triclabendazole residues measured by concentrations of radioactivity were highest in liver (0.283 mg equivalents/kg) and muscle (0.209 mg equivalents/kg). The residues in kidney were lower (0.163 mg equivalents/kg) and much lower residue amounts were detected in fat (0.026 mg equivalents/kg). The systemic levels of radioactivity in the blood (0.070 mg equivalents/kg) and plasma (0.051 mg equivalents/kg) were generally lower than in tissues.

The studies demonstrated that triclabendazole was rapidly absorbed following administration of oral therapeutic dose to cattle (12 mg/kg body weight) and principally excreted *via* faeces. The major metabolites in faeces were similar to those of rats. Residue concentrations in tissues 28 day

after dosing were highest in liver followed by muscle and kidney. The residues in fat were negligible compared to the other tissues.

Sheep

The absorption, distribution and excretion studies of triclabendazole in sheep and goats reported in the previous evaluation by the Committee indicated a similar metabolism of triclabendazole in sheep and goats to other species tested (FAO, 1993). The orally administered dose was absorbed effectively and metabolized rapidly. The same metabolites were excreted by sheep and goats, and the elimination was nearly complete by 10 days post dosing. More than 90% of the administered dose was recovered in faeces, 2-3% in urine and 0.5% in milk. Disposition of triclabendazole residues in sheep and goat tissue indicated by the amount of radioactivity was similar to that observed in cattle. At 28 days after dosing, liver contained the highest concentration, followed by muscle and kidney, whereas radioactivity amounts in fat tissue were comparatively minor.

New GLP studies of triclabendazole metabolism in ruminating sheep demonstrated a corresponding metabolic pattern to the previous studies. Following a single oral administration of ¹⁴C triclabendazole at nominal dose level (10 mg/kg body weight) to a male and a female sheep, the average recovery of radioactivity was 85% of dose at 7 days post-dosing (Study 380/215-1011, 1994). The primary route of excretion was in faeces, accounting for 77% of the administered dose. Absorption of triclabendazole, as indicated by radioactivity in plasma, was highest at 8 hours (19.59 mg equivalents/kg) and decreased to 10.05 mg equivalents/kg at 48 hours post-dosing. Distribution of radioactivity in tissues at 28 days post-dosing revealed highest levels in muscle (0.237-0.306 mg equivalents/kg), followed by liver (0.237 mg equivalents/kg) and kidney (0.198 mg equivalents/kg); while substantially lower levels were detected in fat tissue (0.02 mg equivalents/kg).

Chromatographic analysis of the excreta revealed 11 metabolite fractions in the faecal extracts and 5 metabolite fractions in urine (Study 017AM03, 1995). Only 5 components in faecal extracts co-chromatographed with the reference standards and corresponded to sulfoxide, sulfone, hydroxylated metabolites and unchanged triclabendazole. The major metabolic pathways in sheep were oxidation to the sulfoxide, with further oxidation to the sulfone, and hydroxylation of the dichlorophenyl moiety, essentially the same as found in cattle. As with the metabolite pattern observed for excretion in cattle (Study 380/214-1011, 1994; Study 017AM02, 1995; Study 1969/023, 2004), unchanged triclabendazole recovered from faecal samples was a dominant metabolite fraction, accounting for 16-17% of the dose. Metabolism and elimination in sheep was similar to that observed in the rat.

TISSUE RESIDUE DEPLETION STUDIES

Radiolabelled Residue Depletion Studies

Cattle

In a pilot GLP study to investigate depletion of total residues of triclabendazole, two ruminating cows (7-month old heifers) each received a single oral dose of ¹⁴C-triclabendazole at 12 mg/kg body weight (Study 400-05, 1991). The cows were sacrificed at 28 and 42 days, respectively, following drug administration and liver, kidney and composite muscle and fat samples were analyzed by combustion analysis to determine total residues in each tissue. Limits of determination were 0.002 mg/kg for liver, 0.003 mg/kg for kidney and muscle and 0.007 mg/kg for fat. The total residues found in tissues from each animal are given in Table 1.

Table 1: Total residues of ¹⁴C-triclabendazole in tissues of cows after treatment with a single oral dose (12 mg/kg body weight) of ¹⁴C-triclabendazole

Days post-treatment	Total ¹⁴ C-triclabendazole residues in tissues (Mean±SD, mg/kg)			
	muscle	liver	kidney	fat
28	0.131 ± 0.017	0.241 ± 0.013	0.106 ± 0.016	0.013 ± 0.003
42	0.097 ± 0.007	0.093 ± 0.009	0.069 ± 0.011	<0.008 ± 0.001

Tissues collected from the cow sacrificed at 28 days following drug administration were subsequently analyzed after approximately 5 months frozen storage at -20°C (Study 400-05A, 1992). Tissue samples (20 g) were extracted sequentially with 3 40-mL portions of methanol, followed by 3 portions of ethyl acetate. Recoveries of radiolabelled residues were low (liver, 13.8%; kidney, 4.7%; muscle, 4.7%; fat, 0.0%), so further characterization of the extracted residue was not attempted.

In a subsequent GLP study, liver, kidney and muscle tissues from a single male calf sacrificed 28 days following administration of ¹⁴C-triclabendazole, 12 mg/kg body weight, were analyzed to determine the relationship between the residues measured as keto-triclabendazole and the total residues (Study 1969/023, 2004). Residues measured as keto-triclabendazole accounted for 24% of the total residue in liver, 27% of the total residue in kidney and 32% of the total residue in muscle at 28 days post-administration.

Tissues collected from two ruminating calves slaughtered 28 days after administration of a single oral dose of ¹⁴C-triclabendazole, 12 mg/kg body weight (Study 380/214-1011, 1994), were analyzed to determine both keto-triclabendazole residues and total radiolabelled residues (Study 132/94, 1995). The results of the keto-triclabendazole analyses were not corrected for recovery in this study, conducted in compliance with GLP. Residues measured as keto-triclabendazole accounted for 13% of the total residue in liver, 21% of the total residue in kidney and 31% of the total residue in muscle at 28 days post-administration. After correcting the residues measured as keto-triclabendazole for recovery using the mean recoveries reported in the study for muscle, liver and kidney fortified at 0.1 mg/kg, the corrected percentages of marker-to-total residues were: muscle, 42%; liver, 19%; kidney, 24%.

Sheep

Muscle and liver tissues collected from two sheep slaughtered 28 days after administration of a single oral dose of ¹⁴C-triclabendazole, 10 mg/kg body weight (Study 380/215-1011, 1994), were analyzed to determine both keto-triclabendazole residues and total radiolabelled residues (Study 132/94, 1995). Concentrations of keto-triclabendazole (not corrected for recovery) accounted for 29% of the total residues in muscle and 17% of the residues in liver. After correction for analytical recovery, residues measured as keto-triclabendazole account for 39% and 24%, respectively, of the total residues in muscle and liver.

Residue Depletion Studies with Unlabelled Drug

Cattle

Three residue studies were reported in the monograph prepared by the 40th Committee (FAO, 1993) in which cattle received a single oral dose of 12 mg/kg body weight triclabendazole. In these studies, residues were measured as 5-chloro-6-(2,3'-dichlorophenoxy)-benzimidazole-2-one and converted to triclabendazole equivalents using a conversion factor of 1.0913. Two animals were slaughtered at each time point in the first two studies, while four cattle were slaughtered at each time point in the third study. The first and third studies included time points from 2 - 28 days,

while the second study was extended to 42 days. The studies demonstrated a consistent depletion profile, although the residue concentrations varied at the same or equivalent time points in the studies. In general, highest residues were observed in liver and kidney at times up to 7 days following treatment, while residues in fat were near or below the detection limits of the analytical methods used (0.03-0.06 mg/mg) at 14 days post-treatment. Residue concentrations in muscle tissue were lower than those in liver and kidney at 7-14 days post-treatment, but were similar at later time points. It was not stated whether these studies were conducted in compliance with GLP.

A new study was conducted in compliance with GLP in which 24 cattle (168 - 367 kg) were treated orally with triclabendazole at 18 mg/kg body weight, with a repeat treatment 28 days following the initial dose (Study Y03/49, 2004). Six animals were slaughtered at each of the 14, 28, 42 and 56 days sampling times following the second treatment. Samples of muscle (tenderloin), liver, kidney and renal fat were collected and analyzed for residues of keto-triclabendazole using a liquid chromatography method with a limit of quantification of 0.05 mg/kg. Results were corrected for analytical recovery. As in the earlier studies (FAO, 1993), highest residues were observed in kidney and liver at 14 days post-treatment, while mean residues in fat were <0.10 mg/kg. At 42 days post-treatment, residues in muscle and liver were similar, approximately 2.5 times higher than those in kidney, while residues were only detectable in muscle and liver at 56 days post-treatment (Table 2).

Table 2: Residues of triclabendazole measured as keto-triclabendazole in cattle tissues following two oral treatments (28 days between treatments) with triclabendazole (Fasinex® 10%) at 18 mg/kg body weight

Time following second treatment(days)	Residues of triclabendazole measured as keto-triclabendazole (Mean±SD, mg/kg)			
	Muscle	Liver	Kidney	Fat
14	0.238 ± 0.027	0.979 ± 0.235	0.656 ± 0.265	0.089 ± 0.029
28	0.14 ± 0.027	0.365 ± 0.083	0.129 ± 0.020	<0.050 - 0.062 ^a
42	0.127 ± 0.021	0.228 ± 0.054	0.066 ± 0.015	<0.050
56	0.091 ± 0.015	0.102 ± 0.033	<0.050	N.A. ^b

^a Only one of 6 fat samples contained residues at >0.050 mg/kg. ^b Not analyzed.

Sheep

Three residue depletion studies in which sheep were orally dosed with triclabendazole (single dose of 10 mg/kg body weight or 15 mg/kg body weight) were reported in the monograph prepared for the 40th meeting of the Committee (FAO, 1993). Residues depleted to below detection limits in fat (0.03 mg/kg) within 14-21 days after administration, but remained detectable in liver, kidney and muscle for 28 days. Highest residues were reported in liver at 21 days post-treatment, but results were similar in liver, kidney and muscle at 28 days post-treatment. It was not stated whether these studies were conducted in compliance with GLP.

A GLP study was provided to the current meeting of the Committee in which 24 lambs (29-42 kg body weight) received a single oral dose of 0.2 mL, equivalent to 10 - 13 mg/kg of triclabendazole body weight (Study Y04/22, 2004). Six animals were slaughtered at each of the time points 14, 28, 42 and 56 days post-treatment. Two control animals did not receive the treatment and were slaughtered prior to the first group of treated animals. Samples of liver, kidney, muscle and fat were collected from each animal and analyzed for residues of keto-triclabendazole by liquid chromatography, with results corrected for analytical recovery. Samples of some tissues were not analyzed from the later collection dates as all samples of these tissues collected at the previous date had been below the limit of quantification. Most persistent residues were found in muscle and were detectable in 3 of 6 animals at 56 days post-treatment. Residues were not detected in liver or kidney samples at 42 days post-treatment, or in fat samples at 14 days post-treatment.

Table 3: Residues of triclabendazole measured as keto-triclabendazole in sheep tissues following a single oral treatment with triclabendazole (Fasinex®-5 %) at 10 - 13 mg/kg b.w.

Days Post-Treatment	Triclabendazole residues measured as keto-triclabendazole (Mean±SD mg/kg)			
	Muscle	Liver	Kidney	Fat
Control	<0.05	<0.05	<0.05	<0.05
14	0.154 ± 0.030	0.429 ± 0.073	0.242 ± 0.031	<0.05
28	0.112 ± 0.030	0.158 ± 0.037	0.096 ± 0.022	N.A.
42	0.065 ± 0.014	<0.05	<0.05	N.A.
56	0.054 ± 0.003 ^a	N.A. ^b	N.A.	N.A.

^a Average for muscle from 3 animals with detectable residues. ^b Not analyzed.

METHODS OF ANALYSIS FOR RESIDUES IN TISSUES

Analytical methods for triclabendazole residues reviewed in the monograph prepared for the 40th meeting of the Committee were based on reversed phase liquid chromatography with UV-detection (FAO, 1993). The method used in the depletion studies considered by the 40th Committee measures the hydrolyzable residues of triclabendazole after oxidation to keto-triclabendazole, or 5-chloro-6-(2',3'-dichlorophenoxy)-benzimidazole-2-one, designated as the marker residue. Analytical recoveries were reported for tissues from cattle and sheep. A factor of 1.0913 was applied to convert the marker residue to triclabendazole equivalents. Several methods from the open literature were also noted in the monograph. However, validation of the methods reported was not to contemporary standards.

A report on the validation of an analytical method for the determination of triclabendazole residues in cattle and sheep tissues (liver, kidney, muscle, fat) was reviewed by the present Committee (Study V03/57, 2004). This is an up-dated version of a method considered by the 40th Committee. Tissues are initially digested with hot alkali solution to release bound residues, then acidified, cooled and extracted with dichloromethane. For fatty tissues, an additional step to remove lipids by hexane - acetonitrile partitioning is included. The extract is evaporated to dryness, then taken up in ethanol:glacial acetic acid (1:1) and heated following addition of hydrogen peroxide to oxidize the residues to keto-triclabendazole (the marker residue, identified as 5-chloro-6-(2',3'-dichlorophenoxy)-benzimidazole-2-one in the report of the 40th Committee). After a further partitioning step and evaporation to remove acetic acid, the residues are dissolved in dichloromethane, loaded on an anion exchange solid phase extraction cartridge and eluted with isopropyl alcohol/ dichloromethane (12% v/v).

The dried eluate is dissolved in acetonitrile and injected into the liquid chromatograph, with separation on a reversed phase (C-18) column and UV-detection at 296 nm. Quantification is by external standard curve. Performance characteristics determined for the method are summarized in Table 4. It should be noted that the limits of detection and quantification are based on estimates from calibration curves. The lowest concentration at which accuracy and recovery were tested and demonstrated to meet acceptable performance criteria was 0.050 mg/kg triclabendazole equivalents (0.046 mg/kg keto-triclabendazole).

No endogenous substances present in extracts produced a response in excess of the limit of quantification for keto-triclabendazole in any tissue. Other benzimidazole drugs, such as fenbendazole, thiabendazole and albendazole were not detected. It was noted that the detection wavelength of 296 nm limits potential interferences. The metabolites of triclabendazole, triclabendazole sulphoxide and triclabendazole sulphone, were detected, as was parent drug triclabendazole, but are fully separated by the chromatography conditions used in the method. It should be noted that these compounds would normally be oxidized to keto-triclabendazole during

the analysis. A confirmatory method was proposed which uses a phenyl liquid chromatography column as an alternative liquid chromatography system. Limits of quantification were higher than for the original method and the information obtained does not provide sufficient evidence for structural confirmation.

Table 4: Summary of validation study results for analysis of triclabendazole residues by liquid chromatography in various edible tissues

Species	Edible Tissue	Limit of Detection ^a (mg/kg)	Limit of Quantification ^b (mg/kg)	Mean Recovery (%)	Repeatability ^c (%)
Cattle	Muscle	0.012	0.036	81-100	2.1-8.5
	Liver	0.024	0.074	84-87	1.7-9.6
	Kidney	0.020	0.058	89-97	2.8-8.9
	Fat	0.007	0.020	78-90	10.1-6.1
Sheep	Muscle	0.014	0.041	80-102	3.1-5.2
	Liver	0.008	0.024	90-102	2.3-4.3
	Kidney	0.012	0.034	89-93	5.0-6.5
	Fat	0.015	0.042	79-102	10.0-6.8

^a Based on mean response of blank, plus 3 standard deviations

^b Based on mean response of blank, plus 10 standard deviations

^c Within run, measured at 0.050, 0.100 and 0.200 mg/kg

Further validation of the method for analysis of sheep and cattle tissues was provided in a subsequent report (Study V05/24, 2005). These studies demonstrated no background interferences, confirmed that precision was $\leq 15\%$ at concentration > 0.10 mg/kg and demonstrated the stability of the residues under freeze/thaw conditions.

The method has also been extended to the analysis of tissues from goats (study Y04/51, 2004). Results, given in Table 5, are based on analysis of three replicates at each of three concentrations for the three tissues tested (muscle, liver, kidney).

Table 5: Recovery and precision for determination of keto-triclabendazole residues in goat tissues

Tissue	Concentration keto-triclabendazole(mg/kg)					
	50		100		100 ^a	
	Recovery (%)	CV (%)	Recovery (%)	CV (%)	Recovery (%)	CV (%)
Muscle	99	2.2	102	2.2	95	4.1
Liver	110	13	97	3.4	91	11
Kidney	98	1.7	85	2.7	85	5.4

^a Fortified samples, analyzed after storage at room temperature for 16-24 hours.

The stability of residues of triclabendazole in cattle tissues, measured as keto-triclabendazole, was determined using incurred tissues from two animals collected in Study Y03/49 (Study V03/57, 2004a). Three replicates of each tissue were analyzed prior to storage and then at 1.5, 3 and 6.5 months after storage in a freezer room that was maintained at a temperature ranging from a maximum average of -8°C to a minimum average of -22°C over the time period of the study. The average results, corrected for recovery, given in Table 6, demonstrate that the residues remain essentially stable during this time period, with some decrease (maximum 33 %) being seen at the final time point.

Table 6: Stability of incurred triclabendazole residues in cattle tissues under typical conditions of frozen storage

	Residues measured as keto-triclabendazole, corrected for analytical recovery (mg/kg)		
	0 months (pre-storage)	2 months	4 months
Muscle 1	0.17 ± 0.01	0.15 ± 0.00	0.16 ± 0.01
Muscle 2	0.13 ± 0.01	0.12 ± 0.00	0.11 ± 0.006
Kidney 1	0.25 ± 0.013	0.27 ± 0.01	0.24 ± 0.00
Kidney 2	0.17 ± 0.01	0.15 ± 0.02	0.15 ± 0.00
Liver 1	0.47 ± 0.02	0.41 ± 0.04	0.41 ± 0.05
Liver 2	0.34 ± 0.01	0.27 ± 0.02	0.28 ± 0.02

A similar study of residue stability in sheep tissues under typical conditions of frozen storage was undertaken using incurred muscle, liver and kidney samples from two animals from Study Y04/22 (Study Y04/22, 2004a). Three replicates of each tissue were analyzed prior to storage and after 2 and 4 months of frozen storage. The storage temperature varied from -5°C to -21°C during the period of storage. As with the cattle tissues, there was minimal change in the residue concentrations during the period of storage (Table 7).

Table 7: Stability of incurred triclabendazole residues in sheep tissues under typical frozen storage conditions

	Residues measured as keto-triclabendazole, corrected for analytical recovery, (mg/kg)			
	0 months (pre-storage)	1.5 months	3 months	6.5 months
Muscle 1	0.23 ± 0.01	0.24 ± 0.00	0.21 ± 0.00	0.19 ± 0.02
Muscle 2	0.25 ± 0.01	0.24 ± 0.02	0.20 ± 0.01	0.17 ± 0.02
Kidney 1	0.48 ± 0.03	0.42 ± 0.01	0.43 ± 0.05	0.36 ± 0.02
Kidney 2	0.47 ± 0.03	0.47 ± 0.06	0.44 ± 0.04	0.41 ± 0.02
Liver 1	0.85 ± 0.04	0.80 ± 0.02	0.78 ± 0.15	0.70 ± 0.04
Liver 2	0.75 ± 0.04	0.76 ± 0.04	0.81 ± 0.05	0.62 ± 0.01

APPRAISAL

The previous evaluation by the 40th meeting of the Committee addressed studies using ¹⁴C-labelled triclabendazole in rats, rabbits, dogs, sheep, goats, cattle and pigs. The absorption, distribution, metabolism and excretion of triclabendazole were qualitatively similar in both laboratory animals and food producing animals. Following an oral dose of ¹⁴C-labelled triclabendazole, the biotransformation and excretion of triclabendazole was very rapid. Absorbed triclabendazole which entered the circulation was rapidly metabolized *via* two major pathways: oxidation of the methyl thiol group initially to a sulfoxide and later to a sulfone metabolite, and 4-hydroxylation of the dichlorophenoxy ring. Five identified metabolites, triclabendazole, sulfoxide, sulfone, ring-hydroxylated metabolites and keto-triclabendazole accounted for approximately 40-60% of the administered dose. Quantitative differences in relative proportions of metabolites were observed between species. Elimination of triclabendazole was nearly complete within 10 days after administration. Faecal excretion of triclabendazole and its metabolites accounted for the principal portion of the dose, with only minor elimination *via* urinary excretion.

New studies confirmed the findings in the report of the 40th Committee that absorption is rapid and is not dose-dependent in rats after oral dosing, reaching a maximum plasma concentration 8 hrs post-dose. The studies also confirmed that elimination is rapid, with approximately 90% of the dose eliminated through urine and faeces within 48 hrs, primarily through faeces (>80%). Studies in which rats were fed lyophilized tissues containing incurred residues of triclabendazole demonstrated that the bioavailability of these residues was low (<20%)

The biotransformation of triclabendazole is also rapid in dogs, with the sulfoxide and sulfone metabolites accounting for approximately all of an administered oral dose in plasma. Following oral administration, approximately 35-53% of a 0.5 mg/kg dose was absorbed, with a decrease to about 25% at higher doses. Maximum concentration in plasma occurred 8-24 hours after oral administration and elimination of triclabendazole was almost exclusively *via* faeces.

Previous studies have indicated rapid metabolism of triclabendazole following intravenous administration in cattle, with the sulfoxide metabolite achieving maximum concentrations in blood 4 hours after treatment, with terminal half-life of approximately 13 hours. Maximum plasma concentrations of the sulfone metabolite were observed 32 hours after dosing, with terminal elimination half-life of 40 hours.

The new studies confirmed that absorption and elimination were rapid in cattle and that, as in rats and dogs, elimination is primarily in faeces. The major metabolites in cattle faeces were similar to those of rats. Residue concentrations in tissues 28 day after dosing were highest in liver followed by muscle and kidney. The residue in fat was negligible compared to other edible tissues.

The studies of absorption, distribution and excretion of triclabendazole reviewed by the 40th Committee indicated that the metabolism of triclabendazole in sheep and goats was similar to that seen in other species tested. At 28 days after dosing with ¹⁴C- triclabendazole, liver contained the highest residue concentrations, followed by muscle and kidney, whereas residues were relatively negligible in fat tissue. The results of new studies of triclabendazole metabolism in ruminating sheep were consistent with the metabolic pattern seen in the previous studies. Faecal elimination accounted for 77% of the administered dose. Distribution of radioactivity in tissues at 28 days post-dosing revealed highest total residues in muscle, followed by liver and kidney.

Three residue depletion studies in cattle considered by the 40th Committee demonstrated that at 28 days following a single oral dose of 12 mg/kg body weight, average residue concentrations were 0.12 mg/kg in liver, 0.07 mg/kg in kidney, 0.11 mg/kg in muscle and 0.05 mg/kg in fat, representing, respectively, 50%, 66%, 84% and >100% of the total residues in these tissues.

Two new GLP studies using ¹⁴C-triclabendazole by oral administration at 12 mg/kg body weight provided additional information on the relationship between the marker and the total residues in cattle. In the first study, two ruminating calves were slaughtered 28 days after administration of a single oral dose of ¹⁴C-triclabendazole, 12 mg/kg body weight. Residues measured as keto-triclabendazole, corrected for analytical recovery, accounted for 24% of the total residue in liver, 19% of the total residue in kidney and 42% of the total residue in muscle at 28 days post-administration. Subsequently, residues were measured as keto-triclabendazole in tissues from a single calf killed 28 days after a single oral dose of ¹⁴C-triclabendazole, 12 mg/kg body weight. Residues measured as keto-triclabendazole accounted for the following percentages of the total residue in each tissue: liver 24%, kidney 27% and muscle 32%. These studies demonstrated that the relationships of marker to total residue calculated from information available to the 40th meeting of the Committee over-estimated the proportion of total residue present as marker residue.

In muscle and liver tissues collected from two sheep slaughtered 28 days after administration of a single oral dose of ¹⁴C-triclabendazole, 10 mg/kg body weight, residues measured as keto-triclabendazole, corrected for analytical recovery, accounted for 39% of the total residues in

muscle and 24% of the residues in liver. These results are consistent with those found in incurred tissues from cattle and with the relationships reported for sheep by the 40th Committee.

Based on the results of the new studies in cattle and sheep, factors for conversion of recovery-corrected residues measured as keto-triclabendazole to total residues are 4 for liver, 3.7 for kidney and 2.5 for muscle. No conversion factor was considered necessary for fat, given the limited distribution of residues in that tissue.

The new GLP studies in cattle and sheep gave results consistent with the distribution and depletion studies reviewed by the 40th Committee. Unlike the earlier studies, however, the new GLP study in cattle was conducted under conditions of repeat treatment, 28 days subsequent to the initial treatment, using a dose 1.5 times the recommended treatment. Highest residues measured as keto-triclabendazole were found in liver at all time points (14, 28, 42, 56 days), but residues in muscle were similar to those found in liver at 56 days after the second treatment. Residues were below the detection limit of 0.05 mg/kg in kidney at 56 days and were only detectable in fat at 14 days post-treatment. There were no detectable residues in fat at the later timepoints when residues in other tissues were approaching the MRLs. This eliminated residues in fat from inclusion in the calculation of theoretical maximum daily intake.

The three residue depletions studies with sheep orally dosed with triclabendazole (single dose of 10 mg/kg body weight or 15 mg/kg body weight) considered by the 40th Committee demonstrated that residues depleted to below detection limits in fat (0.03 mg/kg) within 14-21 days after administration, but remained detectable in liver, kidney and muscle for 28 days. Highest residues were reported in liver at 21 days post-treatment, but results were similar in liver, kidney and muscle at 28 days post-treatment. In the new GLP study considered by the present Committee, sheep received a single oral dose of 10-13 mg/kg body weight. Most persistent residues were in muscle, detectable in muscle from 50% of the animals at 56 days post-treatment. Residues were not detected in liver or kidney samples at 42 days post-treatment or in fat samples at 14 days post-treatment.

The results of the studies demonstrate that while liver is the tissue in which highest residues are initially found, particularly for cattle within approximately 4 weeks of treatment, muscle is also a suitable target tissue and is the preferred target tissue at longer times following treatment.

A suitable validated liquid chromatographic method was available for regulatory use to detect and quantify residues as keto-triclabendazole. However, a confirmatory method which meets contemporary criteria in many countries, such as one based on LC/MS, was not provided for review.

The median residues calculated for the residues represented by an MRL established at the 95/95 limit, reflecting the normal distribution in a group of animals in which the residues are below the MRL in 95% of the treatment group, were also considered as an alternative approach to estimation of a dietary intake. The median residue concentrations calculated from the data were: muscle, 88.5 µg/kg; liver, 99.5 µg/kg; kidney, 25 µg/kg; fat, 12.5 µg/kg. The value for fat is a default value intermediate between the LODs of the proposed regulatory method for fat of cattle and sheep and was selected to reflect that there were no detectable residues in fat when residues in liver and muscle are approaching the MRLs. Using the median residues approach, an estimate of dietary intake of residues from fat is included in the estimated daily intake calculation. Based on the median values, the corresponding daily intake estimate is 121.7 µg.

MAXIMUM RESIDUE LIMITS

In recommending MRLs, the Committee took into account the following factors:

- The marker residue is keto-triclabendazole.
- The appropriate target tissue is muscle.
- A validated analytical method is available for analysis of triclabendazole residues in edible tissues of cattle, sheep and goats.
- The bioavailability of incurred triclabendazole residues in tissues fed to rats did not exceed 20%.
- The factors calculated for conversion of marker-to-total residue in cattle tissues by the 40th meeting of the Committee, based on the then available studies, have been demonstrated to be incorrect by data from the more recent GLP studies which provided both total residue and marker residue concentrations from the same tissues.
- The factors to convert from marker to total residue, derived from mean results of the new GLP studies in cattle and sheep, are 4.3 for liver, 4.2 for kidney and 2.7 for muscle of cattle and sheep, calculated at 28 days after a single administration at the recommended dose. When multiple doses are used, these factors are sufficiently conservative to apply to the various timepoints where residues are at the MRLs. The same factors are applicable to goats, based on the available information. A factor was required for kidney as detectable residues were present below the LOQ at the timepoint used for calculation of the MRLs for liver and muscle, requiring their inclusion in the intake estimate. Due to the rapid depletion of residues in fat, a factor to convert marker to total residues was not required as the intake estimate based on one-half the LOQ of the analytical method provides a conservative estimate.
- Maximum residue limits for liver and muscle of cattle, sheep and goats were based on the mean residue concentrations plus 3 standard deviations from the new GLP studies in cattle and sheep. The time point for which the MRLs for cattle were calculated is 56 days following the second treatment at 1.5 times the recommended dose. Residues deplete more rapidly in cattle following a single treatment at the recommended dose. These MRLs will be achieved in sheep at a time point intermediate between 28 and 42 days after a single treatment at the recommended dose.
- Maximum Residue Limits for kidney and fat were based on twice the limit of quantification.
- An ADI of 0-3 µg per kg of body weight was established by the 40th meeting of the Committee, equivalent to 0-180 µg for a 60 kg person (WHO, 1993).

On the basis of the above considerations, the Committee recommended the following MRLs for edible tissues of cattle, sheep and goats, expressed as the marker residue, keto-triclabendazole.

Muscle	150 µg/kg
Liver	200 µg/kg
Kidney	100 µg/kg
Fat	100 µg/kg

The MRLs recommended above would result in a theoretical daily maximum intake of 230 µg, based on a daily food intake of 300 g of muscle, 100 g of liver, 50 g each of kidney and fat, or 128% of the upper bound of the acceptable daily intake. An estimate of residue intake calculated as the TMDI is tabulated as follows:

Table 8: Theoretical Maximum Daily Intake (TMDI) of Triclabendazole Residues

Food Item	MRL ($\mu\text{g}/\text{kg}$)	Standard Food Basket (kg)	MR/TR ¹	TMDI (μg)
Muscle	150	0.300	2.7	121.5
Liver	200	0.100	4.5	90
Kidney	100	0.050	3.7	18.5
Fat	100	0.050	1	-
Total:				230.0

¹ MR = marker residue (parent drug); TR = total residue

The Committee also calculated long term (chronic) exposure an estimated median daily intake, using the median values from the residue data used in recommending the MRLs. The median value of the distribution of residue concentrations from which the MRL is derived is used as new point estimate instead of the MRL. The Committee considers that this represents a more realistic estimate of intake, consistent with the approach to intake calculations used by the Joint FAO/WHO meeting on Pesticide Residues (JMPR). The median residue concentrations calculated from the data are: muscle, 88.5 $\mu\text{g}/\text{kg}$; liver, 99.5 $\mu\text{g}/\text{kg}$; kidney, 25 $\mu\text{g}/\text{kg}$; fat, 25 $\mu\text{g}/\text{kg}$. In the absence of quantifiable residues in kidney and fat at the time point where the MRLs were recommended, a value equal to one-half the LOQ was assigned as a conservative estimate of intake from kidney and fat. The median residue concentrations above would result in an estimated daily intake of 121 μg , based on a daily food intake of 300 g of muscle, 100 g of liver, 50 g each of kidney and fat, or 67% of the upper bound of the acceptable daily intake. Estimates of the residue intake calculated as the EDI are tabulated in Table 9.

Table 9: Estimated Daily Intake of triclabendazole residues

Tissue	Median residue concentration ($\mu\text{g}/\text{kg}$)	Standard Food Basket (kg)	MR/TR ¹	EDI (μg)
Muscle	88.5	0.300	2.7	71.7
Liver	99.5	0.100	4.3	42.8
Kidney	25	0.050	4.2	5.2
Fat	25	0.050	1	1.3
Total:				121.0

¹ MR = marker residue (parent drug); TR = total residue

REFERENCES

EMEA (1997). Committee for Veterinary Medicinal Products. Triclabendazole. Summary report (3), EMEA/MRL/196/97-FINAL.

FAO (1993). Triclabendazole. Residues of some veterinary drugs in animals and food (Monographs prepared by the fortieth meeting of the Joint FAO/WHO Expert Committee on Food Additives). FAO Food and Nutrition Paper 41/5, 63-86 Rome.

Study 86/12/1099 (1986). The Bioavailability of Triclabendazole and Its Sulphoxide Metabolite in Cattle. Ciba-Geigy Australia Ltd.

Study 400-05 (1991). Report No. 1375: Depletion of Total Drug-Related residues in Tissues of Beef Cattle treated with [¹⁴C]Triclabendazole (Pilot Study). Ciba-Geigy Corporation, Greensboro, North Carolina, U.S.A.

Study 400-05A (1992). Report No. 1375: The Characterization of [¹⁴C]Triclabendazole-Related Residues in Tissues from a Cow Treated with a Single Dose of [¹⁴C]Triclabendazole. Ciba-Geigy Corporation, Greensboro, North Carolina, U.S.A.

Study 380/214-1011 (1994). [¹⁴C]-CGA 89317: Absorption, Distribution and Excretion Following a Single Oral Administration of Fasinex[®]-10% to Ruminating Cattle. Hazleton Europe, Department of Metabolism and Environmental Chemistry, Harrogate, England.

Study 380/215-1011 (1994). [¹⁴C]-CGA 89317: Absorption, Distribution and Excretion Following a Single Oral administration of Fasinex[®]-5% to Ruminating Sheep. Hazleton Europe, Department of Metabolism and Environmental Chemistry, Harrogate, England.

Study 017AM02 (1995). Report No. 2/95. The Metabolite Profiles in Urine and Faeces Extract of Ruminating Cattle after Administration of [U-¹⁴C]Benz-Imidazole CGA 89317. Ciba-Geigy.

Study 017AM03 (1995). Report No. 3/95. The Metabolite Profiles in Urine and Faeces Extract of Ruminating Sheep after Administration of [U-¹⁴C]Benz-Imidazole CGA 89317. Ciba-Geigy.

Study 017AM04 (1995). Report No. 6/95. Bioavailability Study in Rats Fed with CGA 89317 Related Tissue Residues from Cattle and Sheep. Ciba-Geigy.

Study 132/94 (1995). Validation of Method REM 15/83: Determination of Common Moiety CGA 110754 in Muscle, Liver, Kidney and Fat of Cattle as well as in Muscle and Liver of Sheep After Administration of ¹⁴C-CGA 89317 by High Performance Liquid Chromatography (HPLC). Ciba-Geigy Limited, Basel, Switzerland.

Study DM23/1991 (1996). [¹⁴C]-CGP 23030: Absorption and Distribution Studies in Rats and Dogs. Ciba-Geigy Limited, Basel, Switzerland.

Study 1969/023 (2004). Report No. 1969/023-D1145. [¹⁴C]Triclabendazole: Distribution and Excretion Following Oral Administration to Cattle. Covance Laboratories Ltd, Harrogate, England.

Study 1969/024 (2004). Report No.1969/024-D1145. [¹⁴C]Triclabendazole: Absorption, Distribution, Excretion and Metabolism in the Rat. Covance Laboratories Ltd, Harrogate, England.

Study 1969/025 (2004). [¹⁴C]-Triclabendazole: Bioavailability of Total Residues in Bovine Tissue to Rats. Covance Laboratories Ltd.

Study 1969/026 (2004). Report No. 1969/026-D1145. [¹⁴C]-Triclabendazole: Pharmacokinetics in the Rat Following Oral and Intravenous Administration. Covance Laboratories Ltd, Harrogate, England.

Study V03/57 (2004). Report No. TR 04/05/1886. Validation of Analytical procedure No. 193F.00 - Determination of Residues of Triclabendazole in Animal Tissues by HPLC. Novartis Animal Health Australasia Pty. Ltd.

Study V03/57 (2004a). Report No. TR 04/07/1895. Addendum 1. Validation of Analytical procedure No. 193F.00 - Stability of Incurred Residues of Triclabendazole in Cattle Tissues Under Freezer Storage Conditions. Novartis Animal Health Australasia Pty. Ltd.

Study Y03/49 (2004). Tissue Residues Measured as CGA 110 754 in Cattle Following Repeated Oral Dosing with Fasinex 10%. Novartis Animal Health Australasia Pty. Ltd.

Study Y04/22 (2004). Tissue Residues of Triclabendazole Measured as CGA 110 754 in sheep following oral dosing with Fasinex 5%. Novartis Animal Health Australasia Pty. Ltd.

Study Y04/22 (2004a). Addendum 1. Tissue Residues of Triclabendazole Measured as CGA 110 754 in sheep following oral dosing with Fasinex 5% - Stability of Incurred Residues of Triclabendazole in Sheep Tissues Under Freezer Storage Conditions. Novartis Animal Health Australasia Pty. Ltd.

Study Y04/51. (2004). Report No. TR 04/09/1901. Validation of Analytical Procedure No. 193F.00 for Goat Tissues. Novartis Animal Health Australasia Pty. Ltd.

Study V05/24. (2005). Report No. TR 05/06/1945. Extended Validation of Analytical Procedure 193F.00 for Sheep and Cattle Tissues. Novartis Animal Health Australasia Pty. Ltd.

WHO (1993). Evaluation of Certain Veterinary Drug Residues in Food (Fortieth report of the Joint FAO/WHO Expert Committee on Food Additives). WHO Technical Report Series, No. 832.

ANNEX 1

Colistin (antimicrobial agent)

Acceptable daily intake: The Committee established an ADI of 0–7 µg/kg b.w., on the basis of the MIC₅₀ of 1 µg/g of colistin base for *E. coli*.

Residue definition: Sum of colistin A and colistin B

Recommended maximum residue limits (MRLs)

Species	Fat ^a (µg/kg)	Kidney (µg/kg)	Liver (µg/kg)	Muscle (µg/kg)	Milk ^b (µg/kg)	Eggs (µg/kg)
Cattle	150	200	150	150	50	
Sheep	150	200	150	150	50	
Goat	150	200	150	150		
Pig	150	200	150	150		
Chicken	150	200	150	150		300
Turkey	150	200	150	150		
Rabbit	150	200	150	150		

^a The MRL includes skin + fat where appropriate.

Erythromycin (antimicrobial agent)

Acceptable daily intake: The Committee established an ADI of 0–0.7 µg/kg b.w., on the basis of the MIC₅₀ of 0.1 µg/g for *Bifidobacterium*.

Residue definition: Erythromycin A

Recommended maximum residue limits (MRLs)

Species	Fat ^a (µg/kg)	Kidney (µg/kg)	Liver (µg/kg)	Muscle (µg/kg)	Eggs (µg/kg)
Chicken	100	100	100	100	50
Turkey	100	100	100	100	

^a The MRL includes skin + fat where appropriate.

Flumequine (antimicrobial agent)

Acceptable daily intake: The Committee established an ADI of 0–30 µg/kg b.w. at its sixty-second meeting (WHO TRS No. 925, 2004).

Residue definition: Flumequine

Recommended maximum residue limits (MRLs)

Species	Muscle (µg/kg)
Black tiger shrimp (<i>Penaeus monodon</i>)	500 ^a
Shrimp	500 ^{a,b}

^a The MRL is temporary. The following information is requested by the end of 2008:
(1) Information on the approved dose for the treatment of diseases in shrimp and the results of residue depletion studies conducted at the recommended dose.

^b The assignment of the temporary MRL applies to all freshwater and marine shrimp.

Melengestrol acetate (production aid)

Acceptable daily intake: The Committee established an ADI of 0–0.03 µg/kg bw at its fifty-fourth meeting (WHO TRS No. 900, 2001).

Residue definition: Melengestrol acetate

Recommended maximum residue limits (MRLs)

Species	Fat (µg/kg)	Kidney (µg/kg)	Liver (µg/kg)	Muscle (µg/kg)
Cattle	18	2	10	1

Ractopamine hydrochloride (production aid)

Acceptable daily intake: The Committee established an ADI of 0–1 µg/kg b.w. at its sixty-second meeting (WHO TRS No. 925, 2004).

Residue definition: Ractopamine

The Committee maintained the MRLs recommended at its sixty-second meeting (WHO TRS No. 925, 2004):

Species	Fat (µg/kg)	Kidney (µg/kg)	Liver (µg/kg)	Muscle (µg/kg)
Cattle	10	90	40	10
Pig	10	90	40	10

Trichlorfon (Metrifonate) (insecticide)

Acceptable daily intake: The Committee confirmed the ADI of 0–2 µg/kg b.w. established at its sixtieth meeting (WHO TRS No. 918, 2003).

Residues: The MRLs that were recommended by the sixtieth meeting of the Committee were not reconsidered and were maintained.

Triclabendazole (anthelmintic)

Acceptable daily intake: The Committee established an ADI of 0–30 µg/kg b.w. at its fortieth meeting (WHO TRS No. 832, 1993).

Residue definition: Keto-triclabendazole

Recommended maximum residue limits (MRLs)

Species	Fat (µg/kg)	Kidney (µg/kg)	Liver (µg/kg)	Muscle (µg/kg)
Cattle	100	100	200	150
Sheep	100	100	200	150
Goat	100	100	200	150

ANNEX 2

SUMMARY OF JECFA EVALUATIONS OF VETERINARY DRUG RESIDUES FROM THE 32ND MEETING TO THE PRESENT

The following table summarises the veterinary drug evaluations conducted by JECFA at the 32nd (1987), 34th (1989), 36th (1990), 38th (1991), 40th (1992), 42nd (1994), 43rd (1994), 45th (1995), 48th (1997), 50th (1998), 52nd (1999), 54th (2000), 58th (2002), 60th (2003), 62nd (2004) and 66th (2006) meetings. These meetings were devoted exclusively to the evaluation of veterinary drug residues in food. **This table must be considered in context with the full reports of these meetings, published as WHO Technical Report Series.**

Some notes regarding the table:

- The “ADI Status” column refers to the ADI and indicates whether an ADI was established; If a full ADI was given, or if the ADI is temporary (T).
- Where an MRL is temporary, it is indicated by “T”.
- Where a compound has been evaluated more than once, the data given are for the most recent evaluation, including the 66th meeting of the Committee.

Substance	ADI (µg/kg bw) (JMPR 1995)	ADI Status	JECFA ¹	MRL (µg/kg)	Tissue	Species	Marker residue and other remarks
Abamectin	0-1 (JMPR 1995)	Full	47 (1996)	100 50	Liver, Fat Kidney	Cattle	Avermectin B _{1a}
Albendazole	0-50	Full	34 (1989)	100 5000	Muscle, Fat, Milk Liver, Kidney	Cattle, Sheep	MRLs analyzed as 2-amino-benzimidazole, expressed as albendazole equivalents
Azaperone	0-6	Full	50 (1998)	60 100	Muscle, Fat Liver, Kidney	Pigs	Sum of azaperone and azaperol
Benzylpenicillin	<30µg/person/ day of the penicillin moiety	Full	36 (1990)	50	Muscle, Liver, Kidney	All species	Benzylpenicillin
Bovine Somatotropins	Not specified	Full	50 (1998)	Not specified	Muscle, Liver, Kidney, Fat, Milk	Cattle	
Carazolol	0-0.1	Full	43 (1994)	5 25	Muscle, Fat/skin Liver, Kidney	Pigs	Carazolol. The Committee noted that the concentration of carazolol at the injection site may exceed the ADI that is based on the acute pharmacological effect of carazolol
Carbadox	No ADI		60 (2003)	No MRL			The Committee decided that quinoxaline-2-carboxylic acid is not an appropriate marker residue
Ceftiofur	0-50	Full	48 (1997)	1000 2000 6000 2000 100	Muscle Liver Kidney Fat Milk	Cattle, Pigs	Desfuroylceftiofur
Cefuroxime	No ADI		62 (2004)	No MRL			
Chloramphenicol	No ADI		62 (2004)	No MRL			
Chlorpromazine	No ADI		38 (1991)	No MRL			
Chlortetracycline Oxytetracycline Tetracycline	0-30 (Group ADI)	Full	58 (2002)	200 600 1200 400 100 200 100	Muscle Liver Kidney Eggs Milk Muscle Muscle	Cattle, Pigs, Sheep, Poultry Poultry Cattle, Sheep Fish Giant prawn	Parent drugs, either singly or in combination Oxytetracycline only

¹ Only the last meeting of the Committee where the substance was on the agenda; earlier evaluations are referred to in the respective reports from the meetings

Substance	ADI ($\mu\text{g}/\text{kg bw}$)	ADI Status	JECFA	MRL ($\mu\text{g}/\text{kg}$)	Tissue	Species	Marker residue and other remarks
Clenbuterol	0-0.004	Full	47 (1996)	0.2 0.6 0.05	Muscle, Fat Liver, Kidney Milk	Cattle, Horses Cattle	Clenbuterol Closantel
Closantel	0-30	Full	40 (1992)	1000 3000 1500 5000 2000	Muscle, Liver Kidney, Fat Muscle, Liver, Kidney Fat	Cattle Sheep	Closantel
Colistin	0-7	Full	66 (2006)	150 200	Muscle, Liver, Fat Kidney	Cattle, Sheep, Goat, Chicken, Turkey, Pigs, Rabbits	Residue definition is the sum of Colistin A and colistin B. The MRL includes skin + fat where appropriate (chicken, turkey, pigs).
Cyfluthrin	0-20	Full	48 (1997)	50 300 20 200 40	Milk Eggs Muscle, Liver, Kidney Fat Milk	Cattle, Sheep Chicken Cattle	Cyfluthrin
Cyhalothrin	0-5	Full	62 (2004)	20 400	Muscle, Kidney Fat	Cattle, Sheep, Pigs	Cyhalothrin
Cypermethrin α -Cypermethrin	0-20 (Group ADI)	Full	62 (2004)	50 1000 100	Liver Liver Milk Muscle, Liver, Kidney Fat Milk	Cattle, Sheep Pigs Cattle, Sheep Cattle, Sheep	Total of cypermethrin residues (resulting from the use of cypermethrin or α -cypermethrin as veterinary drugs)
Danofloxacin	0-20	Full	48 (1997)	200 400 100 100 50 200 100	Milk Muscle Liver, Kidney Fat Muscle Liver Kidney Fat	Cattle, Sheep Cattle, Chicken Pigs	Danofloxacin For chicken fat/skin

Substance	ADI (µg/kg bw) (1982 JMPR)	ADI Status	JECFA	MRL (µg/kg)	Tissue	Species	Marker residue and other remarks
Deltamethrin	0-10 (1982 JMPR)	Full	60 (2003)	30	Muscle	Cattle, Chicken, Sheep, Salmon	Deltamethrin
Dexamethasone	0-0.015	Full	50 (1998)	No MRL	Liver, Kidney Fat	Cattle, Sheep, Chicken	
Diclazuril	0-30	Full	50 (1998)	50 3000 2000 1000	Muscle Liver Kidney Fat	Sheep, Rabbits, Poultry	Diclazuril
Dicyclanil	0-7	Full	60 (2003)	150 125 200	Muscle Liver, Kidney Fat	Sheep	Poultry skin + fat Dicyclanil
Dihydro- streptomycin Streptomycin	0-50 (Group ADI)	Full	58 (2002)	600 1000 200	Muscle, Liver, Fat Kidney Milk	Cattle, Pigs, Chicken, Sheep Cattle, Sheep	Sum of dihydrostreptomycin and streptomycin
Dimetridazole	No ADI		34 (1989)	No MRL			
Diminazene	0-100	Full	42 (1994)	500 12000 6000 150	Muscle Liver, Kidney Milk	Cattle	Diminazene
Doramectin	0-1	Full	62 (2004)	10 5 100 30 150	Muscle Muscle Liver Kidney Fat	Cattle Pigs Cattle, Pigs	Doramectin
Enrofloxacin	0-2	Full	48 (1997)	15 No MRL	Milk	Cattle	

Substance	ADI ($\mu\text{g}/\text{kg bw}$)	ADI Status	JECFA	MRL ($\mu\text{g}/\text{kg}$)	Tissue	Species	Marker residue and other remarks
Eprinomectin	0-10	Full	50 (1998)	100 2000 300 250 20	Muscle Liver Kidney Fat Milk	Cattle	Eprinomectin B _{1a}
Erythromycin	0-0.7	Full	66 (2006)	100 50	Muscle, Liver, Kidney, Fat/skin Eggs	Chicken, Turkey Chicken	Erythromycin.
Estradiol-17 β	0-0.05	Full	52 (1999)	Not specified	Muscle, Liver, Kidney, Fat	Cattle	
Febantel Fenbendazole Oxfendazole	0-7 (group ADI)	Full	50 (1998)	100 500	Muscle, Kidney, Fat Liver	Cattle, Goat, Horses, Pigs, Sheep	Sum of febantel, fenbendazole and oxfenbendazole, expressed as oxfendazole sulfone equivalents
Fenbendazole (see Febantel)							
Fluazuron	0-40	Full	48 (1997)	200 500 7000	Muscle Liver, Kidney Fat	Cattle	Fluazuron
Flubendazole	0-12	Full	40 (1992)	10 200 500 400	Muscle, Liver Muscle Liver Eggs	Pigs Poultry	Flubendazole
Flumequine	0-30	Full	66 (2006)	500 1000 500 3000	Muscle Fat Liver Kidney	Cattle, Sheep, Pigs, Chicken	Flumequine.
Furazolidone	No ADI		40 (1992)	No MRL			
Gentamicin	0-20	Full	50 (1998)	100 2000 5000 200	Muscle, Fat Liver Kidney Milk	Trout Black Tiger Shrimp Shrimp Cattle, Pigs Cattle	The MRLs are temporary for Black Tiger Shrimp and Shrimp. The MRLs for shrimp applies to all fresh water and marine shrimp. Gentamicin

Substance	ADI (µg/kg bw)	ADI Status	JECFA	MRL (µg/kg)	Tissue	Species	Marker residue and other remarks
Imidocarb	0-10	Full	60 (2003)	300 1500 2000 50	Muscle Liver Kidney Fat, Milk	Cattle	Imidocarb, free base
	No ADI		34 (1989)	No MRL			
Isometamidium	0-100	Full	40 (1992)	100 500 1000	Muscle, Fat, Milk Liver Kidney	Cattle	Isometamidium
	0-1	Full	58 (2002)	100 40	Liver Fat	Cattle	Ivermectin B _{1a}
Levamisole	0-6	Full	42 (1994)	10 100	Muscle, Kidney, Fat Liver	Cattle, Sheep, Pigs, Poultry	Levamisole
	0-30	Full	58 (2002)	200 500 1500 500 100 150	Muscle Liver Kidney Kidney Fat Milk	Chicken, Pigs Chicken, Pigs Pigs Chicken Chicken, Pigs Cattle	Lincomycin A separate MRL of 300 µg/kg for skin with adhering fat in pigs was recommended in order to reflect the concentrations found in skin of pigs. For consistency, an MRL of 300 µg/kg for skin with adhering fat for chicken was recommended.
Melengestrol	0-0.03	Full	66 (2006)	1 10 2 18	Muscle Liver Kidney Fat	Cattle	Melengestrol acetate
	No ADI		34 (1989)	No MRL			
Moxidectin	0-2	Full	50 (1998)	20 50 100 50 500	Muscle Muscle Liver Kidney Fat	Cattle, Deer Sheep Cattle, Deer, Sheep	Moxidectin The Committee noted very high concentrations and great variation in the residue levels at the injection site in cattle over a 49-day period after dosing.

Substance	ADI (µg/kg bw)	ADI Status	JECFA	MRL (µg/kg)	Tissue	Species	Marker residue and other remarks
Neomycin	0-60	Full	60 (2003)	500	Muscle, Fat, Liver	Cattle, Chicken, Sheep, Turkey Goat, Pigs, Duck	Neomycin
Nicarbazin	0-400	Full	50 (1998)	10000 500 1500 200	Kidney Eggs Milk Muscle, Liver, Kidney, Fat/skin	Cattle, Chicken, Sheep, Turkey Goat, Pigs, Duck Chicken Cattle Chicken (broilers)	N,N'-bis(4-nitrophenyl)urea
Nitrofurazone/ Nitrofuraf	No ADI		40 (1992)	No MRL			
Olaquinox	No ADI		42 (1994)	No MRL			The Committee recommended no MRLs but noted that 4µg/kg in muscle of pigs of the metabolite MQCA (3-Methylquinoxaline-2-carboxylic acid) is consistent with Good Veterinary Practice.
Oxendazole (See Febantel)							
Oxolinic acid	No ADI		43 (1994)	No MRL			
Oxytetracycline (See chlortetracycline)							
Permethrin	No ADI		54 (2000)	No MRL			
Phoxim	0-4	Full	62 (2004)	50 400	Muscle, Liver, Kidney Fat	Goat, Pigs, Sheep	Phoxim
Pirlimycin	0-8	Full	62 (2004)	100 1000 400 100	Muscle, Fat Liver Kidney Milk	Cattle	Pirlimycin
Porcine Somatotropin	Not Specified		52 (1999)	Not Specified	Muscle, Liver, Kidney, Fat	Pigs	
Procaine benzylpenicillin	< 30µg/person/ day of the penicillin moiety	Full	50 (1998)	50 4	Muscle, Liver, Kidney Milk	All species	Benzylpenicillin

Substance	ADI (µg/kg bw)	ADI Status	JECFA	MRL (µg/kg)	Tissue	Species	Marker residue and other remarks
Progesterone	0-30	Full	52 (1999)	Not Specified	Muscle, Liver, Kidney, Fat	Cattle	
Propionyl-promazine	No ADI		38 (1991)	No MRL			
Ractopamine	0-1	Full	66 (2006)	10 40 90	Muscle, Fat Liver Kidney	Cattle, Pigs	Ractopamine
Ronidazole	No ADI		42 (1994)	No MRL			
Sarafloxacin	0-0.3	Full	50 (1998)	10 80 20	Muscle Liver, Kidney Fat/skin	Chicken, Turkey	Sarafloxacin
Spectinomycin	0-40	Full	50 (1998)	500 2000 5000	Muscle Liver, Fat Kidney	Cattle, Chicken, Pigs, Sheep	Spectinomycin
Spiramycin	0-50	Full	48 (1997)	200 600	Eggs Milk Muscle Liver	Chicken Cattle Pigs	For cattle and chicken, MRLs are expressed as the sum of spiramycin and neospiramycin. For pigs, the MRLs are expressed as spiramycin equivalents (antimicrobial active residues).
Streptomycin (See dihydro-streptomycin)				300 800	Kidney Kidney	Cattle, Chicken, Pigs	
Sulfadimidine	0-50	Full	42 (1994)	300 200	Fat Milk	Cattle, Chicken, Pigs Cattle	Sulfadimidine
Sulfathiazole	No ADI		34 (1989)	100 25 No MRL	Muscle, Liver, Kidney, Fat Milk	Cattle, Sheep, Pigs, Poultry Cattle	

Substance	ADI ($\mu\text{g}/\text{kg bw}$)	ADI Status	JECFA	MRL ($\mu\text{g}/\text{kg}$)	Tissue	Species	Marker residue and other remarks
Testosterone	0-2	Full	52 (1999)	Not specified	Muscle, Liver, Kidney, Fat	Cattle	
Tetracycline (See chlortetracycline)							
Thiamphenicol	0-5	Full	58 (2002)	No MRL			
Tiabendazole (Thiabendazole)	0-100	Full	58 (2002)	100	Muscle, Liver, Kidney, Fat	Cattle, Pigs, Goat, Sheep	Sum of tiabendazole + 5-hydroxy tiabendazole
				100		Cattle, Goat	
Tilmicosin	0-40	Full	47 (1996)	100	Muscle, Fat	Cattle, Pigs, Sheep	Tilmicosin
				1000	Liver	Cattle Sheep	
				1500	Liver	Pigs	
				300	Kidney	Cattle, Sheep	
				1000	Kidney	Pigs	
				50 T	Milk	Sheep	
Trenbolone acetate	0-0.02	Full	34 (1989)	2	Muscle	Cattle	β Trenbolone for muscle
				10	Liver		α -Trenbolone for liver
Trichlorfon (Metrifonate)	0-2	Full	66(2006)	50	Milk	Cattle	Trichlorfon
				50	Muscle, Liver, Kidney, Fat		Guidance MRLs at the limit of quantitation of the analytical method for monitoring purposes. No residues should be present in tissues when used with Good Veterinary Practice.
Triclabendazole	0-3	Full	66 (2006)	150	Muscle	Cattle, Sheep, Goats	Keto-triclabendazole
				100	Fat, Kidney		
				200	Liver		
Tylosin	No ADI		38 (1991)	No MRL			
Xylazine	No ADI		47 (996)	No MRL			
Zeranol	0-0.5	Full	32 (1987)	2	Muscle	Cattle	Zeranol
				10	Liver		

CORRIGENDUM

RESIDUES OF SOME VETERINARY DRUGS IN ANIMALS AND FOODS FAO FOOD AND NUTRITION PAPER 41/12, ROME, 1999.

Table 61, pages 85-86, is replaced by the table below.

Table 61. Calculations of excess TMDI from bovine animals treated with estradiol-17 β , progesterone and testosterone

	Animals	Comments	Description of the treatment of the animals	Theoretical Maximum Daily Intakes [nanograms/person/day]					
				E ₁	E ₂ -17 α	E ₂ -17 β	excess E ₁ +E ₂ - β	P	T
Synovex-S (E ₂ -b+P)	Steers	1	Control animals Animals slaughtered 15 days after implantation	1.0		0.5		190	
				2.0		6.3	6.8	254	
Synovex H (E ₂ -b+T-p)	Heifers	1	Control animals Animals slaughtered 15 days after implantation	1.4		1.5			17
				3.9		15	16		70
Synovex-C (E ₂ -b+T) Synovex-H (E ₂ -b+T-p)	Calves a) female	1	Control animals, slaughtered on day 61 Control animals, slaughtered on day 119 Control animals, slaughtered on day 240 Control animals, slaughtered on day 301 Control animals, slaughtered on day 329 Control animals, slaughtered on day 360 implanted day 0; slaughtered on day 119	1.1		3.5		22	
				1.2		2.2		53	
				0.8		1.7			13
				1.4		4.4			22
				0.7		2.1			22
				2.0		3.0			51
				3.0		3.7	3.3	520	
				0.8		0.7		501	
				0.4		0.5		552	
				1.1		1.2		669	
Synovex S (E ₂ -b+P)	Calves castrated males	1	Control animals, slaughtered on day 61 Control animals, slaughtered on day 119 Control animals, slaughtered on day 240 Control animals, slaughtered on day 301 Control animals, slaughtered on day 329 Control animals, slaughtered on day 360 implanted on days 0, 118, 240; slaughtered on day 301	0.5		0.9		421	
				1.2		0.7		536	
				0.8		1.0		1170	
				3.7		11	13.3	540	
				93		16			203
				113		16			172
				34		15	-80		233
				280		48			282
				107		24	-197		237
				326		139			377
377		49	-39		326				
Synovex H (E ₂ -b+T-p)	Pregnant heifers	2	120 days pregnant, unsynchronized controls 120 days pregnant, synchronized controls 120 days pregnant, 61 days implanted 180 days pregnant, synchronized controls 180 days pregnant, 61 days implanted 240 days pregnant, synchronized controls 240 days pregnant, 61 days implanted						
Steer-oid (E ₂ + P) Heifer-oid (E ₂ +T-p)	Steers Heifers	3	Control animals Animals slaughtered 15 days after implantation Control animals Animals slaughtered 15 days after implantation					299	
							4	375	43
CompuDose (E ₂)	Steers	4	Control animals Animals implanted 70-180 days	4.4		4.5			
				7.4		5.7	4.2		48

Table 61. Calculations of excess TMDI from bovine animals treated with estradiol-17 β , progesterone and testosterone

Product	Animals	Comments	Description of the treatment of the animals	Theoretical Maximum Daily Intakes [nanograms/person/day]					
				E ₁	E ₂ -17 α	E ₂ -17 β	excess E ₁ +E ₂ - β	P	T
Compoundose (E ₂)	heifers	4	Control animals Animals implanted 84 days	3.1		3.7			
				3.6		4.3			
Compoundose (E ₂)	Bull calves	4	Control animals Animals implanted	4.0		4.0	15		
				9.0		14			
Compoundose (E ₂)	Bulls	4	Control animals Animals implanted	3.8		3.3	3.8		
				5.0		5.9			
FINAPLIX (Tb-ac)	ZEBU Steers	4	Control animals Animals implanted	6.1		3.6	-1.9		
				4.4		3.4			
FINAPLIX (Tb-ac)	Heifers	5	implanted animals, slaughtered on day 15 implanted animals, slaughtered on day 30 implanted animals, slaughtered on day 60 implanted animals, slaughtered on day 75	4.6		23	27.6		
				5.2		29	34.2		
				3.9		13	16.9		
				3.7		14	17.7		
				3.1		19			
TORELOR (Tb-ac+E ₂)	Steers	5	Control animals Animals implanted on day 0; slaughtered on day 30 Animals implanted on days 0, 60; slaughtered on day 90	11		66	54.9		
				7.3		89	74.2		
Revalor (Tb-ac +E ₂)	Heifers Steers	6	Control animals Animals implanted 30 days Control animals Animals implanted 15 days			1.0	5.6		
						6.6		2.0	
Revalor (Tb-ac +E ₂) Implix BM (E ₂ +P)	Calves	7	Male control animals, slaughtered on day 30 Male control animals, slaughtered on day 80 Revalor implanted, slaughtered on day 80 Revalor/Implix implanted, slaughtered on day 100	57		6.6	628		
				69		7.7	493		
Revalor (Tb-ac +E ₂) Implix BF (E ₂ +T)	Calves	7	Female control animals, slaughtered on day 30 Female control animals, slaughtered on day 80 Revalor implanted, slaughtered on day 80 Revalor/Implix implanted, slaughtered on day 15	132		63	55.3		
				233		97	667		
				60		6.5		19	
				59		8.6		493	
				111		61	52.4		
				179		99	83.9		208

The calculations of intakes are based on determinations of the concentrations of free hormones in muscle, liver, kidney and fat. The fractions of the conjugated hormones were not determined. To obtain an estimate of the degree of under-estimation of the "true" TMDI, information from a study with implants containing ¹⁴C-labelled hormones/hormone esters in the same proportions as in the commercial products can be used. Based on total radioactivity found in tissues of animals slaughtered 15 days after implantation and on the fractions of total residues identified as conjugates the individual contributions in percent of the TMDI of the free vs. conjugated fractions present in the four standard edible tissues have been calculated as follows in the below table. From these data it appears justifiable to multiply the estimates of TMDI's for consumption of tissues from steers/heifers implanted with Synovex S / Synovex H with a factor of two. This correction is probably not relevant in the case of progesterone, where the tentatively identified conjugated metabolites have no significant gestagenic properties.

FAO TECHNICAL PAPERS

FAO JECFA MONOGRAPHS

- 1 Combined compendium of food additive specifications – JECFA specifications monographs from 1st to 65th meeting. (E)
Vol. 1 Food additives A – D
Vol. 2 Food additives E – O
Vol. 3 Food additives P – Z
Vol. 4 Analytical methods, test procedures and laboratory solutions (not available yet)

Availability: 2006

Ar – Arabic	Multil – Multilingual
C – Chinese	* Out of print
E – English	** In preparation
F – French	
P – Portuguese	
S – Spanish	

The FAO Technical Papers are available through the authorized FAO Sales Agents or directly from Sales and Marketing Group, FAO, Viale delle Terme di Caracalla, 00100 Rome, Italy.

RESIDUE EVALUATION OF CERTAIN VETERINARY DRUGS

Joint FAO/WHO Expert Committee on Food Additives

66th meeting 2006

This document contains monographs on residue evaluations of certain veterinary drugs, prepared at the sixty-sixth meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA), held in Rome, Italy, from 22 to 28 February 2006. Two substances were evaluated for the first time for the animal species concerned (colistin and erythromycin) and four substances were reassessed (flumequine, melengestrol acetate, ractopamine hydrochloride and triclabendazole). The residue monographs provide information on chemical identity and properties of the compounds, pharmacokinetics and metabolism, residue depletion studies and analytical methods validated and used for the detection and quantification of the compounds. This publication and other documents produced by JECFA contain information that is useful to those who work with or are involved in recommending or controlling maximum residue limits for veterinary drugs in foods.

